The United States of America

The Director of the United States Patent and Trademark Office

Has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this

United States Patent

Grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, or importing into the United States of America, products made by that process, for the term set forth in 35 U.S.C. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b). See the Maintenance Fee Notice on the inside of the cover.

Michelle K. Lee

Director of the United States Patent and Trademark Office

MAINTENANCE FEE NOTICE

If the application for this patent was filed on or after December 12, 1980, maintenance fees are due three years and six months, seven years and six months, and eleven years and six months after the date of this grant, or within a grace period of six months thereafter upon payment of a surcharge as provided by law. The amount, number and timing of the maintenance fees required may be changed by law or regulation. Unless payment of the applicable maintenance fee is received in the United States Patent and Trademark Office on or before the date the fee is due or within a grace period of six months thereafter, the patent will expire as of the end of such grace period.

PATENT TERM NOTICE

If the application for this patent was filed on or after June 8, 1995, the term of this patent begins on the date on which this patent issues and ends twenty years from the filing date of the application or, if the application contains a specific reference to an earlier filed application or applications under 35 U.S.C. 120, 121, 365(c), or 386(c), twenty years from the filing date of the earliest such application ("the twenty-year term"), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b), and any extension as provided by 35 U.S.C. 154(b) or 156 or any disclaimer under 35 U.S.C. 253.

If this application was filed prior to June 8, 1995, the term of this patent begins on the date on which this patent issues and ends on the later of seventeen years from the date of the grant of this patent or the twenty-year term set forth above for patents resulting from applications filed on or after June 8, 1995, subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b) and any extension as provided by 35 U.S.C. 156 or any disclaimer under 35 U.S.C. 253.

US009428770B2

(12) **United States Patent**
Keller et al.

(10) **Patent No.: US 9,428,770 B2**
(45) **Date of Patent: *Aug. 30, 2016**

(54) **OVER-PRODUCTION OF SECONDARY METABOLITES BY OVER-EXPRESSION OF THE VEA GENE**

(71) Applicant: **WISCONSIN ALUMNI RESEARCH FOUNDATION**, Madison, WI (US)

(72) Inventors: **Nancy P. Keller**, Madison, WI (US); **Saori Amaike Campen**, Madison, WI (US)

(73) Assignee: **Wisconsin Alumni Research Foundation**, Madison, WI (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/485,985**

(22) Filed: **Sep. 15, 2014**

(65) **Prior Publication Data**

US 2015/0037862 A1 Feb. 5, 2015

Related U.S. Application Data

(63) Continuation of application No. 12/799,505, filed on Apr. 26, 2010, now Pat. No. 8,871,494.

(60) Provisional application No. 61/172,514, filed on Apr. 24, 2009.

(51) **Int. Cl.**

C12P 1/02	(2006.01)
C12N 5/00	(2006.01)
C12N 5/02	(2006.01)
C12N 1/00	(2006.01)
C12Q 1/68	(2006.01)
C12N 9/20	(2006.01)
A01H 5/12	(2006.01)
C12N 15/80	(2006.01)
A61K 38/00	(2006.01)
C12R 1/645	(2006.01)

(52) **U.S. Cl.**

CPC ***C12P 1/02*** (2013.01); ***C12Q 1/6895*** (2013.01); *A01H 5/12* (2013.01); *A61K 38/00* (2013.01); *C12N 9/20* (2013.01); *C12N 15/80* (2013.01); *C12Q 2600/158* (2013.01); *C12R 1/645* (2013.01)

(58) **Field of Classification Search**

CPC A61K 38/00; C12R 1/645; C12N 15/80; C12N 9/20; A01H 5/12

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,469,863	A	9/1984	Ts'o et al.
4,683,195	A	7/1987	Mullis et al.
5,034,506	A	7/1991	Summerton et al.
5,216,141	A	6/1993	Benner
5,235,033	A	8/1993	Summerton et al.
5,386,023	A	1/1995	Sanghvi et al.
5,602,240	A	2/1997	De Mesmaeker et al.
5,637,684	A	6/1997	Cook et al.
5,644,048	A	7/1997	Yau
5,952,174	A	9/1999	Nikiforov et al.

OTHER PUBLICATIONS

Dreyer et al., Applied and Environmental Microbiology, 2007; 73(10): 3412-22.*
Bowie et al (Science, 1990, 257:1306-1310).*
Adams, et al., Microbiol. Mol. Biol. Rev. 62:35-54 (1998).
Bayram, et al., Fungal Genet. Biol. 45:127-138 (2008).
Bayram, et al., Science 320:1504-1506 (2008).
Brakhage, FEMS Microbiol. Lett. 148:1-10 (1997).
Bok, et al., Eukaryotic Cell 3:527-535 (2004).
Bok, et al., Eukaryotic Cell 4:1574-1582 (2005).
Bok, et al., Mol. Microbiol. 61:1636-1645 (2006).
Brodhagen, et al., Mol. Microbiol. 67:378-391 (2008).
Busch, et al., Mol. Microbiol. 49:717-730 (2003).
Busch, et al., Proc. Natl. Acad. Sci USA 104:8089-8094 (2007).
Calvo, et al., Microbiol. Mol. Biol. Rev. 66:447-459 (2002).
Calvo, et al., Appl. Environ. Microbiol. 65:3668-3673 (1999).
Calvo, et al., Appl. Environ. Microbiol. 70:4733-4739 (2004).
Chaveroche, et al., Nucleic Acids Res. 28:e97 (2000).
Cho, et al., The Journal of Microbiology 41:46-51 (2003).
Champe, et al., J. Gen. Microbiol. 133:1383-1387 (1987).
Chen, et al., Proc. Natl. Acad. Sci. USA 101:5048-5052 (2004).
Chen, et al., Genes Dev. 20:1150-1161 (2006).
Cseke, et al., Handbook of Molecular and Cellular Methods in Biology and Medicine, 2nd ed., CRC Press, Boca Raton, FL (2004).
Dagenais, et al., Infect. Immun. 76:3214-3220 (2008).
Diener, et al., Ann. Rev. Phytopathol. 25:249-270 (1987).
Dreyer, et al., Appl. Environ. Microbiol. 73:3412-3422 (2007).
Duran, et al., Appl. Microbiol. Biotechnol. 73:1158-1168 (2007).
Duran, et al., Open Mycol. J. 3:27-36 (2009).
Eng, et al., J. Am. Soc. Mass. Spectrom 5:976-989 (1994).
Etxebeste, et al., Eukaryotic Cell 7(1):38-48 (2008).
Feinberg, et al., Anal. Biochem. 132:6-13 (1983).
(Continued)

Primary Examiner — Gary Nickol
Assistant Examiner — Lakia Tongue
(74) *Attorney, Agent, or Firm* — Boyle Fredrickson, S.C.

(57) **ABSTRACT**

The invention provides a general and facile method to obtain secondary metabolites from fungal sources. The invention is based on the discovery that the fungal gene veA and protein encoded thereby regulates the activity of multiple secondary metabolite gene clusters in fungi. Over expression of the gene veA provides increased production of secondary metabolites in engineered cells. In particular, such a method of increasing secondary metabolite production allows the production of improved yields of valuable secondary metabolite products.

5 Claims, 23 Drawing Sheets
(11 of 23 Drawing Sheet(s) Filed in Color)

(56) **References Cited**

OTHER PUBLICATIONS

Fernandez-Abalos, et al., Mol. Microbiol. 27(1):121-130 (1998).
Fray, Ann. Bot. 89:245-253 (2002).
Georgianna, et al., Fungal Genet. Biol. 46:113-125 (2009).
Ausubel, et al. (ed.), Current Protocols in Molecular Biology, Contents, vols. 1-5, John Wiley & Sons, Inc. (2007).
Gyuris, et al., Cell 75:791-803 (1993).
Greenspan, et al., J. Cell Biol. 100:965-973 (1985).
Hanahan, et al., Methods Enzymol. 204:63-113 (1991).
Hicks, et al., The Mycota XI, Kempken (Ed.), Springer-Verlag Berlin Heidelberg, pp. 55-69 (2002).
Hu, et al., Mol. Cell 9:789-798 (2002).
Hornby, et al., Appl. Environ. Microbiol. 67:2982-2992 (2001).
Brown, et al., Appl. Environ. Microbiol. 74:5674-5685 (2008).
Jensen, et al., Appl. Environ. Microbiol. 58:2505-2508 (1992).
Kale, et al., Fungal Genet. Biol. 45:1422-1429 (2008).
Kato, et al., Eukaryotic Cell 2:1178-1186 (2003).
Kim, et al., Fungal Genet. Biol. 37:72-80 (2002).
Klich, Mol. Plant Pathol. 8:713-722 (2007).
Keller, et al., Nat. Rev. Microbiol. 3:937-947 (2005).
Keller, et al., Appl. Environ. Microbiol. 60:1444-1450 (1994).
Kolar, et al., Gene 62:127-134 (1998).
Krappmann, et al., Eukaryotic Cell 4:1298-1307 (2005).
Krappmann, et al., Mol. Microbiol. 61(1):76-88 (2006).
Kunkel, Proc. Natl. Acad. Sci. USA 82:488-492 (1985).
Li, et al., Mol. Microbiol. 62(5):1418-1432 (2006).
Link, et al., Nat. Biotechnol. 17:676-682 (1999).
Lillie, et al., Histopathologic Technic and Practical Histochemistry, 4th ed., McGraw-Hill Book Company, New York, NY (1976).
Maggio-Hall, et al., Mol. Microbiol. 54:1173-1185 (2004).
Maggio-Hall, et al., Mol. Plant-Microbe Interact. 18:783-793 (2005).
Michailides, et al., Plant Pathol. 56:352 (2007).
Miller, et al., Mol. Cell. Biol. 5:1714-1721 (1985).
Mooney, et al., Genes Dev. 4:1473-1482 (1990).
Muyrers, et al., Genet. Eng. 22:77-98 (2000).
Muture, et al., East Afr. Med. J. 82:275-279 (2005).
Nayak, et al., Genetics 172:1557-1566 (2006).
Ni, et al., PLoS One 2(10):e970 (2007).
Perrin, et al., PLoS Pathog. 3(4):e50 (2007).
Puig, et al., Methods 24:218-229 (2001).
Punt, et al., Methods Enzymol 216:447-457 (1992).
Purschwitz, et al., Curr. Biol. 18:255-259 (2008).
Pettit, Yellow Mold and Aflatoxin, p. 35-36, In D. M. Porter, D. H. Smith, and R. Rodriguez-Kabana (ed.) Compendium of Peanut Diseases. The American Phytopathological Society, St. Paul, MN (1984).
Robens, et al., The Costs of Mycotoxin Management in the United States, p. 1-13. In H. K. Abbas (ed.) Aflatoxin and Food Safety. CRC Press, Boca Raton, FL (2005).
Rohila, et al., Plant J. 38:172-181 (2004).
Saiki, et al., Nature 324:163-166 (1986).
Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, NY (1989).
Seiler, et al., Mol. Biol. Cell 17:4080-4092 (2006).
Shevchenko, et al., Anal. Chem 68, 850-858 (1996).
Shwab, et al., Eukaryotic Cell 6:1656-1664 (2007).
Southern, J. Mol. Biol. 98:503-517 (1975).
Sprote, et al., Arch. Microbiol. 188:69-79 (2007).
Stinnett, et al., Mol. Microbiol. 63(1):242-255 (2007).
Shchepin, et al., Chem. Biol. 10:743-750 (2003).
Shimizu, K., et al., Genetics 157:591-600 (2001).
Smart, et al., Phytopathology 80:1287-1294 (1990).
Szewczyk, et al., Nat. Protoc. 1:3111-3120 (2006).
Thompson, et al., Nucleic Acids Res 22:4673-4680 (1994).
Tsitsigiannis, et al., Mol. Microbiol. 59:882-892 (2006).
Tsitsigiannis, et al., Microbiology 151:1809-1821 (2005).
Tsitsigiannis, et al., J. Biol. Chem. 279:11344-11353 (2004).
Williams, Microbiology 153:3923-3938 (2007).
Wilson, et al., Microbiology 150:2881-2888 (2004).
Woloshuk, et al., Appl. Environ. Microbiol. 60:2408-2414 (1994).
Yu, et al., Fungal Genet. Biol. 41:973-981 (2004).
Yu, et al., Rev. Iberoam. Micol. 22:194-202 (2005).
Yu, et al., Mycotoxin Production and Prevention of Aflatoxin Contamination in Food and Feed. In G. H. Goldman and S. A. Osmani (ed.), The Aspergilli. CRC Press, Boca Raton, FL (2008), pp. 457-472.
Bowie et al., Science, 1990. 257:1306-1310.

* cited by examiner


A
kDa
wt
veA::ctap*
180
130
100
73
54
48
35
1
2
3
4
5
B
VeA::TAP*
1. VeA
2. VeA & VelB
3. VeA & VelB & KapA
4. VeA & VelB & LaeA
5. VeA & VelB
VelB-VeA-LaeA & KapA
C
N
37
VeA
265 276 360
C
C
VelB
231 142
N
N
111 21
LaeA
C

FIG. 1


A
TAP* tag
2nd Purification
1st Purification
Codon optimized amino acids
CBP
Protein A
Protein A
EKCS
TCS
Amino acids
Leu
Val
Ala
Former codon
TTA or CTA
GTA
GCG
Usage
0.55 or 0.95 %
0.69 %
1.93 %
Optimized codon
CTC
GTC
GCC
Usage
2.38 %
2.23 %
2.53 %
B
kDa L D L D
130
100
73
54
48
35
VeA-TAP* tag
Actin
C
kDa M wt laeA::ctap* velB::ctap*
180
130
100
72
54
48
35
1
2
3
4
5
D
LaeA::TAP*
1. VeA
2. LaeA & VeA
3. LaeA & VeA & VelB
4. LaeA & VelB
VelB::TAP*
1. VeA
2. VelB & VeA
3. VelB & VeA & VosA
4. VelB & VeA & LaeA & VosA
5. VelB & VeA & LaeA & VosA
VelB-VeA-LaeA
VelB-VeA-LaeA-VosA

FIG. 2


A
EcoRI
BamHI
HindIII
BamHI
EcoRV EcoRV
ApaI
FGSC A4
1000 bp
B
SEQ ID NO: 117
SEQ ID NO: 116
VelB
VeA
NLS
NES
PEST
PEST
C
Vegetative
Asexual
Sexual
Co 6 12 18 24 6 12 24 48 24 48 72 96 As
velB
rRNA

FIG. 3


β-gal unit
-UTL
-UHTL
5mM 3AT
593±24
468±11
25±4
17±7
26±9
14±7
44±14
601±13
694±15
19±3
384±10
543±12
798±8
803±18
560±17
682±11
787±24
18±5
558±18
17±9
601±19
24±5
10±1
31±4
11±4
693±13
448±19
566±27
692±15
19±3
533±17
26±3
19±4
21±4
20±9
VeA / LaeA
VeA1 / LaeA
VeA / LaeA N-term
VeA / LaeA C-term
VeA1 / LaeA N-term
VeA1 / LaeA C-term
LaeA / VeA N-term
LaeA / VeA C-term
LaeA / VosA
LaeA / VosA N-term
LaeA / VosA C-term
LaeA C-term / VosA
LaeA N-term / VosA
LaeA / LaeA
LaeA / LaeA N-term
LaeA / LaeA C-term
VeA / VelB
VeA1 / VelB
VeA / VelB N-term
VeA / VelB C-term
VelB / VeA N-term
VelB / VeA1 N-term
VelB / VeA C-term
VelB / VelB
LaeA / VelB
VelB / VosA
VelB N-term / VosA
VelB C-term / VosA
VelB / VosA N-term
VelB / VosA C-term
VeA / VosA
VeA1 / VosA
VeA / VeA
VeA / VeA1
VeA1 / VeA1
Dilution
0 1/2 1/4 1/8
0 1/2 1/4 1/8
0 1/2 1/4 1/8

FIG. 4


A
Light
Dark
VeA-LaeA
DIC
5 μm
5 μm
B
Light
Dark
VeA-VelB
5 μm
5 μm
C
WT
laeA△
veA△
velB△
L
D
STs V20 24 48 24 48 V20 24 48 24 48 V20 24 48 24 48 V20 24 48 24 48
D
ST amount
(% of wild type in 24hr light)
350
300
250
200
150
100
50
0
B
B
B
24 48 24 48
Light
Dark

FIG. 5



FIG. 6



FIG. 7



FIG. 8



B

Nuclear / Cytoplasmic ratio for VeA	
Light	Dark
0.3 ± 0.17	8.34 ± 2.7

Nuclear / Cytoplasmic ratio for VelB	
Light	Dark
1.80 ± 0.44	2.90 ± 0.89

Nuclear / Cytoplasmic ratio for LaeA	
Light	Dark
3.99 ± 1.27	4.20 ± 1.25

FIG. 9


A
Dark
VelB::sGFP
Dark
veA+
veAΔ
DIC
B
Nuclear / Cytoplasmic ratio for VelB
in veA+
in veAΔ
2.90 ± 0.89
1.04 ± 0.29
C
Light
Dark
CYTOPLASM
NUCLEUS
VelB
VeA
LaeA
Sexual development
Less secondary metabolism (ST production)
Secondary metabolism (ST production)

FIG. 10


A
PstI
NheI
PciI
PvuII
velB
TNO2A3
[velB]
1090 bp
5' probe
AGB278
[velB::pntA]
wt
Δ
B
SmaI
velB-tap
AGB398
[velB::ctap* natR]
C
EcoRV
NruI
ORF probe
[ssuA]
AGB390
[ssuA::ctap* natR]

FIG. 11

SEQ ID NO: 116 - VeA protein [*Aspergillus nidulans*]
GENBANK REF: AAD42946.

matlaapppp lgesgnsnsv sritregkki tyklnimqqp kraracgqgs kshtdrrpvd 61
pppvielnif esdphddsnk tditfvynan fflfatlepe rpiatgklmt nqgspvltgv 121
pvagvayldk pnragyfifp dlsvrnegsy rfsfhlfeqi kdpkdategt qpmpspvpgk 181
lsspqeflef rlevisnpfi vysakkfpgl ttstpisrmi aeqgcrvrir rdvrmrrrgd 241
krtedydydn ergynnrrpd qyagsdayan aperprstsi stnmdpysyp srrpsaveyg 301
qpiaqpyqrp mastpapsst pipapipmpg pvalppstps pasahapapp svplaapppl 361
htpsyqshls fgatqtqypa pqlshipqqt ttpthpyspr ssishsrnqs iseyepsmgy 421
pgsqtrlsae rpsygqpsqt tslpplrhsl epsvnsrskt psnmitslpp iqslselpst 481
tsqpssaigs spanepgprl wetnsmlskr tyeesfghdd rplyngmrpd sesypggmqr 541
rpsyerssll dgpdqmaykr angrmvskpa tmr

FIG. 12


A
probe
K
1.1kb
K
6.8kb
K
5'flank
veA
3'flank
5'flank
A. fumigatus pyrG
3'flank
K
1.1kb
K
2.2kb
K
4.7kb
K
5'flank
veA
3'flank
A. fumigatus pyrG
K
K
0.3kb
3.6kb
K
probe
H
5.4 kb
H
5'flank
laeA
3'flank
5'flank
A. fumi pyrG
3'flank
4.5 kb
H
H
2.8 kb
H
5'flank
laeA
3'flank
A. parasiticus niaD
H
7.8 kb
H
6 kb
B
WT
Δ veA
MC veA
Δ laeA
MC laeA
MC veA-laeA
WT
Δ veA
MC veA
Δ laeA
MC laeA
MC veA-laeA
6.8 kb
4.7 kb
3.6 kb
2.2 kb
1.1 kb
7.8 kb
5.6 kb
4.4 kb
4.5 kb
3.2 kb
1.7 kb
veA
laeA

Figure 13


Light
Dark
Colony diameter (cm)
0
2
4
6
8
b
cd
b
d
a
c
b
b
b
c
a
a
WT
Δ veA
MC veA
Δ laeA
MC laeA
MC veA-laeA
day3
day6

Figure 14


WT
Δ veA
MC veA
Δ laeA
MC laeA
MC veA-laeA
veA
laeA
aflR
actin
rRNA

Figure 15


A
Light
Conidia (10^5 spores/ml)
1500
1200
900
600
300
0
WT
Δved
MC ved
Δ loed
MC loed
MC ved-loed
Dark
Conidia (10^5 spores/ml)
10^2
10^4
10^6

Figure 16



Figure 16 (continued)


C
WT
Δ vvd
MC vvd
Δ lreg1
MC lreg1
MCvvd-lreg1
C
Light
Dark
10⁶
10⁴
10²
10⁶
10⁴
10²

Figure 17


A
SunRunner
10000
8000
6000
4000
2000
0
a
e
c
d
b
e
f
WT
Δvel1
MC vel1
Δlae1
MC lae1
MCvel1-lae1
MOCK
FloRunner
Conidia (10^4 spores /ml)
10000
8000
6000
4000
2000
0
b
de
bc
cde
a
bcd
e
WT
Δvel1
MC vel1
Δlae1
MC lae1
MCvel1-lae1
MOCK

Figure 18

A - Continued





Figure 18 (continued)



Figure 19



Figure 19 (continued)


1.2
1
0.8
0.6
0.4
0.2
0
A
A
B
C
A
B
C
D
A
B
B
C
WT
Δfrc1
Δfrc1
glucose
g+hexanoic
g+oleic
g+erucic

Figure 20

OVER-PRODUCTION OF SECONDARY METABOLITES BY OVER-EXPRESSION OF THE VEA GENE

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/799,505, filed Apr. 26, 2010, which claims priority to U.S. Provisional Application No. 61/172,514, filed Apr. 24, 2009, both of which are incorporated by reference for all purposes.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under 0236393 awarded by the National Science Foundation and 09-CRHF-0-6055 awarded by the USDA/CSREES. The government has certain rights in the invention.

FIELD OF THE INVENTION

The invention relates generally to methods of over-producing secondary metabolites. More particularly, the present invention is directed to methods of over-producing secondary metabolites by manipulating fungal regulatory genes involved in the control of secondary metabolite gene clusters.

BACKGROUND OF THE INVENTION

Secondary metabolites are organic compounds that are not directly involved in the normal growth, development or reproduction of organisms. They are often used as defenses against predators, parasites and diseases, for interspecies competition, and to facilitate the reproductive processes (coloring agents, attractive smells, etc).

Secondary metabolites of fungi include both "friends and foes" of human health. For example, penicillin and derivatives produced by *Aspergillus, Cephalosporium* and *Penicillium* species are widely used antibiotics, lovastatin is a potent cholesterol-lowering drug produced by *Aspergillus terreus* and aflatoxins, produced by several *Aspergillus* species, are highly toxic carcinogens contaminating many crops.

Secondary metabolic pathways are often tightly correlated with the fungal developmental program and response to external cues including light. Since secondary metabolites are usually restricted to a much more limited group of organisms, they have long been of prime importance in taxonomic research. Secondary metabolites are especially useful for drug or other technological development, or as an inspiration for unnatural products. Biosynthetic genes for fungal secondary metabolites are often clustered and regulated by pathway-specific transcription factors. Secondary metabolism is also regulated at an upper hierarchic level by a global epigenetic control mechanism. However, methods of producing large amounts of secondary metabolites are difficult and provide unpredictable results. Therefore a need exists for methods of producing large amounts of secondary metabolites that address these problems.

The distribution of natural products is characteristically restricted to certain fungal taxa, particularly the Ascomycetes. Perhaps the greatest number of known secondary metabolites has been ascribed to the Ascomycete genus *Emericella* (asexual stage=*Aspergillus*). Much of the current understanding of fungal secondary metabolite regulation arises from studies of the genetic model *Aspergillus nidulans*. This organism produces many natural products including sterigmatocystin ST (ST; the penultimate precursor to aflatoxin) and penicillin and has been used as a heterologous host to study the biosynthesis of other natural products including lovastatin. Critical advances in understanding fungal secondary metabolism have been largely based on primary studies from *A. nidulans* and/or secondary studies in other fungi where researchers were able to exploit the knowledge gained from *A. nidulans* to their fungus of choice.

A. nidulans, a mold, produces many compounds relevant to biotechnology and human health and is a well-suited model for the analysis of the interplay between secondary metabolism, light and differentiation. *A. nidulans* grows vegetatively in the soil by hyphal tip extension until competent for development and secondary metabolism. In reproduction, *A. nidulans* forms airborne asexual spores in light but preferentially undergoes sexual reproduction in the dark. Sexual reproduction in the dark results in an increase in secondary metabolism and in the formation of sexual fruit bodies called cleistothecia, which consist of different cell types. Mutations resulting in defects in fungal development often impair secondary metabolism. There is genetic evidence for a connection between fruitbody formation, secondary metabolism, and light in *A. nidulans* reproduction, but the molecular mechanism is not known.

Aspergillus flavus, an opportunistic pathogen of oil seeds, occurs as a saprophyte in soils worldwide and colonizes several important agricultural crops, such as maize, peanut, and cottonseed, before and after harvest. The pathogen generates asexual spores, conidia, as the source of inoculum and overwinters as sclerotia which germinate to produce conidia in the subsequent season. *A. flavus* and other aspergilli, such as *Aspergillus parasiticus*, can produce the polyketide-derived carcinogenic secondary metabolite aflatoxin. In the United States, annual yield losses in the million-dollar range from aflatoxin contamination on peanut and maize crops are frequently reported. Aflatoxin-contaminated food and feed is also a major problem in developing countries, especially in Asia and Africa. Recently, an outbreak of aflatoxin poisoning from maize was reported to have killed a hundred people in Kenya. Therefore, measures to control *Aspergillus* infections and aflatoxin production are urgently needed to protect human and animal health. The identification and characterization of molecules necessary for *A. flavus* conidial, sclerotial, and aflatoxin production are critical to develop rational control strategies.

VeA, a conserved velvet protein encoded by the veA gene, increases expression during sexual development. However, VeA transport into the nucleus is inhibited by light. It acts as a negative regulator of asexual development. VeA is required for cleistothecial production in *A. nidulans* and sclerotial production in both *A. parasiticus* and *A. flavus*. In addition, the VeA gene regulates the expression of sterigmatocystin (a precursor of aflatoxin) and penicillin genes in *A. nidulans* and aflatoxin genes in *A. parasiticus* and *A. flavus*. VeA interacts with LaeA in an as-yet-unclear mechanism, although analysis shows that VeA and LaeA negatively regulate each other at the transcript level in *A. nidulans* (1) and LaeA negatively regulates veA in *A. flavus* (21).

LaeA, another protein located in the cell nucleus, is present in numerous fungi and is a master regulator of secondary metabolism in Aspergilli and other fungal genera. LaeA is also necessary for sclerotial formation in *A. flavus* and affects cleistothecial development in *A. nidulans*.

The deletion of LaeA silences numerous secondary metabolite gene clusters, including those responsible for the syntheses of the antibiotic penicillin as well as for toxins such as ST or gliotoxin. It has been suggested that LaeA might control the accessibility of binding factors to chromatin regions of secondary metabolite clusters because LaeA prevents heterochromatin maintenance of some clusters.

Other factors have been reported which link morphological development with secondary metabolism. Of particular interest are a family of oxylipin-producing oxygenases (encoded by ppo and lox genes) which have been shown to balance ascospore and conidial production in *A. nidulans* (40, 41) and sclerotial and conidial production in *A. flavus*, as well as secondary metabolite production in both species. Most recently, a density-dependent switch from sclerotial-to-conidial development in *A. flavus* was found to be affected by oxylipin production. Both oxylipin production and the response to oxylipin signaling are dependent on an intact VeA protein. VeA is also required for ppoA expression, and VeAPpoA interactions affect both sexual and asexual development in *A. nidulans*. The impact of the loss of these proteins on pathogenesis has been explored to some degree for LaeA and Ppo mutants but not yet reported for VeA. LaeA is a key determinant in aspergillosis caused by *A. fumigatus* and seed rot by *A. flavus* and Ppo loss impacts virulence attributes of *A. fumigatus, A. nidulans*, and *A. flavus*.

Despite present methodologies, a need exists for improved methods of controlling production of secondary metabolites to obtain improved production of important natural products and/or novel natural products with medicinal value.

BRIEF DESCRIPTION OF THE DRAWINGS

The present patent application contains at least one drawing executed in color. Copies of this patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

FIG. **1**(A) shows identification of VeA-associated proteins in *A. nidulans*. Brilliant blue G-stained 10% SDS-polyacrylamide gel electrophoresis of TAP procedure for VeA. kD, kilodaltons. (B) The polypeptides identified from the bands of affinity purification belong to corresponding proteins (details in table 4). (C) Domain mapping of the interactions based on Y2H data (FIG. **4**). N, N terminus; C, C terminus.

FIG. **2**(A) shows Modified TAP tag* and VeA expression. Depiction of the TAP tag. The codons for 18 amino acids were changed by site-directed mutagenesis and are designated as differently colored spheres. (B) Immunoblotting with antibody against calmodulin binding peptide: 85 kDa VeA::TAP* tag. In the light (L), expression is relatively low in comparison to the expression in the dark (D); as a control antiactin antibody was used. (C) Brilliant Blue G-stained 10% SDS-PAGE gel of the TAP for VelB and LaeA. (D) The polypeptides identified from the bands of two affinity purifications belong to corresponding proteins (see Table 4).

FIG. **3**(A) shows velB gene structure and alignment of VeA (SEQ ID NO: 116) and VelB (SEQ ID NO: 117; Genbank Accession No. CBF89638). Architecture of the velB locus of *A. nidulans*. Exons are indicated as E1, E2, E3, E4 (confirmed in cDNA) and recognition sites of common restriction endonucleases are shown. (B) Local alignment of the VelB and VeA proteins. Identical residues are indicated by an asterisk (*), conserved amino acid substitutions (similar amino acids) as two dots (:), and semi-conserved amino acid substitutions as one dot (.). The red rectangle indicates a putative nuclear localization signal (NLS) of VeA, the blue rectangle indicates a putative nuclear export signal (NES) and the black rectangle marks a conserved PEST (Pro, Glu (or Asp), Ser, Thr) motif. Red: small and hydrophobic (including aromatic amino acid), Blue: acidic, Magenta: basic, Green: hydroxyl, amine and basic amino acids. (C) Northern hybridization of VelB during different life stages of *A. nidulans*. It is highly expressed in asexual conidia and sexual ascospores. VelB expression stays at basal levels during vegetative growth and increases during late asexual (24, 48 h) or sexual (98 h and ascospores) development.

FIG. **4**. Interaction domain mapping among VeA, VeA1, VosA, LaeA and VelB by yeast two-hybrid assay. Derivatives of yeast strain L40 expressing the different bait and prey fusion proteins were spotted in serial dilutions for growth on −UHTL (uracil, histidine, tryptophan and leucine), −UHTL with 5 mM 3−AT and −UTL media, and then incubated at 30° C. for 5 days. Their β-galactosidase activities were analyzed using ONPG.

FIG. **5**(A) shows BiFC studies of velvet complex components and their effect on ST production. Enhanced yellow fluorescent protein fused to the N terminus of veA gene (N-EYFP::VeA) interacts with C-EYFP::LaeA in vivo, which is indicated as yellowish green specks in the nucleus. Histone 2A red fluorescent protein (H2A::mRFP) fusion visualizes the entire nucleus. Interaction does not take place in the whole nucleus but in certain points (gene clusters) that LaeA probably acts on (indicated by arrows). Differential interference contrast (DIC) shows hyphal cells. (B) N-EYFP::VeA fusion protein interacts with C-EYFP::VelB in the cytoplasm and nucleus. (C) ST production in respective mutant backgrounds and WT at different time points. STs, ST standard; V20, 20 hours vegetative growth; L, light; D, dark. 24 and 48 hour time points are shown. (D) Quantification of ST production using thin layer chromatography: In the dark, more ST is produced in the WT. Deletion of either laeA or veA results in no ST above background (denoted by B) fluctuations. Loss of velB results in basal ST production in dark.

FIG. **6**(A) shows Deletion of velB and impairment of sexual fruit body formation. Phenotypic characterization of the velBΔ deletion strain AGB279. Defects are restored in AGB280 (+velB). Fruit body formation (FB) in TNO2A3 and AGB280 appeared as normal (red arrows), whereas aerial hyphae (white arrows) and red pigment accumulation accompanied by a lack of fruit bodies were evident for velBΔ and veAΔ strains. Pictures of cleistothecia and hyphae were taken at 10^8-fold magnification. (B) ST standard HPLC (retention time (RT): 21.58) and the corresponding mass spectrum. (C) Confirmation of sterigmatocystin (ST) production by LC-MS in the velBΔ mutant. HPLC condition: A=0.1% formic acid in water, B=acetonitrile+ 0.1% formic acid, gradient=2% B to 100% B in 30 min, re-equil=18 min/flow rate=0.200 ml/min, column=ZORBAX C-18 SB, 2.1×50 mm (100 Å, 1.8 U Agilent), Temperature=40° C. Mass spectrum condition: Agilent ESITOF, source Temp=325° C., electrospray=3500 V, drying gas=91/min, nebulizer gas=30 PSI. Tolerance=less than 3 ppm. Actual was 1.6 ppm at Mass 325.0712.

FIG. **7**. Expression of extra copy of laeA in the veAΔ background. RDIT9.32 (wild-type) and RJW108.1 (veAΔ:: argB; trpC::laeA) were grown on sexual induction condition and metabolites extracted and run on a thin layer chromatography plate (chloroform:acetone=4:1). An extra copy of laeA does not restore sterigmatocystin in the veAΔ background. ST=sterigmatocystin standard.

FIG. **8**. Northern blot analyses. Levels of veA, velB, laeA mRNA in WT. (RDIT9.32), laeAΔ (RJW41.A), veAΔ (RJW112.2) and velBΔ (RNI18.2). All strains were grown in liquid *Aspergillus* rich medium at 37° C., 250 rpm for 20 h (shown as V20 in the figure) and then transferred onto solid MM plus supplements with or without 0.1% casamino acids for the concomitant induction. The strains grown on MM without casamino acids were incubated at 37° C. under white fluorescent light (shown as L in the figure), while the strains grown on MM with casamino acids were sealed with parafilm, wrapped with foil and incubated at 37° C. in the darkness (shown as D in the figure). Samples for RNA extraction were collected at 24 h and 48 h after induction. Twenty micrograms of total RNA were loaded in each lane. EtBr-stained rRNA evaluated equal loading of total RNA.

FIG. **9**(A) shows Subcellular localization of the subunits of the velvet complex. VeA-, LaeA-, and VelB-sGFP localizations in the presence or absence of light. VeA-sGFP shows light-dependent nuclear enrichment (counterstained with H2A::mRFP for visualization of the entire nucleus). (B) Nuclear/cytoplasmic GFP signal ratio of 100 hyphal cells each (Openlab software 5.0.1). Growth in the dark results in increased nuclear and decreased cytoplasmic fluorescence for VeA. VelB and LaeA distribution is hardly affected by illumination.

FIG. **10**(A) shows VeA supports nuclear localization of VelB and formation of the velvet complex. Fluorescence patterns in strains expressing velB::sgfp in the dark in veA+ and veAD backgrounds. (B) Nuclear/cytoplasmic GFP signal ratio of 100 hyphal cells each. Nuclear signal intensity is higher in the veA+ strain background than in veAD. (C) Model: (Light) VeA is mostly retained in the cytoplasm, VelB supports asexual spore formation, and LaeA shows low activity. (Dark) An increased amount of VeA is imported into the nucleus by KapA and, in addition, supports the nuclear transport of VelB. Dotted lines indicate the decreased amount of VeA that is present in the cell in the light and the impairment of VeA nuclear transport in the light. VelB/VeA control development and LaeA activity by formation of the velvet complex that affects secondary metabolite clusters expression.

FIG. **11**(A) shows Deletion of the velB locus and TAP tagging fusion genes at the velB and laeA loci. Comparative depiction of the wild-type velB locus (TNO2A3) and the velB::ptrA locus (AGB279). The black bar indicates the probe for Southern hybridization. (B) The result of TAP tagging of velB locus is depicted. Autoradiography of Southern hybridization confirms the gene replacement. (C) The TAP tagged laeA locus is shown. Autoradiography of Southern hybridization confirms the homologous gene replacements for the velB and laeA loci. For the deletion of velB, the ptrA (pyrithiamine resistance gene) marker was used and for the TAP tagging of velB and laeA, the (nourseothricin resistance gene) nat marker was utilized.

FIG. **12**. Sequence Listing for VeA (*A. nidulans*) (SEQ ID NO: 116).

FIG. **13**(A) shows Deletion, MCveA, and MClaeA mutants of *A. flavus*. Diagram of the strategy of replacement of *A. flavus* NRRL 3357.5 veA with *A. fumigatus* AF293 wild-type pyrG gene shows the restriction enzyme digestion sites of KpnI for Southern analysis with veA probe. To confirm gene replacement or MC transformants using Southern analysis, at least two restriction enzymes for each probe were utilized, KpnI (K) and SapI (data not shown) for veA and HindIII (H) and BamHI (data not shown) for laeA. *A. fumi, A. fumigatus*. (B) Southern analysis. The KpnI digest shows 6.8-kb and 1.1-kb veA fragments in the wild type and 4.7-kb, 2.2-kb, and 1.1-kb fragments in the ΔveA strain. The MCveA strain shows both wild-type 6.8-kb and 1.1-kb fragments, as well as 3.6-kb and 0.3-kb (not shown) fragments. The laeA probe presented a 5.6-kb fragment in the wild type; 4.5-kb, 3.2-kb, and 1.7-kb fragments in the ΔlaeA strain; and several extra bands in the MClaeA strain. The laeA mutants have been described before, in reference 21. WT, wild type.

FIG. **14**. Colony diameters of veA and laeA mutants of *A. flavus*. A 5-μl amount of a suspension of 10^6 spores/ml of each strain was point inoculated on 30 ml of 1.6% GMM. Cultures were grown at 29° C. under continuous dark or light conditions, and growth diameters measured at 3 and 6 days after inoculation. Letters indicate differences between strains that were statistically significant ($P<0.05$) according to the Tukey-Kramer multiple comparison test. Error bars show the standard deviations of the results of four replications. Strains were grown in both light and dark conditions. WT, wild type.

FIG. **15**. Gene expression levels of veA and laeA in *A. flavus* mutants. Each strain was grown in liquid GMM culture with shaking (250 rpm at 29° C.) under dark conditions. Total RNA was extracted from two replicates at 48 hrs after inoculation. Northern blots were probed with internal or ORF fragments of each gene (Table 2). rRNA and actin were the loading and expression controls. WT, wild type.

FIG. **16**(A) shows Effects of veA and laeA allele numbers on density-dependent conidial and sclerotial production in *A. flavus*. Each strain was grown from 10^2, 10^4, and 10^6 spores/plate as described in Materials and Methods. Conidial counts. (B) Sclerotial weight. Letters indicate statistically significant differences ($P<0.05$) for each strain at different population levels according to the Tukey-Kramer multiple comparison test. Error bars show standard deviations of the results of four replications. WT, wild type.

FIG. **17**. Aflatoxin production of veA and laeA mutants. Aflatoxin from each strain was assessed at three different spore inoculation levels. The experiment was replicated three times, as shown. C, aflatoxin B1 control; WT, wild type.

FIG. **18**(A) Conidium production and aflatoxin production on peanut and maize seeds. Seeds of two peanut cultivars and one maize line were inoculated with 10^5 spores/ml of the wild type and the veA and laeA mutants and incubated for either 3 days (peanut cultivar SunRunnner and maize kernels) or 5 days (peanut cultivar FloRunner) after inoculation at 29° C. under dark conditions. For conidium counting, 1-ml amounts of homogenized suspensions of five peanut cotyledons or maize kernels of inoculated seeds were diluted to 1× and conidia counted. Letters indicate statistically significant differences ($P<0.05$) of different strains, according to Tukey-Kramer multiple comparison test. Error bars show the standard deviations of the results of three replications. (B) Aflatoxin was extracted from inoculated peanut cotyledons and maize kernels and resuspended in 500 μl of chloroform, and 10 μl of each extract was spotted on a TLC plate and separated with chloroform/acetone (95:5, vol/vol). C, aflatoxin B1 control; WT, wild type; MOCK, control inoculated with water.

FIG. **19**(A) Histological examination reveals differences in seed ingress and lipid utilization of ΔveA and ΔlaeA strains compared to these functions in the wild type. Tissues were stained with Gomori methenamine-silver for detection of fungal hyphae. (B) Tissues were stained with Nile red for lipid body detection in seeds. To observe tissues, a bright-field microscope was used for Gomori stain and a tetram-

ethyl rhodamine 5-isothiocyanate filter in a fluorescent microscope was used for Nile red. Seeds infected with the wild-type fungus show diminishment of lipid bodies near the surface (white line) of the seed. Scale bars=100 μm. WT, wild type; Mock, control inoculated with water.

FIG. **20**. Loss of veA and laeA sensitizes the fungus to oleic acid. Inhibition of colony diameters of ΔveA and ΔlaeA mutants but not the wild type is observed when GMM is supplemented with 6 mM oleic acid at 3 (data not shown) and 6 days after inoculation. Letters indicate statistically significant differences ($P<0.05$) at 6 days after inoculation with different strains, according to Tukey-Kramer multiple comparison test. Error bars show the standard deviations of the results of four replications. WT, wild type; g, glucose; hexanoic, hexanoic acid; oleic, oleic acid; erucic, erucic acid.

SUMMARY OF THE INVENTION

The present invention provides a novel method of increasing the amount of a secondary metabolite produced by a cell or organism. The method comprises the steps of obtaining a cell or an organism capable of biosynthesizing a secondary metabolite; transforming the cell or organism with a nucleic acid which encodes a veA polypeptide, a polypeptide having substantial sequence identity thereto, or a fragment thereof having secondary metabolite gene cluster regulating activity; and culturing the transformed cell or organism so that an increase in production of the secondary metabolite occurs in the transformed cell or organism as compared to a non-transformed cell or organism. In one embodiment, the cell or organism is an *Aspergillus* species such as *A. nidulans* or *A. flavus*.

In another embodiment, the present invention provides a novel method of decreasing the production of a secondary metabolite by a transformed cell or organism. The method comprises the steps of: obtaining a transformed cell or organism capable of biosynthesizing a secondary metabolite, the transformed cell or organism having a defective veA gene wherein the defective veA gene is no longer biologically active and expression of secondary metabolite gene clusters is reduced; and culturing the transformed cell or organism so that a decrease in production of the secondary metabolite occurs in the transformed cell or organism as compared to a non-transformed cell or organism. In one embodiment, the cell or organism is an *Aspergillus* species such as *A. nidulans* or *A. flavus*.

In another embodiment, the present invention provides a novel method of producing an isolated secondary metabolite. The method comprises the steps of: obtaining a cell or an organism capable of biosynthesizing a secondary metabolite; transforming the cell or organism with a nucleic acid which encodes a veA polypeptide, a polypeptide having substantial sequence identity thereto, or a fragment thereof having secondary metabolite gene cluster regulating activity; culturing the transformed cell or organism under conditions conducive to increasing production of the secondary metabolite in the transformed cell or organism as compared to a non-transformed cell or organism; and recovering the secondary metabolite from the transformed cell or organism or from the culture in which the transformed cell or organism was grown in an isolated form. In one embodiment, the cell or organism is an *Aspergillus* species such as *A. nidulans* or *A. flavus*.

In another embodiment, the present invention provides a novel method for identifying a novel secondary metabolite biosynthesis gene cluster in a fungus. The method comprises the steps of: obtaining a transformed fungus having a disrupted veA gene; isolating a sample of nucleic acids from the transformed fungus, wherein the sample of nucleic acids is representative of the expressed genes of the transformed fungus; hybridizing the sample of nucleic acids isolated above or nucleic acid equivalents of same with an array comprising a plurality of nucleic acids representative of the expressed genes of a non-transformed fungus under conditions conducive to forming one or more hybridization complexes; detecting the hybridization complexes; comparing the detected levels of the hybridization complexes with the level of hybridization complexes detected in a sample of nucleic acids isolated from a veA-expressing fungus, wherein the nucleic acids isolated from a veA-expressing fungus are representative of the expressed genes of the veA-expressing fungus, and wherein an altered level of hybridization complexes detected above compared with a level of hybridization complexes of the sample of nucleic acids from the veA-expressing fungus correlates with and identifies at least one gene under regulatory control of a veA gene product; and examining genomic nucleotide sequence surrounding the at least one gene identified above to determine if the at least one gene is clustered with other secondary metabolite biosynthesis genes, thereby identifying a novel secondary metabolite biosynthesis gene cluster. In one embodiment, the cell or organism is an *Aspergillus* species such as *A. nidulans* or *A. flavus*.

DETAILED DESCRIPTION OF THE INVENTION

I. In General

Before the present materials and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, materials, and reagents described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by any later-filed nonprovisional applications.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. As well, the terms "a" (or "an"), "one or more" and "at least one" can be used interchangeably herein. It is also to be noted that the terms "comprising", "including", and "having" can be used interchangeably.

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Molecular Cloning A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols.

154 and 155 (Wu et al. eds.), Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Cell Culture and Somatic Cell Genetics of Plants, Vol. 1 (I. K. Vasil, ed. 1984); R. V. Stanier, J. L. Ingraham, M. L. Wheelis, and P. R. Painter, The Microbial World, (1986) 5th Ed. Prentice-Hall.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications and patents specifically mentioned herein are incorporated by reference for all purposes including describing and disclosing the chemicals, instruments, statistical analysis and methodologies which are reported in the publications which might be used in connection with the invention. All references cited in this specification are to be taken as indicative of the level of skill in the art. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

II. Definitions

"VeA", as used herein, refers to the amino acid sequences of the VeA protein obtained from *Aspergillus nidulans*. In addition, VeA shall also refer to the amino acid sequences of VeA obtained from any species (i.e., orthologs), particularly fungi (e.g. other strains and/or species of *Aspergillus*, and other genera), from any source whether natural, synthetic, semi-synthetic, or recombinant. The term encompasses proteins encoded by nucleotide sequences representing allelic variants as well as those containing single nucleotide polymorphisms (SNPs).

"veA", as used herein, refers to the nucleotide sequences of the veA gene obtained from *Aspergillus nidulans*. In addition, veA shall also refer to the nucleotide sequences of the veA gene obtained from any species, particularly fungi (e.g. other strains and/or species of *Aspergillus*, and other genera), from any source whether natural, synthetic, semi-synthetic, or recombinant. The term encompasses allelic variants and single nucleotide polymorphisms (SNPs).

An "allele" or "allelic sequence", as used herein, is an alternative form of the gene encoding VeA. Alleles may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding VeA, as used herein, include those with deletions, insertions, or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent protein to VeA. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding VeA, and improper or unexpected hybridization to alleles, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding VeA. The encoded protein may also be "altered" and contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent VeA. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological or immunological activity of VeA is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine, glycine and alanine, asparagine and glutamine, serine and threonine, and phenylalanine and tyrosine.

"Amino acid sequence", as used herein, refers to an oligopeptide, peptide, polypeptide, or protein sequence, and fragment thereof. Where "amino acid sequence" is recited herein to refer to a particular amino acid sequence "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete amino acid sequence referenced but shall be understood to include fragments of the complete amino acid sequence. The term shall further encompass synthetic molecules as well as those occurring naturally. The term "portion" or "fragment", as used herein, with regard to an amino acid sequence (as in "a fragment of SEQ ID NO:1"), specifically refers to segments of that amino acid sequence which are not naturally occurring as fragments and would not be found in the natural state. The segments may range in size from five amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a polypeptide "comprising at least a portion of the amino acid sequence of SEQ ID NO:1" or "including an amino acid sequence as set forth in SEQ ID NO:1 or fragments thereof" encompasses the full-length VeA amino acid sequences and segments thereof.

"Amplification", as used herein, refers to the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction (PCR) technologies well known in the art (Dieffenbach, C. W. and G. S. Dveksler (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, N.Y.).

"Antisense", as used herein, refers to any composition containing nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense molecules include peptide nucleic acids and may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and block either transcription or translation. The designation "negative" is sometimes used in reference to the antisense strand, and "positive" is sometimes used in reference to the sense strand.

"Biologically active", as used herein, refers to a protein, polypeptide, amino acid sequence, or nucleotide sequence encoding a product having structural, regulatory, or biochemical functions of a naturally occurring molecule. Preferably, a biologically active fragment of VeA will have the secondary metabolite gene cluster regulatory capabilities of a naturally occurring VeA molecule disclosed herein.

"Complementary" or "complementarity", as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing. For example, the sequence "A-G-T" binds to the complementary sequence "T-C-A". Complementary between two single-stranded molecules may be "partial", in which only some of

the nucleic acids bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands and in the design and use of PNA molecules.

A "composition comprising a given polynucleotide sequence", as used herein, refers broadly to any composition containing the given polynucleotide sequence. Compositions comprising polynucleotide sequences encoding VeA or fragments thereof, may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., SDS) and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

The phrase "correlates with expression of a polynucleotide", as used herein, indicates that the detection of the presence of ribonucleic acid that is similar to SEQ ID NO:1 by northern analysis or equivalent analysis is indicative of the presence of mRNA encoding VeA in a sample and thereby correlates with expression of the transcript from the polynucleotide encoding the protein.

"Deletion", as used herein, refers to a change in the amino acid or nucleotide sequence and results in the absence of one or more amino acid residues or nucleotides.

"Derivative", as used herein, refers to the chemical modification of a nucleic acid encoding or complementary to veA or the encoded VeA protein itself. Such modifications include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative encodes a polypeptide which retains the biological or immunological function of the natural molecule. A derivative polypeptide is one which is modified by glycosylation, or any similar process which retains the biological function of the polypeptide from which it was derived.

"Homology", as used herein, refers to sequence similarity between two peptides or between two nucleic acid molecules. Homology may be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base or amino acid, then the molecules are homologous at that position. A degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences. A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (i.e., Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or hybridization probe will compete for and inhibit the binding of a completely homologous sequence to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementary (e.g., less than about 30% identity). In the absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.

"Identity", as used herein, means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Substantial sequence identity" as used herein means at least 80% identical, more preferably 95%, 96%, 97%, 98% or 99% identical. "Identity" and "homology" can be readily calculated by known methods, including but not limited to those described in (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073 (1988). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and homology are codified in publicly available computer programs. Preferred computer program methods to determine identity and homology between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S. F. et al., J. Molec. Biol. 215: 403-410 (1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al, NCBI NLM NIH Bethesda, Md. 20894; Altschul, S., et al., J. Mol. Biol. 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

"Hybridization", as used herein, refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

"Hybridization complex", as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., Co t or Ro t analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

An "insertion" or "addition", as used herein, refers to a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, as compared to the naturally occurring molecule.

"Isolated" or "purified" or "isolated and purified" means altered "by the hand of man" from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any

other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living. As so defined, "isolated nucleic acid" or "isolated polynucleotide" includes nucleic acids integrated into a host cell chromosome at a heterologous site, recombinant fusions of a native fragment to a heterologous sequence, recombinant vectors present as episomes or as integrated into a host cell chromosome. As used herein, the term "substantially purified", refers to nucleic or amino acid sequences that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated. As used herein, an isolated nucleic acid "encodes" a reference polypeptide when at least a portion of the nucleic acid, or its complement, can be directly translated to provide the amino acid sequence of the reference polypeptide, or when the isolated nucleic acid can be used, alone or as part of an expression vector, to express the reference polypeptide in vitro, in a prokaryotic host cell, or in a eukaryotic host cell.

"Exon", as used herein, refers to a nucleic acid sequence found in genomic DNA that is bioinformatically predicted and/or experimentally confirmed to contribute contiguous sequence to a mature mRNA transcript.

"Open reading frame" and the equivalent acronym "ORF", as used herein, refer to that portion of a transcript-derived nucleic acid that can be translated in its entirety into a sequence of contiguous amino acids. As so defined, an ORF has length, measured in nucleotides, exactly divisible by 3. As so defined, an ORF need not encode the entirety of a natural protein.

"Microarray" refers to an ordered arrangement of hybridizable array elements. The array elements are arranged so that there are preferably at least one or more different array elements, more preferably at least 100 array elements, and most preferably at least 1,000 array elements, on a 1 cm^2 substrate surface. The maximum number of array elements is unlimited, but is at least 100,000 array elements. Furthermore, the hybridization signal from each of the array elements is individually distinguishable. In a preferred embodiment, the array elements comprise polynucleotide representative of fungal-derived polynucleotide sequences.

"Modulate", as used herein, refers to a change in the activity of VeA. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional or immunological properties of VeA.

"Nucleic acid sequence" or "nucleotide sequence" or "polynucleotide sequence", as used herein, refers to an oligonucleotide, nucleotide, or polynucleotide, and fragments thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. Where "nucleic acid sequence" or "nucleotide sequence" or polynucleotide sequence" is recited herein to refer to a particular nucleotide sequence (e.g., the nucleotide sequence set forth in SEQ ID NO:2), "nucleotide sequence", and like terms, are not meant to limit the nucleotide sequence to the complete nucleotide sequence referenced but shall be understood to include fragments of the complete nucleotide sequence.

In this context, the term "fragment" may be used to specifically refer to those nucleic acid sequences which are not naturally occurring as fragments and would not be found in the natural state. Generally, such fragments are equal to or greater than 15 nucleotides in length, and most preferably includes fragments that are at least 60 nucleotides in length. Such fragments find utility as, for example, probes useful in the detection of nucleotide sequences encoding VeA.

"Sample", as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding VeA, or fragments thereof, or VeA itself may comprise a bodily fluid, extract from a cell, chromosome, organelle, or membrane isolated from a cell, a cell, genomic DNA, RNA, or cDNA (in solution or bound to a solid support, a tissue, a tissue print, and the like).

A "substitution", as used herein, refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively. The term "conservative substitution" is used in reference to proteins or peptides to reflect amino acid substitutions that do not substantially alter the activity (specificity or binding affinity) of the molecule. Typically conservative amino acid substitutions involve substitution one amino acid for another amino acid with similar chemical properties (e.g. charge or hydrophobicity). The following six groups each contain amino acids that are typical conservative substitutions for one another: 1) Alanine (A), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

"Transformation", as defined herein, describes a process by which exogenous DNA enters and changes a recipient cell. It may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. Such "transformed" cells include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome. They also include cells which transiently express the inserted DNA or RNA for limited periods of time.

A "variant" of VeA, as used herein, refers to an amino acid sequence that is altered by one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. The term also includes variations on the traditional peptide linkage joining the amino acids making up the polypeptide. Where the terms are recited herein to refer to a polypeptide, peptide or protein of a naturally occurring protein molecule, the terms are not meant to limit the polypeptide, peptide or protein to the complete, native amino acid sequence associated with the recited protein molecule but shall be understood to include fragments of the

complete polypeptide. The term "portion" or "fragment", as used herein, with regard to a protein or polypeptide (as in "a fragment of the VeA polypeptide") refers to segments of that polypeptide which are not naturally occurring as fragments in nature. The segments may range in size from five amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a polypeptide "as set forth in SEQ ID NO:1 or a fragment thereof" encompasses the full-length amino acid sequence set forth in SEQ ID NO:1 as well as segments thereof. Fragments of VeA preferably are biologically active as defined herein.

The terms "nucleic acid" or "oligonucleotide" or "polynucleotide" or grammatical equivalents herein refer to at least two nucleotides covalently linked together. A nucleic acid of the present invention is preferably single-stranded or double stranded and will generally contain phosphodiester bonds, although in some cases, as outlined below, nucleic acid analogs are included that may have alternate backbones, comprising, for example, phosphoramide (Beaucage et al. (1993) Tetrahedron 49:1925) and references therein; Letsinger (1970) J. Org. Chem. 35:3800; Sprinzl et al. (1977) Eur. J. Biochem. 81: 579; Letsinger et al. (1986) Nucl. Acids Res. 14: 3487; Sawai et al. (1984) Chem. Lett. 805, Letsinger et al. (1988) J. Am. Chem. Soc. 110: 4470; and Pauwels et al. (1986) Chemica Scripta 26: 1419), phosphorothioate (Mag et al. (1991) Nucleic Acids Res. 19:1437; and U.S. Pat. No. 5,644,048), phosphorodithioate (Briu et al. (1989) J. Am. Chem. Soc. 111:2321, O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and linkages (see Egholm (1992) J. Am. Chem. Soc. 114:1895; Meier et al. (1992) Chem. Int. Ed. Engl. 31: 1008; Nielsen (1993) Nature, 365: 566; Carlsson et al. (1996) Nature 380: 207). Other analog nucleic acids include those with positive backbones (Denpcy et al. (1995) Proc. Natl. Acad. Sci. USA 92: 6097; non-ionic backbones (U.S. Pat. Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; Angew. (1991) Chem. Intl. Ed. English 30: 423; Letsinger et al. (1988) J. Am. Chem. Soc. 110:4470; Letsinger et al. (1994) Nucleoside & Nucleotide 13:1597; Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y. S. Sanghui and P. Dan Cook; Mesmaeker et al. (1994), Bioorganic & Medicinal Chem. Lett. 4: 395; Jeffs et al. (1994) J. Biomolecular NMR 34:17; Tetrahedron Lett. 37:743 (1996) and non-ribose backbones, including those described in U.S. Pat. Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Ed. Y. S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within the definition of nucleic acids (see Jenkins et al. (1995), Chem. Soc. Rev. pp 169-176). Several nucleic acid analogs are described in Rawls, C & E News Jun. 2, 1997 page 35. These modifications of the ribose-phosphate backbone may be done to facilitate the addition of additional moieties such as labels, or to increase the stability and half-life of such molecules in physiological environments. As used herein, oligonucleotide is substantially equivalent to the terms "amplimers", "primers", "oligomers", and "probes", as commonly defined in the art.

The term "heterologous" as it relates to nucleic acid sequences such as coding sequences and control sequences, denotes sequences that are not normally associated with a region of a recombinant construct, and/or are not normally associated with a particular cell. Thus, a "heterologous" region of a nucleic acid construct is an identifiable segment of nucleic acid within or attached to another nucleic acid molecule that is not found in association with the other molecule in nature. For example, a heterologous region of a construct could include a coding sequence flanked by sequences not found in association with the coding sequence in nature. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (e.g., synthetic sequences having codons different from the native gene). Similarly, a host cell transformed with a construct which is not normally present in the host cell would be considered heterologous for purposes of this invention.

A "coding sequence" or a sequence which "encodes" a particular polypeptide (e.g. a methyltransferase, etc.), is a nucleic acid sequence which is ultimately transcribed and/or translated into that polypeptide in vitro and/or in vivo when placed under the control of appropriate regulatory sequences. In certain embodiments, the boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and even synthetic DNA sequences. In preferred embodiments, a transcription termination sequence will usually be located 3' to the coding sequence.

The term "ortholog" refers to genes or proteins which are homologs via speciation, e.g., closely related and assumed to have common descent based on structural and functional considerations. Orthologous proteins function as recognizably the same activity in different species.

Expression "control sequences" or "regulatory elements" refers collectively to promoter sequences, ribosome binding sites, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, which collectively provide for the transcription and translation of a coding sequence in a host cell. Not all of these control sequences need always be present in a recombinant vector so long as the desired gene is capable of being transcribed and translated.

"Recombination" refers to the reassortment of sections of DNA or RNA sequences between two DNA or RNA molecules. "Homologous recombination" occurs between two DNA molecules which hybridize by virtue of homologous or complementary nucleotide sequences present in each DNA molecule.

The terms "stringent conditions" or "hybridization under stringent conditions" refers to conditions under which a probe will hybridize preferentially to its target subsequence, and to a lesser extent to, or not at all to, other sequences. "Stringent hybridization" and "stringent hybridization wash conditions" in the context of nucleic acid hybridization experiments such as Southern and northern hybridizations are sequence dependent, and are different under different environmental parameters. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes. Generally, highly stringent hybridization and wash conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Very stringent conditions are selected to be equal to the Tm for a particular probe.

An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have

more than 100 complementary residues on a filter in a Southern or northern blot is 50% formamide with 1 mg of heparin at 42° C., with the hybridization being carried out overnight. An example of highly stringent wash conditions is 0.15 M NaCl at 72° C. for about 15 minutes. An example of stringent wash conditions is a 0.2×SSC wash at 65° C. for 15 minutes (see, Sambrook et al. (1989) Molecular Cloning—A Laboratory Manual (2nd ed.) Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY, for a description of SSC buffer). Often, a high stringency wash is preceded by a low stringency wash to remove background probe signal. An example medium stringency wash for a duplex of, e.g., more than 100 nucleotides, is 1×.SSC at 45° C. for 15 minutes. An example low stringency wash for a duplex of, e.g., more than 100 nucleotides, is 4-6×SSC at 40° C. for 15 minutes. In general, a signal to noise ratio of 2× (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization. Nucleic acids which do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.

"Expression vectors" are defined herein as nucleic acid sequences that are direct the transcription of cloned copies of genes/cDNAs and/or the translation of their mRNAs in an appropriate host. Such vectors can be used to express genes or cDNAs in a variety of hosts such as bacteria, bluegreen algae, plant cells, insect cells and animal cells. Expression vectors include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses. Specifically designed vectors allow the shuttling of DNA between hosts, such as bacteria-yeast or bacteria-animal cells. An appropriately constructed expression vector preferably contains: an origin of replication for autonomous replication in a host cell, a selectable marker, optionally one or more restriction enzyme sites, optionally one or more constitutive or inducible promoters. In preferred embodiments, an expression vector is a replicable DNA construct in which a DNA sequence encoding VeA or a fragment thereof is operably linked to suitable control sequences capable of effecting the expression of the products in a suitable host. Control sequences include a transcriptional promoter, an optional operator sequence to control transcription and sequences which control the termination of transcription and translation, and so forth.

A "polymorphism" is a variation in the DNA sequence of some members of a species. A polymorphism is thus said to be "allelic," in that, due to the existence of the polymorphism, some members of a species may have the unmutated sequence (i.e. the original "allele") whereas other members may have a mutated sequence (i.e. the variant or mutant "allele"). In the simplest case, only one mutated sequence may exist, and the polymorphism is said to be diallelic. In the case of diallelic diploid organisms, three genotypes are possible. They can be homozygous for one allele, homozygous for the other allele or heterozygous. In the case of diallelic haploid organisms, they can have one allele or the other, thus only two genotypes are possible. The occurrence of alternative mutations can give rise to trialleleic, etc. polymorphisms. An allele may be referred to by the nucleotide(s) that comprise the mutation.

"Single nucleotide polymorphism" or "SNPs are defined by their characteristic attributes. A central attribute of such a polymorphism is that it contains a polymorphic site, "X," most preferably occupied by a single nucleotide, which is the site of the polymorphism's variation. Methods of identifying SNPs are well known to those of skill in the art (see, e.g., U.S. Pat. No. 5,952,174).

Abbreviations used herein include "aa", amino acid; "MMG", minimal media glucose; "MMT", minimal media threonine; "OE", over expression; "LB", Luria-Bertani; "nt", nucleotide; "ORF", open reading frame; "PCR", polymerase chain reaction; "PEG", polyethyleneglycol; "R", resistant; "WT", wild-type; and "TS", temperature sensitive.

III. The Invention

The present invention provides a novel method for producing secondary metabolites by inducing the over-expression of the fungal gene veA (SEQ ID NO: 116—see FIG. **12**). Such methods include steps of: (a) obtaining a cell or an organism capable of biosynthesizing a secondary metabolite; (b) transforming the cell or organism with an nucleic acid encoding a VeA polypeptide capable of regulating biosynthesis of the secondary metabolite; and (c) culturing the transformed cell or organism so that an increase in production of the secondary metabolite occurs in the transformed cell or organism as compared to a non-transformed cell or organism.

In one embodiment of the present invention, methods of increasing the amount of a secondary metabolite as described and claimed herein are practiced in an *Aspergillus* species such as *A. nidulans. A. flavus* or *A. terreus*. Secondary metabolites increased by the methods include but are not limited to lovastatin or penicillin.

The invention also provides methods of decreasing the production of a secondary metabolite in a transformed cell or organism. Such methods include the steps of: (a) obtaining a transformed cell or organism capable of biosynthesizing a secondary metabolite, the transformed cell or organism having a defective veA gene wherein the defective veA gene is no longer biologically active and expression of secondary metabolite gene clusters is reduced; and (b) culturing the transformed cell or organism so that a decrease in production of the secondary metabolite occurs in the transformed cell or organism as compared to a non-transformed cell or organism. Such a gene replacement exercise could be carried out by one of skill in the art using techniques presently known in the field. Such a method would be useful in reducing or eliminating production of toxic secondary metabolites in certain organisms. For example, a non-functional variant of veA would be useful in reducing or eliminating aflatoxin production in an *A. parasiticus* or *A. flavus* strain transformed thereby. In addition, veA may be targeted by a therapeutic such that veA's ability to regulate secondary metabolite gene cluster activity is inhibited. This approach would provide a therapeutic compound able to reduce the virulence of cells or organisms, thereby providing a treatment for medical maladies involving fungal infections. Methods of identifying inhibitors of target molecules are well known in the art.

In yet another embodiment, the present invention encompasses methods of producing an isolated secondary metabolite. These methods include steps of: (a) obtaining a cell or an organism capable of biosynthesizing a secondary metabolite; (b) transforming the cell or organism with a nucleic acid encoding a VeA polypeptide capable of regulating biosynthesis of the secondary metabolite; (c) culturing the transformed cell or organism under conditions conducive to increasing production of the secondary metabolite in the transformed cell or organism as compared to a non-trans-

formed cell or organism; and (d) recovering the secondary metabolite from the transformed cell or organism in an isolated form.

The invention also provides methods for identifying yet undiscovered secondary metabolite biosynthesis gene clusters in a variety of fungi based on the nucleic acids and transformed cells disclosed herein. Such methods are preferably carried out in a microarray format. For example, using standard microarray technology now commonly employed in the field, one of skill in the art may construct a microarray containing, for example, nucleic acids representative of the expressed genes of wild-type *A. nidulans* (see, for example, D. Bowtell and J. Sambrook, DNA Microarrays: A Molecular Cloning Manual (2000) Cold Spring Harbor Laboratory Press and P. Baldi and G. W. Hatfield, DNA Microarrays and Gene Expression: From Experiments to Data Analysis and Modeling (2002) Cambridge University Press describing standard microarray techniques data analyses applicable in the present invention). The entire genome for *A. nidulans* has been sequenced and the sequence is available in annotated form for public use (see the Whitehead Institute/MIT Center for Genome Research website). Construction of the specific nucleic acids affixed to the array substrate may be based on, for example, an expressed sequence tag database provided by the University of Oklahoma.

Using the microarray and standard hybridization techniques known in the field, the expression levels of genes in wild-type *A. nidulans, A. flavus* or other wild-type fungus versus a veA deletion mutant may then be compared to identify genes whose expression is reduced or absent in the veA deletion mutant compared to the wild-type line. The artisan may subsequently examine the genomic sequence available of, for example, *A. nidulans* or *A. flavus* to identify putative secondary metabolite biosynthesis cluster genes in the immediate vicinity of the relevant gene whose expression is initially identified as affected by the absence of veA expression. As secondary metabolite biosynthesis genes are well known to occur in clustered fashion, as described in a plurality of references cited herein, new putative secondary metabolite gene clusters may be identified by this approach.

Further, genes within a putative gene cluster may subsequently be disrupted and the mutant line's production of secondary metabolite products may then be compared with wild-type production in plus/minus fashion to identify the specific natural product produced by the newly-identified gene cluster. The natural product may then be isolated and characterized using standard techniques described and referenced herein.

The above-described screening strategies may be carried out not only between wild-type and veA deletion mutants but also, and more preferably, between veA overexpression mutants and veA deletion mutants to obtain the greatest contrast in veA-influenced secondary metabolite biosynthesis gene expression. As well, the screening methodology described herein is not limited to any one particular fungus but may be applied to any fungus having a veA ortholog (e.g., *Aspergillus* other than *A. nidulans* and *A. flavus*). For example, the genome for *Fusarium graminearum* is now available and screens utilizing veA overexpression or disruption strains to identify new *F. graminearum* secondary metabolite gene clusters may certainly be carried out based on the novel materials and teachings provided herein (also see Whitehead Institute/MIT Center for Genomic Research website).

In another embodiment of the invention, nucleotide sequences or fragments thereof which encode VeA may be used in recombinant DNA molecules to direct expression of VeA, fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced, and these sequences may be used to clone and express VeA.

As will be understood by those of skill in the art, it may be advantageous to produce VeA-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter VeA-encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding VeA may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of VeA activity, it may be useful to encode a chimeric VeA protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the VeA encoding sequence and the heterologous protein sequence, so that VeA may be cleaved and purified away from the heterologous moiety.

In another embodiment, sequences encoding VeA may be synthesized, in whole or in part, using chemical methods well known in the art. Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of VeA, or a fragment thereof. For example, peptide synthesis can be performed using various solid-phase techniques and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer).

The newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing. Additionally, the amino acid sequence of VeA, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active VeA, the nucleotide sequences encoding VeA or functional equivalents may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding VeA and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination.

A variety of expression vector/host systems may be utilized to contain and express sequences encoding VeA. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

The "control elements" or "regulatory sequences" are those non-translated regions of the vector—enhancers, promoters, 5' and 3' untranslated regions—which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, La Jolla, Calif.) or PSPORT1 plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding VeA, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

The following examples describing materials and methodology are offered for illustrative purposes only, and are not intended to limit the scope of the present invention.

III. EXAMPLES

Example 1

In the present invention, tandem affinity purification (TAP) was used to identify VeA-interacting proteins (FIG. **1**A and FIG. **2**A). Final eluates of dark- and light-grown *A. nidulans* carrying the functional veA gene tagged at its C terminus by TAP tag (veA::ctap*) were analyzed by mass spectrometry. The velvet-like protein B (VelB) (FIG. **3**A, **3**B), the regulator LaeA, and the α importin KapA were identified as proteins that interact with VeA in the dark (FIG. **1**B and Table 4). (Importin is a type of protein that moves other protein molecules into the nucleus by binding to a specific recognition sequence, called the nuclear localization signal (NLS)).

In the light, tagged VeA protein is hardly expressed (FIG. **2**B) and only copurifies with VelB. Reciprocal affinity purifications of tagged VelB and LaeA in the dark confirmed the interaction partners, except for the α importin KapA (FIGS. **2**C and D). Only tagged VelB can additionally recruit the regulator of sporogenesis VosA in the dark, which seems to be an alternative binding partner for this protein.

Yeast two-hybrid (Y2H) analysis confirmed the VeA-VelB and VeA-LaeA interactions, where VelB and LaeA do not interact in this assay, suggesting that VeA acts as a bridge between VelB and LaeA (FIG. **1**C).

The Y2H VosA-LaeA interaction supports a role of LaeA in development (FIG. **4**). The C-terminal part of VeA interacts with LaeA, whereas the N-terminal part of VeA, which includes the nuclear localization signal (NLS), is required for interaction with VelB (FIG. **1**C and FIG. **4**).

VelB, which is conserved in the fungal kingdom, shares 18% amino acid identity with VeA but has no typical NLS (FIG. **3**B). Transcript analysis reveals that VelB expression increases like that of VeA at late developmental stages (FIG. **3**C). The VeA-LaeA and VeA-VelB interactions were visualized by bimolecular fluorescence complementation (BiFC) in living cells. Distinct fluorescent specks show that the VeA-LaeA interaction occurs in the nucleus, whereas VeA and VelB interact in the cytoplasm and within the nucleus (FIGS. **5**A and B).

The physical interaction of VeA with VelB, as well as with LaeA, leads to the novel understanding of the present invention that VeA and VelB are functionally interdependent. Similar to veAD, the velBD mutant (FIG. **6**A) no longer displays a light-dependent developmental pattern and is unable to form sexual fruit bodies, even in the dark. Asexual sporulation in velBD is impaired but not as strongly as in a veA deletion strain.

Reintroduction of the velB locus fully rescued all of the defects (FIG. **6**A). The veAD/velBD double mutant exhibited a near-identical phenotype to that of the veAD single mutant. Neither VelB overexpression in a veAD background nor VeA overexpression in a velBD background rescued the defects of the individual mutants; likewise, LaeA overexpression could not rescue secondary metabolite defects of veAD (FIG. **7**).

Unlike overproduction of VeA, overexpression of VelB in a veA+ background does not cause excessive production of cleistothecia, but it induces a twofold increase in asexual sporulation in comparison to the wild type (WT). This suggests that VeA controls the number of sexual structures, whereas VelB has additional developmental functions. Secondary metabolism is impaired in veAD, resulting in a similar brownish pigment as is produced by the velBD strain.

Changes in gene expression and in LaeA activity were monitored in the veAD and velBD strains (FIGS. **5**C and D, FIGS. **6**B and C, and FIG. **8**). ST production is abolished in veAD and laeAD strains. In contrast, reduced and delayed but significant ST production in VelBD suggests residual activity of a VeA/LaeA complex in the dark. VeA is enriched in the nucleus in the dark, whereas VelB was found in both the nucleus and the cytoplasm and is hardly affected by illumination (FIGS. **9**A and B).

Because LaeA is constitutively nuclear (FIGS. **9**A and B) and the interaction of VeA and LaeA occurs in the nucleus (FIG. **5**A), VelB has to enter the nucleus, despite the lack of an obvious NLS to fully control LaeA. Localization of the VelB-sGFP fusion protein (where GFP is green fluorescent protein) in a veAD background is shifted toward the cytoplasm, whereas the presence of VeA increases the nuclear localization of VelB (FIGS. **10**A and B).

This suggests that VeA can assist VelB to allow an enhanced transport into the nucleus. The data provided herein suggest that the mechanism underlying the coordinated regulation of sexual development and secondary metabolism in *A. nidulans* is the interaction between the key developmental regulatory complex VelB/VeA and LaeA.

Accordingly, in the dark the VelB/VeA/LaeA velvet complex interaction controls and presumably supports the epigenetic activity of LaeA, which subsequently controls the expression of secondary metabolite gene clusters. In the

light, this interaction is diminished because less VeA protein is present, and the entrance of the bridging factor VeA to the nucleus is decreased.

Because the absence of LaeA has a minor impact on development, VeA and VelB have presumably additional functions in fungal differentiation. This is also supported by the identification of VosA, a recently identified regulator of fungal sporogenesis, as an additional binding partner of VelB (FIGS. **2**C and D, and Table 4).

Light triggers asexual development, corresponding to the release of high numbers of asexual spores (conidia) into the environment. These phenotypes correlate with the light-dependent cytoplasmic localization of VeA, the constitutive nuclear function of LaeA, and the partial nuclear localization of VelB, respectively. Under light conditions, when low amounts of VeA and VelB are present in the nucleus, the secondary metabolism regulator LaeA seems to be primarily active in those hyphae that are not exposed to light.

Accordingly, the deletion of laeA results in a loss of mycelial pigmentation at the bottom of the colony. The newly described fungal protein VelB, in conjunction with VeA, connects light-dependent development to LaeA-controlled secondary metabolism in *A. nidulans*. The inventors herein present evidence that the formation of this complex is the molecular basis that synchronizes developmental and metabolic changes to the disappearance of light.

This trimeric complex is designated the "velvet complex". The VelB/VeA is part of the epigenetic control of chromatin remodeling by modulating LaeA methyltransferase activity (FIG. **10**C), in which VeA is functionally active in the dark, forms a complex with increased amounts of VelB, and enhances the transport of VelB to the nucleus.

Because VeA and VelB are both partially nuclear, even in the light, we presume a certain threshold is probably necessary to initiate sexual development and control LaeA. Fungal morphogenesis and secondary metabolism have traditionally been viewed as separate fields. The VelB/VeA/LaeA velvet complex elucidates the molecular mechanisms underlying the intimate relation between fungal development and secondary metabolism.

Strains, media, and growth conditions. Fungal strains used in this study are listed in Table 1.

TABLE 1

Fungal Strains.

Strain	Genotype
Aspergillus nidulans	
FGSC4	Glasgow wild-type
FGSC26	biA1, veA1
FGSC33	biA1; pyroA4, veA1
DVAR1	pabaA1, yA2; argBΔ::trpC; trpC801; veAΔ::argB
AGB154	pabaA1
AGB272	pveA::veA, ptrA; pabaA1, yA2; argBΔ::trpC; trpC801, veAΔ::argB
AGB273	pveA::veA::ctap* tag, ptrA; pabaA1, yA2; argBΔ::trpC; trpC801, veAΔ::argB
AGB274	pveA::veA::sgfp, ptrA; pgpdA::mrfp::h2A, pgpdA::natR; pabaA1, yA2; argBΔ::trpC; trpC801, veAΔ::argB
AGB275	pniiA::velB::sgfp::niiAT, pgpdA::natR; pabaA1, yA2; argBΔ::trpC; trpC801, veAΔ::argB
AGB276	pniiA::velB::niiAT, pgpdA::natR; pabaA1, yA2; argBΔ::trpC; trpC801, veAΔ::argB
AGB152	pyroA4, pyrG89, veA
AGB277	pniiA::velB::sgfp::niiAT, A.f. pyrG; pgpdA::mrfp::h2A, pgpdA::natR; pyroA4, pyrG89
AGB278	pniiA::velB::niiAT, A.f. pyrG; pyroA4, pyrG89
TNO2A3	pyrG89, pyroA4
AGB279	velBΔ::ptrA; pyrG89, pyroA4, argB2; nkuAΔ::argB
AGB280	pvelB::velB, pgpdA::natR; velBΔ::ptrA; pyrG89, pyroA4, argB2; nkuAΔ::argB
AGB281	pniiA::velB::sgfp::niiAT, A.f. pyrG; velBΔ::ptrA; pyrG89, pyroA4, argB2; nkuAΔ::argB
AGB282	pveA::veA::sgfp, pgpdA::natR; velBΔ::ptrA; pyrG89, pyroA4, argB2; nkuAΔ::argB
AGB283	pniiA::veA::niiAT, A.f. pyrG; velBΔ::ptrA; pyrG89, pyroA4, argB2; nkuAΔ::argB
AGB284	pniiA::velB::niiAT, pgpdA::natR; pabaA1, yA2; argBΔ::trpC; trpC801; veAΔ::argB
AGB307	pniiA::nyfp::veA::niiAT- pniaD::cyfp::laeA::niaDT, A.f. pyrG; pgpdA::mrfp::h2A, pgpdA::natR; pyroA4, pyrG89
AGB308	pniiA::laeA::sgfp::niiAT, pgpdA::natR
AGB310	pniiA::laeA::sgfp::niiAT, pgpdA::natR; pabaA1, yA2; argBΔ::trpC; trpC801; veAΔ::argB
AGB311	pniiA::laeA::sgfp::niiAT, pgpdA::natR; velBΔ::ptrA; pyrG89, pyroA4, argB2; nkuAΔ::argB
AGB388	pniiA::nyfp::veA::niiAT- pniaD::cyfp::velB::niaDT, A.f. pyrG; pgpdA::mrfp::h2A, pgpdA::natR; pyroA4, pyrG89

TABLE 1-continued

Fungal Strains.

Strain	Genotype
AGB389	velB::ctap*::pgpdA::natR
AGB390	laeA::ctap*::pgpdA::natR
RNI16.1	pyrG89, pyroA4; nkuAΔ::argB; veA1
TNI7.2	velBΔ:: pyrG; pyrG89, pyroA4; nkuAΔ::argB; veA1
RRAW16	pyrG89, yA2; veA
RNI18.2	velBΔ:: pyrG; veA
RDIT9.32	wild type
RJW41.A	laeAΔ::metG; veA
RJW106.1	velBΔ::pyrG; laeAΔ::metG, veA
RJW108.1	veAΔ::argB; trpC::laeA
RJW112.2	veAΔ::argB
RJW114.11	vosAΔ::argB; laeAΔ::metG, veA
RJW116.2	vosAΔ::argB; veA
RJW117.18	veAΔ::argB; laeAΔ::metG
Saccharomyces cerevisiae	
EGY48-p1840	MATa his3 trp1 ura3-52 leu2::3LexAop-LEU2 LexAop-LacZ/URA3

A. nidulans TNO2A3 which displays a veA+ phenotype served as wild-type for the velB deletion, AGB152 and DVAR1 were used for overexpression experiments. A velB gene replacement cassette comprising 2 kb of velB upstream and downstream flanking regions and the pyrithiamine resistance gene ptrA as selection marker was created (FIG. **11**A) and introduced into the nkuAΔ background strain TNO2A3. The velB deletion mutant TNI7.2 was generated by transforming RNI16.1 with the velB deletion construct with pyrG+. RNI18.2 (ΔvelB; veA+) was isolated from a meiotic cross between RRAW16 and TNI7.2. velB and laeA loci were TAP tagged in nkuAΔ background strain TNO2A3 by using clonNat resistance.

Correct gene replacement was confirmed by Southern analyses (FIG. **11**A-C). AGB389 (veA+, velB::ctap*) and AGB390 (veA+, laeA::ctap*) strains were obtained from a meiotic cross between TNO2A3 and AGB154. *E. coli* DH5α and MACH-1 (INVITROGEN) were applied for plasmid DNA and were propagated in LB medium (1% tryptone, 0.5% yeast extract, 1% NaCl) supplemented with 100-150 $\mu g \cdot ml^{-1}$ ampicillin. The bacterial strain KS272 for recombinogenic engineering was propagated in low-salt (0.5% NaCl) LB medium with 25 $\mu g \cdot ml^{-1}$ chloramphenicol. Minimal medium (0.52 $g \cdot l^{-1}$ KCl, 0.52 $g \cdot l^{-1}$ MgSO4, 1.52 $g \cdot l^{-1}$ KII2PO4, 0.1% trace element solution, pII6.5) was used for growth of fungal strains, supplemented with appropriate amounts of 4-aminobenzoic acid (PABA, 1 $\mu g \cdot ml^{-1}$), Biotin (0.02 $\mu g \cdot ml^{-1}$), Uracil (50 $\mu g \cdot ml^{-1}$), Pyridoxine (0.05 $\mu g \cdot ml^{-1}$), nourseothricin-dihydrogen sulfate (100-120 $\mu g \cdot ml^{-1}$) (clonNAT, WERNER BIOAGENTS), pyrithiamine (TAKARA Bio Inc) (0.1 $\mu g \cdot ml^{-1}$); 1% D-glucose was used as the source of carbon together with 10 mM ammonium or nitrate as nitrogen source. For TAP experiments, fungal strains were grown in complete medium (0.5% yeast extract, 1% bacto-peptone, 1% glucose). Sterigmatocystin (ST) production of strains was assayed as described.

Transformation Procedures.

E. coli and *A. nidulans* cells were transformed as described.

Plasmid Constructions Details.

The plasmids utilized in this work are listed in Table 2, oligonucleotide sequences are given in Table 3.

TABLE 2

Plasmid Constructs.

Plasmid	Description & Characteristics
pPTRII	autonomously replicating *Aspergillus* plasmid [ptrA, AMA1, bla]
pPTRII	Cloning vector for the construction of LexA DNA binding domain
pGAD424	Cloning vector for the construction of GAL4 activation domain
pNJ04	veA ORF in pTLexA
pNJ05	veA ORF in pGAD424
pNJ06	veA N-terminal (1-300a.a.) in pGAD424
pNJ07	veA C-terminal (276-stop.) in pGAD424
pNJ08	veA1 ORF in pTLexA
pNJ09	veA1 ORF in pGAD424
pNJ10	veA1 N-terminal (1-265a.a.) in pGAD424
pNJ11	vosA ORF in pGAD424
pNJ12	vosaA-F239 (1-239a,a) in pGAD424
pNJ13	vosA C-terminal (211a.a-stop) in pGAD424
pNJ14	laeA ORF in pTLexA
pNJ15	laeA-F231 (1-231a.a.) in pTLexA
pNJ16	laeA-121R (121a.a.-stop) in pTLexA
pNJ17	laeA ORF in pGAD424
pNJ18	laeA-F231 (1-231a.a.) in pGAD424
pNJ19	laeA-121R (121a.a.-stop) in pGAD424
pNJ20	velB ORF in pTLexA
pNJ21	velB-F231 (1-231 a.a) in pTLexA
pNJ22	velB-142R (142a.a.-stop) in pTLexA
pNJ23	velB ORF in pGAD424
pNJ24	velB-F231 (1-231 a.a) in pGAD424
pNJ25	velB-142R (142a.a.-stop) in pGAD424
pNV1	Dominant resistance cloning plasmid
pME3024	ptrA cassette with SfiI sites in EcoRV site of pBluescript II KS
pME3154	veA C-Terminus::ctap* tag::veA 3' UTR in pGEM5
pME3155	veA 4.6 kb HindIII genomic fragment in pUC19
pME3156	pveA::veA::ctap* tag in pUC19
pME3157	pveA::veA::ctap* tag, ptrA, in pUC19
pME3158	velB deletion cassette [velB::ptrA]
pME3159	5 kb velB genomic locus amplicon in ApaI site of pNV1
pME3160	Expression module niiAt -pniiA|pniaD-niaDt-Af pyrG, bla
pME3161	pniiA::veA cDNA in PmeI site of pME3160
pME3162	pniiA::velB cDNA in PmeI site of pME3160
pME3163	pniiA::velB::sgfp in PmeI site of pME3160
pME3164	pniiA::velB cDNA in PmeI site of pME3166 expression module

TABLE 2-continued

Plasmid Constructs.

Plasmid	Description & Characteristics
pME3165	pniiA::velB::sgfp in PmeI site of pME3166 expression module
pME3166	Expression module 2.6 kb amplicon from pME3160 with primers Sv315/318 in ApaI site of pNV1
pME3167	pveA::veA::sgfp, pgpdA::natR in pUC19
pME3168	pveA::veA::sgfp in pUC19
pME3169	pveA::veA::sgfp, ptrA in pUC19
pME3173	pgpdA::intron::mrfp::h2A cDNA in EcoRV and pgpdA::natR in SmaI of pBluescript II KS
pME3178	veA 4.6 kb HindIII genomic fragment in HindIII and ptrA in NotI site of pBluescript II KS
pME3188	pniiA::n-eyfp::veA cDNA in PmeI, and pniaD::c-eyfp::laeA cDNA in SwaI site of pME3160 expression module
pME3189	pniiA::n-eyfp::veA cDNA in PmeI, and pniaD::c-eyfp::velB cDNA in SwaI site of pME3160 expression module
pME3190	pniiA::laeA::sgfp in PmeI site of pME3166 expression module

pBluescript II KS (STRATAGENE) and pUC19 (FERMENTAS) were used as cloning plasmids. The plasmid pME3156 containing veA::ctap* tag fusion was constructed by recombineering an 800 bp EarI fragment comprising a C-terminal fusion of the TAP* tag (FIG. **2**A) to the veA coding sequence derived from pME3154 with NaeI-linearised pME3155 in *E. coli*. Recombineering is genetic engineering based on homologous recombination in an *E. coli* host strain expressing phage-derived proteins. In order to create pME3157, a ptrA pyrithiamine resistance cassette was amplified with oligonucleotides Sv129/130 from pPTRII (TAKARA) and inserted into the SmaI site of pME3156, and the final construct was used in tandem affinity purification experiments.

The veA::sgfp fusion in pME3168 was created by replacing the C-TAP* tag module in pME3154 by an OZG28/29-amplified sgfp fragment digested with NcoI/HindIII. pME3168 was digested with SmaI and a blunt ptrA (Sv129/130) was inserted resulting in pME3169. The Gpd1/Nat2-amplified 1.4 kb pgpdA::natR cassette from pNV1 was cloned into SmaI of pME3168 creating pME3167. To create a velB deletion construct, a 2 kb upstream flanking region was amplified (OZG57/58) and inserted into the EcoRV site of pBluescript KS II (STRATAGENE). The resulting plasmid was then used for insertion of a 2 kb velB downstream flanking region (OZG59/60) into SmaI site, which was then digested with SfiI to insert the SfiI-released ptrA marker from pME3024 generating pME3158, from which a 5.9 kb replacement cassette was used for deletion of velB locus.

For complementation, pME3159 was created by cloning a 5 kb velB genomic fragment (OZG99/100) in the ApaI site of pNV1. For overexpression and localization experiments, the nitrogen source-dependent expression module of pME3160 was exploited, which contains the *A. nidulans* niiA/niaD intergenic region flanked by the corresponding termination regions to allow expression of two genes in a bidirectional orientation at the same time. The veA and velB cDNAs were amplified and cloned into the PmeI site of pME3160 yielding pME3161 veA and pME3162 velB overexpression constructs, respectively.

The velB cDNA::sgfp fusion construct was created by fusion PCR with OZG63/116 for velB and OZG115/29 for sgfp. To create a dominant expression module, the expression module (niiAT::pniiA/pniaD::niaDT) of pME3160 was amplified with Sv315/318 and cloned into ApaI-digested flushed pNV1 to yield pME3166. The velB cDNA and velB cDNA::sgfp recombinant DNA fragments were cloned into the PmeI site of pME3166. To obtain the pgpdA::mrfp::h2A construct, the gpdA promoter and intron (Sv337/338), mrfp (Sv339/340), h2A cDNA containing terminator (Sv339/340) were amplified. Final products were fused using the double joint PCR procedure. The pgpdA::mrfp::h2A recombinant fragment was cloned into the EcoRV site of pBluescript KS II followed by pgpdA::natR cassette insertion into the SmaI site yielding pME3173. The n-eyfp::veA and c-eyfp::laeA fusion constructs were cloned into the PmeI and SwaI sites of the pME3160, respectively.

For in vivo interaction analyses, n-eyfp (OZG73/74) and veA cDNA (Sv142/143, same as OZG69/70 without restriction sites) were amplified and fused and combined with c-eyfp (OZG75/76) and laeA cDNA (OZG61/62) in plasmid pME3188 and ceyfp (OZG75/77) with velB cDNA (OZG63/64) in pME3189, respectively. The appropriate neyfp::veA, c-eyfp::laeA or c-eyfp::velB fusion constructs were cloned into the PmeI and SwaI sites of pME3160.

For the construction of the laeA::sgfp fusion plasmid (pME3190), laeA cDNA (OZG61/162) and sgfp (OZG29/161) were amplified, fused and inserted into the PmeI site of the pME3166 expression module under the niiA promoter.

For construction of the velB and laeA TAP* tag fragments, velB including 400 bp of the 5' UTR (OZG210/211) and laeA including 400 bp of the 5' UTR (OZG201/202), velB 1.6 kbp 3'UTR (OZG211/100) and laeA 1.6 kbp 3'UTR (OZG204/205) were amplified from genomic DNA.

These fragments were fused to the ctap*::natR module by fusion PCR, which creates the 5'UTR::velB::ctap*::natR::3'UTR (OZG223/224) and 5'UTR::laeA::ctap*::natR::3'UTR (OZG221/222) gene replacement fragments, respectively.

To confirm protein-protein interaction by a yeast two-hybrid assay, the ORF, N-terminal and C-terminal regions of each gene product were amplified by PCR (Table 3) from an *A. nidulans* cDNA library provided by Kwang-Yeop Jahng (Chonbuk University, Jeonju, Korea). The PCR product of each gene was digested with EcoRI and SalI or XhoI and cloned into the pTLexA or pGAD424 vector, respectively.

TABLE 3

Oligonucleotides utilized for plasmid generations.

Designation	Sequence	Feature
OZG28	5'-TTT GGC CAT GGG TGG TAG CGG TGG TAT GGT GAG CAA GGG CGA GGA GCT G-3' (SEQ ID NO: 1)	sgfp-GGSGG Spacer (NcoI)
OZG29	5'-AAA ATT TAA GCT TCT ACT TGT ACA GTT CGT CCA TGC CGT G-3' (SEQ ID NO: 2)	sgfp 3'end (HindIII)
OZG57	5'-ACT CAC GAA TCC ACG GGA TAC AT-3'(SEQ ID NO: 3)	velB 5'UTR-A

TABLE 3-continued

Oligonucleotides utilized for plasmid generations.

Designation	Sequence	Feature
OZG58	5'-GGC CTG AGT GGC CGG GTG GGA TAC GGT CCA TCG AAA-3' (SEQ ID NO: 4)	velB 5'UTR-B (sfiI)
OZG59	5'-GGC CAT CTA GGC CGA CCG TAT ATT GTT TCA TAA ATC CTT-3' (SEQ ID NO: 5)	velB 3'UTR-A (sfiI)
OZG60	5'-TAT GAC CGC GTG AGC AAA TAG GAC-3'(SEQ ID NO: 6)	velB 3'UTR-B
OZG61	5'-ATG TTT GAG ATG GGC CCG GTG GG-3'(SEQ ID NO: 7)	laeA start
OZG62	5'-TTA TCT TAA TGG TTT CCT AGC CTG GT-3'(SEQ ID NO: 8)	laeA stop
OZG63	5'-ATG TAC GCT GTT GAG GAT AGG GC-3'(SEQ ID NO: 9)	velB start
OZG64	5'-TTA GTA TTC GTT ATC CAG ACC ATC G-3'(SEQ ID NO: 10)	velB stop
OZG68	5'-CTC GAG TTA GTA TTC GTT ATC CAG ACC ATC G-3' (SEQ ID NO: 11)	velB start (XhoI)
OZG69	5'-CCA TGG ATG GCT ACA CTT GCA GCA CCA CCA-3' (SEQ ID NO: 12)	veA start (NcoI)
OZG70	5'-CTC GAG TTA ACG CAT GGT GGC AGG CTT TGA GA-3' (SEQ ID NO: 13)	veA stop(XhoI)
OZG73	5'-ATG GTG AGC AAG GGC GAG GAG-3'(SEQ ID NO: 14)	n-eyfp start
OZG74	5'-GGT GGT GGT GCT GCA AGT GTA GCC ATC GTG GCG ATG GAG CGC ATG ATA TAG-3'(SEQ ID NO: 15)	n-eyfp::veA fusion maker
OZG75	5'-ATG GCC GAC AAG CAG AAG AAC-3(SEQ ID NO: 16)	c-eyfp start
OZG76	5'-ACG AGT TCC CAC CGG GCC CAT CTC AAA CAT GTG GTT CAT GAC CTT CTG TTT CAG-3'(SEQ ID NO: 17)	c-eyfp::laeA fusion maker
OZG77	5'-GGA ATG CGC CCT ATC CTC AAC AGC GTA CAT GTG GTT CAT GAC CTT CTG TTT CAG-3'(SEQ ID NO: 18)	c-eyfp velB
OZG98	5'-TTT GAA TTC ATG CAG CAG CCC AAG CGC GCG AGA G-3' (SEQ ID NO: 19)	veA1 start
OZG99	5'-AAA GGG CCC CGA GAA TGT CCG CCT GAC CCG TGC-3' (SEQ ID NO: 20)	velB complement-A (ApaI)
OZG100	5'-CCA AGT CTG CCC GAC AAG CTC ACT G-3'(SEQ ID NO: 21)	velB complement-B
OZG115	5'-CGC CAC AGC GAC GAG GAC GAT GGT CTG GAT AAC GAA TAC GGT GGT AGC GGT GGT ATG GTG AGC AAG-3' (SEQ ID NO: 22)	velB::sgfp fusion maker
OZG116	5'-GTA TTC GTT ATC CAG ACC ATC GTC-3'(SEQ ID NO: 23)	velB nostop codon
OZG161	5'-CTG CAC ATA TAC CAG GCT AGG AAA CCA TTA AGA GGT GGT AGC GGT GGT ATG GTG AGC-3'(SEQ ID NO: 24)	laeA::sgfp fusion maker
OZG162	5'-TCT TAA TGG TTT CCT AGC CTG GTA-3'(SEQ ID NO: 25)	laeA nostop codon
OZG201	5'-CCT CGC CCT CCT GCA TCA ATA TTC GG-3'(SEQ ID NO: 26)	laeA 5'UTR
OZG202	5'-GAG ACG GCT ATG AAA TTC TTT TTC CAT CTT CTC TTA CCA CCG CTA CCA CCT CTT AAT GGT TTC CTA GCC TGG TAT ATG-3' (SEQ ID NO: 27)	laeA ctap* fusion maker
OZG204	5'-GAG CAG GCG CTC TAC ATG AGC ATG CCC TGC CCC TGA GAG CAA AAG GCG ACC ACA TCC AGG-3'(SEQ ID NO: 28)	laeA 3'UTR-A (fusion maker)
OZG205	5'-TCG TCA ACC GCC TCA GCT GGA ACC-3'(SEQ ID NO: 29)	laeA 3'UTR-B
OZG210	5'-CCT CCT CGC CGC CTC TAG TAC CGT C-3'(SEQ ID NO: 30)	velB 5'UTR
OZG211	5'-GAA ATT CTT TTT CCA TCT TCT CTT ACC ACC GCT ACC ACC GTA TTC GTT ATC CAG ACC ATC GTC C-3'(SEQ ID NO: 31)	velB ctap* fusion maker
OZG212	5'-CGA GCA GGC GCT CTA CAT GAG CAT GCC CTG CCC CTG AAG ACC GTA TAT TGT TTC ATA AAT CC-3'(SEQ ID NO: 32)	velB 3'UTR-A (fusion maker)

TABLE 3-continued

Oligonucleotides utilized for plasmid generations.

Designation	Sequence	Feature
OZG221	5'-CGG CTG TTT ACA TTG TGT TTT CTG G-3'(SEQ ID NO: 33)	laeA-NEST-A for fusion
OZG222	5'-CCG TGA AGA ACT TGG CGT TGT AG-3'(SEQ ID NO: 34)	laeA-NEST-B for fusion
OZG223	5'-GGA CCG TCT AAT TCA ACT CAC AG-3'(SEQ ID NO: 35)	velB-NEST-A for fusion
OZG224	5'-CTT CCA GCG GTT ATC CTC CGT TG-3'(SEQ ID NO: 36)	velB-NEST-A for fusion
Sv129	5'-ATC TGA CAG AGC GGC CGC AAT TGA TTA CG-3' (SEQ ID NO: 37)	ptrA-A
Sv130	5'-ATA TAT GCG GCC GCT CTT GCA TCT TTG TTT-3' (SEQ ID NO: 38)	ptrA-B
Sv315	5'-GAT ACC AAA CGG AAC TGG CTG TTA TGG-3'(SEQ ID NO: 39)	expression module A
Sv318	5'-ATC GAC GCA ACC ATC GAA GCA GC-3'(SEQ ID NO: 40)	expression module B
Sv337	5'-GAT CTT TGC CCG GTG TAT GAA ACC-3'(SEQ ID NO: 41)	gpdA promoter A (-432)
Sv338	5'-TCG GAG GAG GCC ATG GTG ATG TCT GCT CAA GC-3' (SEQ ID NO: 42)	gpdA promoter B
Sv339	5'-GAC ATC ACC ATG GCC TCC TCC GAG GAC GTC ATC-3' (SEQ ID NO: 43)	mrfp start
Sv340	5'-GGC TCC AGC GCC TGC ACC AGC TCC GGC GCC GGT GGA GTG GCG GC-3'(SEQ ID NO: 44)	mrfp stop
Sv341	5'-GGA GCT GGT GCA GGC GCT GGA GCC ACT GGC GGC AAA TCT GGT GG-3'(SEQ ID NO: 45)	h2A start
Sv342	5'-ATC TGG AGG GGA CAG GCA GTT TAT-3'(SEQ ID NO: 46)	terminator for h2A
GpdA	5'-GGG TTT CGA ACT ACA TCA AGG GTC CAA GAC CGA CAT CGA GGC TCT GTA CAG TGA CCG GTG-3'(SEQ ID NO: 47)	gpdA promoter
Nat2	5'-AGG GAA TTC TCA GGG GCA GGG CAT GC-3'(SEQ ID NO: 48)	natR stop
OMN131	5'-GAA GGT CGA TGA TGG TGT GAT G-3'(SEQ ID NO: 49)	velB 5' amplify
OMN132	5'-CTA GAG GTA AAG ATC AAG GTA G-3'(SEQ ID NO: 50)	velB 3' amplify
OMN133	5'-CTG ATG GCT GAA TGA AGC ACA G-3'(SEQ ID NO: 51)	velB 5' nested
OMN134	5'-TGC TTT ACG ACG ATA GCC ATG C-3'(SEQ ID NO: 52)	velB 3' nested
OMN135	5'-**ggtg aag agc att gtt tga ggca** GCG GCC AGT CTT TAG ACA AAT G-3'(SEQ ID NO: 53)	velB 5' rev with pyrG tail (bold)
OMN136	5'-**agt gcc tcc tct cag aca gaa ta** GGA TAA CGA ATA CTA AAG ACC G-3'(SEQ ID NO: 54)	velB 3' for with pyrG tail (bold)
OMN125	5'-TAT GCA CTG GCA CTC AAG CAA CCG-3'(SEQ ID NO: 55)	velB forward primer for probe
OMN126	5'-GTG CAT GAC GGT CGT ATC TGG TCC-3'(SEQ ID NO: 56)	velB reverse primer for probe
OKH181	5'-GGC TGT AGT CGC TTT GTT-3'(SEQ ID NO: 57)	veA forward primer for probe
OKH182	5'-GCC CAG TGT AAG AAA GGA-3'(SEQ ID NO: 58)	veA reverse primer for probe
OJA242	5'-GCT GTC GAT CTT TGT ACC CTG-3'(SEQ ID NO: 59)	laeA forward primer for probe
OJA243	5'-CGT TCC TGG ATG TGG TCG CCT-3'(SEQ ID NO: 60)	laeA reverse primer for probe

TABLE 3-continued

Oligonucleotides utilized for plasmid generations.

Designation	Sequence	Feature
oNK11	5'-ATATAAGCTTAATGGCTACACTTGCAGCACCAC-3' (SEQ ID NO: 61)	veA forward for Y2H
oNK12	5'-ATAT**GTCGACTT**AACGCATGGTGGCAGGCTTTG-3' (SEQ ID NO: 62)	veA reverse for Y2H
oNK13	5'-ATAT**AAGCTT**AATGCAGCAGCCCAAGCGCGCGAG-3' (SEQ ID NO: 63)	veA1 forward for Y2H
oNK14	5'-ATAT**GAATTCAT**GAGTGCGGCGAACTATCCAG-3' (SEQ ID NO: 64)	vosA forward for Y2H
oNK15	5'-ATAT**GTCGACT**CACCGAGGAGTTCCGTTCGCTG-3' (SEQ ID NO: 65)	vosA reverse for Y2H
oNK32	5'-ATATGAATTCATGTTTGAGATGGGCCCGGTGGGAAC-3' (SEQ ID NO: 66)	laeA forward for Y2H
oNK33	5'-ATATGTCGACTTATCTTAATGGTTTCCTAGCCTG-3' (SEQ ID NO:67)	laeA reverse for Y2H
oNK74	5'-ATAT**AAGCTTAT**CAACGAGCATCAGCACAAAC-3' (SEQ ID NO:68)	veA C-terminal forward for Y2H
oNK75	5'-ATAT**GTCGAC**TCCATATTCCACTGCCGACGGAC-3' (SEQ ID NO:69)	veA N-terminal reverse for Y2H
oNK76	5'-ATAT**GAATTC**TCTGATAGGACAGCCATGCAAATC-3' (SEQ ID NO:70)	vosA C-terminal forward for Y2H
oNK78	5'-ATAT**GAATTCATGT**ACGCTGTTGAGGATAG-3'(SEQ ID NO:71)	velB forward for Y2H
oNK79	5'-ATAT**GTCGACTT**AGTATTCGTTATCCAGACCA-3'(SEQ ID NO:72)	velB reverse for Y2H
oNK130	5'-ATAT**GAATTC**ACGGTAGCGCGGGTATCGGAG-3'(SEQ ID NO:73)	laeA-121R forward for Y2H
oNK132	5'-ATAT**GAATTCATGT**CTTCATCGTATCCACCAC-3'(SEQ ID NO:74)	velB-142R forward for Y2H
oNK138	5'-ATAT**CTCGAG**ACCAGGCACCGGGACGGAGATG-3'(SEQ ID NO:75)	laeA-F231 reverse for Y2H
oNK140	5'-ATAT**CTCGAG**AGTAGGAATAGTCCCTACTCGTG-3'(SEQ ID NO:76)	vosA-F239 reverse for Y2H
oNK141	5'-ATATCTCGAGTCCAGGCCCTGGAGTAACTGGCTG-3'(SEQ ID NO:77)	velB-F231 reverse for Y2H
jwbvelBF	5'-TTCGCTAGACAGCTCATTCTACG-3'(SEQ ID NO:78)	velB forward primer for probe
jwbvelBR	5'-TAGTATTCGTTATCCAGACCATCG-3'(SEQ ID NO:79)	velB reverse primer for probe
jwbvelAF	5'-ATACCTGGATAAACCAAATCGAGC-3'(SEQ ID NO:80)	veA forward primer for probe
jwbvelAR	5'-AGGTTCATTCGCAGGGCTAGAC-3'(SEQ ID NO:81)	veA reverse primer for probe
jwblaeAF	5'-ACCACTACAGCTACCACTCTCC-3'(SEQ ID NO:82)	laeA forward primer for probe
jwblaeAR	5'-TTTCGATGCTCTCTGAGACGGC-3' (SEQ ID NO: 83)	laeA reverse primer for probe

Yeast Two-Hybrid Analysis.

pTLex (Cho et al., 2003; kindly provided by Suhn-Kee Chae at Paichai University, Daejeon, Korea) derived bait and pGAD424 (CLONTECH) derived prey constructs were cotransformed into the *Saccharomyces cerevisiae* reporter strain L40 and transformants were selected on -UTL (-ura, -trp, -leu) containing 2% glucose media. To further confirm the interactions of proteins, several transformants of each combination were tested for their coloration on the medium -UTL containing X-Gal, and the transformants were tested for β-galactosidase activity using the yeast β-galactosidase assay kit (PIERCE).

Recombinant DNA Procedures, Hybridization Techniques and Analysis of Nucleic Acids.

For recombinant DNA technology, standard protocols were performed. Taq, Pfu (MBI FERMENTAS) and Platinum Taq DNA polymerase (INVITROGEN) were used in PCR reactions, and cloning steps were confirmed by sequencing. Fungal genomic DNA was prepared from ground mycelia, and Southern blot analyses were conducted as described. Total RNA samples were analyzed by Northern hybridization as described. The STRATAGENE Prime-It II kit was used to radioactively label hybridization probes in the presence of [α-32P]dATP.

To produce autoradiographs, washed membranes were exposed to KODAK X-Omat films. Sequence data were analyzed using the LASERGENE software package from DNASTAR, and alignments were created by the Clustal W method. PEST motifs were analyzed on the web tool and NES patterns were identified on the web tool.

TAP Purification.

The fungal strains AGB272, AGB273 (veA::ctap*), AGB389 (velB::ctap*) and AGB390 (laeA::ctap*) were grown in liquid culture and transferred onto CMM (minimal medium+0.1% casein hydrolysate) plates, wrapped with parafilm and covered with aluminium foil to induce sexual development or were transferred onto MM and incubated under white fluorescent light without wrapping.

At 48 h post induction of sexual and 24 h post induction of asexual development, the differentiating mycelia were ground in liquid nitrogen to prepare crude extracts in B* buffer (100 mM Tris-HCl pH7.6, 250 mM NaCl, 10% glycerol, 0.05% NP-40, 1 mM EDTA, 2 mM DTT) supplemented with an EDTA-free protease inhibitors mix (ROCHE), phosphatase inhibitors (MERCK) and specified protease inhibitors as recommended in the procedure at the NCRR.

Crude extracts were centrifuged for 20 min at 15000 g and transferred into 50 ml falcon tubes. Protein extracts were incubated for 3 h on a rotator with 300 μl of IgG sepharose 6 Fast Flow (AMERSHAM) at 4° C. After that point, the standard protocol (Step 14) as outlined at the NCRR web site was followed with minor modifications. TEV cleavage was executed under rotation using 350U of AcTEV (INVITROGEN) in the presence of 1 μM E-64 (CALBIOCHEM) protease inhibitor at 4° C. for 5 h; 1 mM PMSF (phenylmethanesulfonylfluoride) was included in the calmoduline binding step on affinity resin (STRATAGENE). The TCA (trichloroacetic acid)-precipitated eluate was loaded onto a 10% polyacrylamide gel and stained with Coomassie Brilliant Blue G (Sigma). Protein bands were cut out and submitted for mass spectrometry.

Immunoblotting.

For detection of the VeA::TAP* fusion protein and actin, anti-calmodulin binding peptide antibody (UPSTATE, catalog 07-482) and anti-actin antibody (MP Biomedicals, catalog 69100) were used.

LC-MS/MS Protein Identification.

Excised polyacrylamide gel pieces of stained protein bands were digested with trypsin according to Shevchenko et al. Tryptic peptides extracted from each gel slice were injected onto a reversed-phase liquid chromatographic column (Dionex-NAN75-15-03-C18 PM) by using the ultimate HPLC system (Dionex, Amsterdam, Netherlands) to further reduce sample complexity prior to mass analyses with an LCQ DecaXP mass spectrometer (ThermoElectron Corp, San Jose, Calif.) equipped with a nanoelectrospray ion source. Cycles of MS spectra with m/z ratios of peptides and four data-dependent MS2 spectra were recorded by mass spectrometry.

The "peak list" was created with extracts provided by the Xcalibur software package (BioworksBrowser 3.1). The MS2 spectra with a total ion current higher than 10,000 were used to search for matches against a public *A. nidulans* genome-wide protein sequence database of the BROAD INSTITUTE (9542 sequences, December 2005, plus 180 sequences of the most commonly appearing contaminants, e.g., keratins and proteases, provided with the BioworksBrowser package) using the TurboSEQUEST algorithm of the Bioworks software (Version 3.1, Thermo Electron Corp).

The search parameters included based on the TurboSEQUEST algorithm were: (i) precursor ion mass tolerance less than 1.4 amu, (ii) fragment ion mass tolerance less than 1.0 amu, (iii) up to three missed tryptic cleavages allowed, and (iv) fixed cysteine modification by carboxyamidomethylation (plus 57.05 amu) and variable modification by methionine oxidation (plus 15.99 amu) and phosphorylation of serine, threonine, or thyronine (plus 79.97 amu).

In accordance with the criteria described by Link et al., matched peptide sequences of identified proteins had to pass the following: (i) the cross-correlation scores (Xcorr) of matches must be greater than 2.0, 2.5, and 3.0 for peptide ions of charge state 1, 2, and 3, respectively, (ii) ΔCn values of the best peptide matches must be at least 0.4, and (iii) the primary scores (Sp) must be at least 600.

Protein identification required at least two different peptides matching these criteria. The degree of completeness of the b- and y-ion series for each SEQUEST result was manually checked for every protein identified. Peptides of identified proteins were individually blasted against the NCBI database to ensure their unambiguous assignment to the TurboSEQUEST-specified protein. See also the Multiple Consensus Reports for the detailed TurboSEQUEST identifications in the Table 4. The three top scoring peptides are listed for all identifications.

TABLE 4

Mass Spectrometry Data of Protein Identifications.

Peptide Sequence	MH+	Charge	XCorr	Delta Cn	Sp	RSp	Ions
AN1052.2 (hypothetical protein similar to velvet A)1[1]					1210.3	121	(121-0-0-0-0)
R.LEVISNPFIVYSAK.K(SEQ ID NO: 84)	1580.85	2	5.27	0.59	1188.8	1	21/26

TABLE 4-continued

Mass Spectrometry Data of Protein Identifications.

Peptide Sequence	MH+	Charge	XCorr	Delta Cn	Sp	RSp	Ions
R.LEVISNPFIVYSAK.K(SEQ ID NO: 85)	1425.59	2	4.52	0.32	1075.5	1	18/24
R.LEVISNPFIVYSAK.K(SEQ ID NO: 86)	2135.24	3	6.84	0.66	2085.3	1	37/72
AN0363.2 (hypothetical protein)[2]					1508.3		151 (150-1-0-0-0)
K.IGVWFVLQDLSVR.T(SEQ ID NO: 87)	1532.81	2	5.18	0.37	1490.4	1	18/24
K.SVSDLPQSDIAEVINK.G(SEQ ID NO: 88)	1715.88	2	5.35	0.55	803.4	1	24/30
R.IWSLQVVQQPIR.A(SEQ ID NO: 89)	1467.74	2	4.62	0.35	1568.4	1	17/22
AN0807.2 (hypothetical protein)[3]					186.2		19 (18-0-2-0-0)
K.EIHAYNILHIYQAR.K(SEQ ID NO: 90)	1741.98	2	4.85	0.61	1789.0	1	20/26
R.YAVAGGPAPWNR.N(SEQ ID NO: 91)	1259.40	2	4.70	0.52	1632.0	1	19/22
R.VSESLIYAPHPTNGR.F(SEQ ID NO: 92)	1641.81	2	4.17	0.57	930.5	1	20/28
AN2142.2(hypothetical protein similar to AF465210_1 karyopherin alpha)[4]					660.3		66 (66-0-0-0-0)
K.IIQVALDGLENILK.V(SEQ ID NO: 93)	1539.84	2	5.09	0.57	2402.5	1	22/26
K.IQAVIEAGIPR.R(SEQ ID NO: 94)	1167.38	2	3.87	0.44	1618.2	1	18/20
K.TPQPDWNTIAPALPVLAK.L(SEQ ID NO: 95)	1933.24	2	4.40	0.64	942.9	1	19/34
AN0363.2(hypothetical protein)[5]					220.2		22 (22-0-0-0-0)
K.GTAPILASTFSEPFQVFSAK.K(SEQ ID NO: 96)	2099.37	2	5.28	0.47	1045.5	1	22/38
K.IGVWFVLQDLSVR.T(SEQ ID NO: 97)	1532.81	2	4.30	0.43	1499.0	1	18/24
K.SVSDLPQSDIAEVINK.G(SEQ ID NO: 98)	1715.88	2	5.34	0.48	846.1	1	24/30
AN1052.2 (hypothetical protein similar to velvet A)[6]					778.4		78 (77-1-0-0-0)
K.DATEGTQPMPSPVPGK.L(SEQ ID NO: 99)	1612.79	2	3.70	0.45	516.1	1	18/30
K.KFPGLTTSTPISR.M(SEQ ID NO: 100)	1405.62	2	2.61	0.53	519.5	1	15/24
K.LMTNQGSPVLTGVPVAGVAYLDKPNR.A (SEQ ID NO: 101)	2699.12	2	6.16	0.61	737.2	1	35/100
AN0807.2(hypothetical protein)[7]					454.3		46 (45-0-0-1-0)
K.EIHAYNILHIYQAR.K(SEQ ID NO: 102)	1741.97	2	3.01	0.59	960.3	1	17/26
R.IQQLAADVK.S(SEQ ID NO: 103)	986.15	2	3.12	0.33	1015.4	1	15/16
R.YAVAGGPAPWNR.N(SEQ ID NO: 104)	1259.40	2	3.39	0.58	1119.0	1	17/22
AN1959.2(hypothetical protein)[8]					660.3		66 (66-0-0-0-0)
K.DVDNTDGGFFVWGDLSIK.V(SEQ ID NO: 105)	1986.13	2	4.21	0.56	931.0	1	19/34
R.LKDVDNTDGGFFVWGDLSIK.V(SEQ ID NO: 106)	2227.46	2	4.14	0.56	1200.5	1	21/38
AN0807.2(hypothetical protein)[9]					220.2		22 (22-0-0-0-0)
K.EIHAYNILHIYQAR.K(SEQ ID NO: 107)	1741.97	2	4.15	0.58	1819.4	1	20/26
R.WYNLAVSESIENLSLAPFSR.V(SEQ ID NO: 108)	2297.55	2	4.30	0.54	1495.0	1	22/38
R.YAVAGGPAPWNR.N(SEQ ID NO: 109)	1259.40	2	3.90	0.54	1681.7	1	20/22
AN0363.2(hypothetical protein)[10]					778.4		78 (77-1-0-0-0)
K.GTAPILASTFSEPFQVFSAK.K(SEQ ID NO: 110)	2099.37	3	5.29	0.56	1021.1	1	30/76
K.SVSDLPQSDIAEVINK.G(SEQ ID NO: 111)	1715.88	2	5.59	0.51	799.5	1	21/30
R.IWSLQVVQQPIR.A(SEQ ID NO: 112)	1467.74	2	4.29	0.45	2227.8	1	18/22
AN1052.2(hypothetical protein similar to velvet A)[11]					454.3		46 (45-0-0-1-0)
R.LEVISNPFIVYSAK.K(SEQ ID NO: 113)	1580.85	2	4.44	0.55	1269.4	1	21/26
R.RPDQYAGSDAYANAPERPR.S(SEQ ID NO: 114)	2135.24	3	5.25	0.65	1825.0	1	36/72
R.RPSAVEYGQPIAQPYQR.P(SEQ ID NO: 115)	1961.17	3	3.99	0.56	1044.4	1	29/64

[1]Avg. Mass: 63831.1; pI: 9.43; Coverage (amino acids): 39.4%
[2]Avg. Mass: 37062.4; pI: 5.97; Coverage (amino acids): 30.4%
[3]Avg. Mass: 41578.2; pI: 5.93; Coverage (amino acids): 28.6%
[4]Avg. Mass: 60627.4; pI: 5.00; Coverage (amino acids): 11%
[5]Avg. Mass: 37062.4; pI: 5.97; Coverage (amino acids): 33.3%
[6]Avg. Mass: 63831.1; pI: 9.43; Coverage (amino acids): 40.6%
[7]Avg. Mass: 41578.2; pI: 5.93; Coverage (amino acids): 18.0%
[8]Avg. Mass: 49010.4; pI: 8.45; Coverage (amino acids): 31.5%
[9]Avg. Mass: 41578.2; pI: 5.93; Coverage (amino acids): 36.6%
[10]Avg. Mass: 37062.4; pI: 5.97; Coverage (amino acids): 32.8%
[11]Avg. Mass: 63831.1; pI: 9.43; Coverage (amino acids): 38.9%

Fluorescence microscopy. *A. nidulans* spores (5.5×10^5) were inoculated either on 18 mm×18 mm cover slips submerged in appropriately supplemented liquid medium or on large glass slides covered with a thin layer of medium and incubated at 30° C. overnight. The effect of illumination on localization of VeA and VelB was investigated by growing selected strains in darkness and light on the agar surface or in the submerged culture. Cover slips were mounted on microscope slides using spore storage solution (0.002% Tween, 0.5% NaCl) and fixed with wax.

Fluorescence photographs were taken with a ZEISS Axiovert S100 microscope supported with a HAMAMATSU OCRA-ER digital camera, using the Openlab™ V5.0.1 software package (IMPROVISION, Coventry, UK). For the quantification of the GFP signals, nuclei were defined as ROIs (Area of interest). Pixel intensity within the defined ROIs were analysed by using Openlab tmV5.0.1 software package (IMPROVISION, Coventry, UK). Nuclei were verified by overlaying the GFP and Ds Red signals. Subcellular distribution was observed with a 100× objective using 495 and 558 nm extinction and emission filters. No autofluorescence was observed. All images were taken using the same exposure and microscope settings.

Sterigmatocystin Extraction and Thin Layer Chromatography (TLC) Analysis.

Samples (1.6 cm diameter disc with fungal samples and agar together) were collected after asexual developmental induction. The fungal samples were ground in 3 ml ddH_2O in a homogenizer, and then 3 ml chloroform was added to extract ST from the aqueous phase. About 1.8 ml chloroform containing ST was collected after centrifugation, and air-dried. The dried extracts were resuspended in 50 μl of chloroform, and 10 μl were separated in hexane:ethyl acetate (4:1) or chloroform:acetone (4:1) on TLC plates. ImageQuant TL (Amersham Biosciences Co.) was used for ST densitometry. Data are presented as graphs with bars which stand for mean+/−standard error (FIG. **2**D). For statistical analysis, data were analyzed using the JMP software package (version 3.2.6, SAS Institute, Inc, Cary, N.C.).

According to the Tukey-Kramer multiple comparison test at $P\leq0.05$, the three mean values for WT in the dark are significantly different from WT in the light and velBΔ in the dark after 48 hours (FIG. **5**D). The graphs without bars do not produce ST above background noise (indicated by "B").

Example 2

In this example, the inventors created several *A. flavus* isogenic mutants differing only in copy number of veA and laeA genes, including ΔveA, ΔlaeA, multicopy laeA (MC-laeA), and MCveA strains and a double MC strain (MCveA-laeA). The respective VeA and LaeA mutants exhibited critical differences in cell density responses and invasion of host tissues, despite gross similarities between sclerotial and aflatoxin production.

Considering the interdependence of oxylipin function with VeA coupled with the VeA-LaeA interaction, we postulated that VeA mutants would also be impaired in seed pathogenesis in a manner similar to that of LaeA mutants and, furthermore, that both mutants could be affected in density-dependent development. To explore these hypotheses, we created several *A. flavus* isogenic mutants differing only in copy number of veA and laeA genes, including ΔveA, ΔlaeA, multicopy laeA (MClaeA), and MCveA strains and a double MC strain (MCveA-laeA). The respective VeA and LaeA mutants exhibited critical differences in cell density responses and invasion of host tissues, despite gross similarities between sclerotial and aflatoxin production.

Fungal Strains and Growth Conditions.

The *Aspergillus flavus* strains used and generated in this example are listed in Table 5. ΔveA (SEQ ID NO: 142); containing 5' veA flanking region (nucleotides 1-1314 in SEQ ID NO: 142), *A. fumigatus* pyrG (nucleotides 1315-3264 in SEQ ID NO: 142), and 3' flanking region of the veA open reading frame (nucleotides 3265-4556 in SEQ ID NO: 142). MCveA (SEQ ID NO: 143) was generated by transformation with pSA3.X, and contained *A. flavus* veA (nucleotides 1368-3156 in SEQ ID NO: 143):: *A. fumigatus* pyrG (nucleotides 3700-5681 in SEQ ID NO: 143) in TOPO-TA cloning plasmid (TOPO-TA pCR2.1); *A. flavus* 5' (nucleotides 259-1367 in SEQ ID NO: 143) and 3'flank (nucleotides 3157-3674 in SEQ ID NO: 143); nucleotides 258, 3675-3679, 3699, 5682-5686 in SEQ ID NO: 143 are restriction sites (EcoRI or SpeI). ΔlaeA (SEQ ID NO: 144) was generated by transformation with PLRM5, and contained *A. fumigatus* pyrG (nucleotides 1535-3547 in SEQ ID NO: 144), *A. flavus* 5' (nucleotides 46-1531 in SEQ ID NO: 144) and 3'flank (nucleotides 3554-4933 in SEQ ID NO: 144); nucleotides 43-45, 1532-1534, 3548-3553, and 4934 in SEQ ID NO: 144 are restriction sites. MClaeA (SEQ ID NO: 145) was generated by transformation with pLRM11, and contained *A. parasiticus* niaD (nucleotides 2-5128 in SEQ ID NO: 145):: *A. flavus* laeA (nucleotides 5134-9452 in SEQ ID NO: 145) in Invitrogen pCR bluntII TOPO plasmid (pLRM9); nucleotides 1, and 5129-5133 in SEQ ID NO: 145 are restriction sites. MCveA-laeA was prepared by co-transformation with pSA2.8 and PLRM11 plasmids using *A. flavus* laeA (SEQ ID NO: 146).

TABLE 5

Aspergillus flavus strains.

Strain	Genotype *	Source
NRRL 3357	Wild type	Horowitz Brownet al. 2008. Appl. Environ. Microbiol. 74: 5674-5685.
NRRL 3357.5	pyrG⁻	Horowitz Brownet al. 2008. Appl. Environ. Microbiol. 74: 5674-5685.
TSA 1.54 (ΔveA)	pyrG⁻ ΔveAr::AfpyrG	This study
TSA 2.46 (MCveA)	pyrG⁻ AfpyrG veA	This study
TJW 71.1 (ΔlaeA)	pyrG⁻ ΔlaeA::AfpyrG	Kale, et al.. 2008. Fungal Genet. Biol. 45: 1422-1429.
TJW 79.13 (MClaeA)	pyrG⁻ ΔlaeA::AfpyrG niaD⁻ niaD laeA	Kale, et al.. 2008. Fungal Genet. Biol 45: 1422-1429.
TSA 2.8 (MCveA-laeA)	pyrG⁻ AfpyrG veA niaD laeA	Horowitz Brownet al. 2008. Appl. Environ. Microbiol. 74: 5674-5685.

* Af, *A. fumigatus*

All strains were maintained as stocks in glycerol and grown at 29° C. on glucose minimal medium (GMM) (36) amended with appropriate supplements for spore production.

Fusion PCR and Vector Construction.

All primers used in this example are listed in Table 6.

TABLE 6

Primer sequences.

Primer	Sequence (5'-3')
5'F veA For	ACAACCCTGGACTCTGGAAT (SEQ ID NO: 118)
5'F veA Rev	CGAAGAGGGTGAAGAGCATTGTTTGAGGCAGAGG ACGCGTTGACTGTGATG (SEQ ID NO: 119)
3'F veA For	TGACGACAATACCTCCCGACGATACC TGGGTTGATTCCTGCTTTTCCTCC (SEQ ID NO: 120)
3'F veA Rev	TCTCGTTCTCCCATTTACCT (SEQ ID NO: 121)
A. fumigatus pyrG For	TGCCTCAAACAATGCTCTTC (SEQ ID NO: 122)
A. fumigatus pyrG Rev	CAAGGTATCGTCGGGAGGT (SEQ ID NO: 123)
Nested For	AATCACGGACCTCGAAGCAG (SEQ ID NO: 124)
Nested Rev	GGGGTCTTGATATGGCGAAT (SEQ ID NO: 125)
Int veA For	CAACAAGACCGACATCACCTTC (SEQ ID NO: 126)
Int veA Rev	CCATTCTTGGGATAGCTGCAAC (SEQ ID NO: 127)
MC veA For	CAACGA**ACTAGT**CCGCCTGCCCTTAACCTCCA (SEQ ID NO: 128)
MC veA Rev	GCATAC**ACTAGT**CTCGCATGCCAGTGGATGGG (SEQ ID NO: 129)
veA-pyrG Rev	CATCGGTTGACTACGCTCGCA (SEQ ID NO: 130)
laeA-niaD For	GACCTGTGGTGAAACCTGAGG (SEQ ID NO: 131)
veA Northern For	CTAGCTGGTCATTATTTGATCTCG (SEQ ID NO: 132)
veA Northern Rev	GTTGTAGAGTGGACGATCATCATG (SEQ ID NO: 133)
laeA Northern For	CCTTGTATGATGTATGTATGATGAGC (SEQ ID NO: 134)
laeA Northern Rev	GACAGCGAAAGTGAAGAGGACATC (SEQ ID NO: 135)
actin Northern For	GAAGCGGTCTGAATCTCCTG (SEQ ID NO: 136)
actin Nothern Rev	ACAGTCCAAGCGTGGTATCC (SEQ ID NO: 137)
aflR Northern For	AGAGTCTTCCTTCAGCCAGGTC (SEQ ID NO: 138)
aflR Northern Rev.	GTGGGGCTTTTCTTCATTCTCG (SEQ ID NO: 139)

*Bold characters flag restriction enzyme (SpeI) site.

The veA replacement PCR products were constructed using fusion PCR following Szewczyk et al. Starting with wild type *A. flavus* veA (SEQ ID NO: 141, containing 1314 bp of the 5' flanking region and 1292 bp of the 3' flanking region of the veA open reading frame), the 1.3-kb fragments upstream and downstream of the veA coding region were amplified by PCR with primers 5'F veA For and Rev for the upstream fragment and primers 3'F veA For and Rev for the downstream fragment, using NRRL 3357 (prototroph) genomic DNA as a template. Next, a 1.9-kb fragment of the pyrG auxotrophy marker gene was amplified from *A. fumigatus* AF293 genomic DNA using primers *A. fumigatus* pyrG For and Rev. These three amplified PCR products were cleaned with a QIAquick gel extraction kit (Qiagen), quantified, and fused using published procedures. The PCR product was amplified with primers Nested For and Rev. All PCR steps were performed using an Expand long template PCR system (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions.

The final construct was confirmed with endonuclease digestion and PCR using primers Int veA For and Rev for internal veA and primers *A. fumigatus* pyrG For and Rev for pyrG. The veA complementation vector was constructed in two steps. First, the 1.9-kb *A. fumigatus* pyrG PCR fragment was amplified and ligated into the pCR2.1-TOPO vector (Invitrogen) to create pSA2.4. Next, a 4.4-kb SpeI fragment containing the *A. flavus* veA gene was amplified from *A. flavus* NRRL 3357 genomic DNA with primers MC veA For and Rev and ligated into the SpeI site of pSA2.4 to create the veA complementation vector, pSA3.13. The vector was confirmed by PCR with primers MC veA For and veA pyrG Rev and endonuclease digestion.

Fungal Transformation Procedure and Mutant Confirmation.

For fungal transformation, protoplasts were produced from freshly germinated conidia of NRRL 3357.5 (pyrG auxotroph) and transformed using a polyethylene glycol method. The final fusion PCR product (5 μg) was used for replacement of veA with pyrG after gel purification using a QIAquick gel extraction kit (Qiagen) to create strain TSA 1.54 (SEQ ID NO: 142; containing 1314 bp of the 5' veA flanking region, 1950 bp of *A. fumigatus* pyrG, and 1292 bp of the 3' flanking region of the veA open reading frame). The veA::pyrG vector, pSA3.13, was used alone or else cotransformed with pLRM11.1, a vector containing both laeA and niaD, to create MC strains with multiple copies of veA alone and MC strains with multiple copies of both veA and laeA (TSA 2.46 and TSA 2.8, respectively, were used for these studies).

Correct transformants were identified by analyzing genomic DNA using PCR screens followed by Southern analyses. Primers Int veA For and Rev, Nested For and Rev (4.3 kb for the wild type and 4.6 kb for transformants), and *A. fumigatus* pyrG For and Rev were used to identify pyrG replacement of veA. MC transformants were identified by PCR with primers MC veA For and veA pyrG Rev and primers laeA-niaD For and laeA Northern Rev. Southern analysis was performed for each PCR-identified transformant to confirm single gene replacement of veA in TSA 1.54, at least 2 copies of veA in TSA 2.46, and at least 2 copies of veA and laeA in TSA 2.8. Probes were created with primers Nested For and Rev for the veA open reading frame (ORF) and primers laeA Northern For and Rev for the laeA ORF.

Northern Analysis.

To examine the expression of veA and laeA transcripts, Northern analysis was performed. Fifty-milliliter amounts of liquid GMM were inoculated with 10^6 spores/ml of appropriate strains and incubated with shaking at 250 rpm at 29° C. under dark conditions. After 48 h, the mycelium was collected and total RNA was extracted by using the Trizol

method (Invitrogen). Blots were hybridized with a veA fragment amplified using the primers Northern For and Rev, an laeA fragment amplified using the primers Northern For and Rev, an actin fragment amplified using the primers actin Northern For and Rev, and an aflR fragment amplified using the primers aflR Northern For and Rev from NRRL3357 genomic DNA. Detection of signals was carried out with a Phosphorimager-SI (Molecular Dynamics).

Physiological Experiments.

Conidial production, sclerotial formation, and colony diameter were measured for fungal strains following the methods of Horowitz Brown et al. Briefly, 8-ml amounts of 1.6% GMM plus 2% sorbitol agar were overlaid with 3-ml amounts of 0.7% agar GMM plus 2% sorbitol agar containing 10^2, 10^4, and 10^6 spores/plate of each *A. flavus* strain for culture. For conidial counts, three 1.5-cm plugs from each plate were homogenized in 5 ml of 0.01% Tween 80 (vol/vol) water, diluted to 1×, and counted with a hematocytometer. To visualize sclerotium formation, plates were sprayed with 70% ethanol to kill and wash away conidia. The exposed sclerotia were then collected, lyophilized, and weighed (dry weight per plate). Growth diameter was measured following a point inoculation of 5 μl of 10^6 spores/ml for each strain on 30 ml of 1.6% GMM. Cultures were grown at 29° C. under continuous dark or light conditions for 3 days (conidia production), 7 days (sclerotia formation), and 3 and 6 days (colony diameter). Each treatment was replicated four times.

To assay for growth on different fatty acids, the wild-type, ΔlaeA, and ΔveA strains were examined for growth on (i) 20 mM hexanoic acid (6 C), 6 mM oleic acid (18 C), and 4.9 mM erucic acid (22 C) as the sole carbon source, with the fatty acids substituting for the glucose in GMM, or (ii) GMM supplemented with these same molarities of fatty acids, following the method of Maggio-Hall and Keller. Growth diameter was measured following a point inoculation of 5 μl of 10^6 spores/ml for each strain on 30 ml of medium. Each treatment was replicated four times. The experiment was repeated twice.

Seed Infections.

For seed/fungal studies, two cultivars (SunRunner and Flo-Runner) of peanut (*Arachis hypogaea*) and one (Northup King N33-P3) of non-fungicide treatment maize (*Zea mays* L.) were used. All the steps were aseptically performed as described by Kale et al. Briefly, mature peanuts (20 peanut cotyledons) and maize (10 seeds) were surface sterilized and inoculated with suspensions of 10^5 spores/ml of each respective strain, as well as with a water control (mock inoculation). Seeds were placed in 50-ml Falcon tubes containing either sterile water or the spore suspensions and shaken for 30 min in a rotary shaker at 50 rpm, after which they were placed in a high-humidity chamber. Peanut cotyledons were incubated for 3 days for peanut cultivar SunRunner or 5 days for cultivar FloRunnner at 29° C. under dark conditions, and maize kernels for 3 days. All seed experiments were repeated three times.

Histological Study.

Infected and control peanut cotyledons of cultivar SunRunner were collected after 3 days of inoculation and sliced with a razor blade into 2-cm pieces which were immersed in ice-cold fixative FAA (3.7% formaldehyde, 5% acetic acid, 47.5% ethanol in water) in vials with vacuum pressure for 30 min. Tissues were then removed, incubated with fresh FAA overnight, dehydrated through a tert-butanol series following the method of Cseke et al., and embedded in paraffin (Paraplast Plus). Paraffin blocks were sectioned in 10-μm slices, and serial sections were placed on glass slides and incubated at 37° C. at least overnight, until tissues adhered to the slides. Dewaxing of tissues and staining with Gomori methenamine-silver were performed in the University of Wisconsin—Madison School of Veterinary Medicine histology services laboratory. For lipid staining in peanut tissues, Nile red was applied to tissues following the method of Tsitsigiannis et al. A tetramethyl rhodamine 5-isothiocyanate filter in a fluorescent microscope (Olympus BX-60 with 546-nm excitation and 585-nm emission filters) was used to observe Nile red-stained tissues.

Aflatoxin Extraction from Medium.

Eight-milliliter amounts of 1.6% GMM-2% sorbitol agar were overlaid with 3-ml amounts of 0.7% GMM agar plus 2% sorbitol agar containing 10^2, 10^4, and 10^6 spores/plate of each fungal strain. Cultures were grown for 3 days at 29° C. under dark or light conditions. Three 1.5-cm plugs from each plate were homogenized in 3 ml of 0.01% Tween 80 (vol/vol) water and vortexed vigorously for 1 min. One milliliter of chloroform was added, and the sample vortexed and incubated at room temperature for 30 min. The mixture was vortexed again and then centrifuged for 15 min. The lower layer was collected, allowed to dry for 3 days, and then resuspended in 100 μl of chloroform, and 40 μl of the suspension was spotted onto TLC plates (Whatman, Maidstone, England) using a chloroform/acetone (95:5, vol/vol) solvent system. Each treatment was repeated three times.

Aflatoxin Extraction from Seed.

Peanut cotyledons and maize kernels inoculated as described above were collected in 50-ml Falcon tubes with the addition of 5 ml of 0.01% Tween 80 and vortexed vigorously for 1 min. One milliliter was removed from each sample for conidium counting prior to aflatoxin extraction. Five milliliters of acetone was then added to the samples, followed by shaking for 10 min in a rotary shaker at 150 rpm. Samples were allowed to stand for 5 min at room temperature, and then 5 ml of chloroform was added to each sample, followed by shaking for 10 min at 150 rpm. Samples were allowed to stand for an additional 10 min at room temperature, vortexed briefly, and centrifuged for 15 min at 2,000 rpm to collect the organic lower phase. This phase was placed in a new tube and then dried completely for 3 days. Five milliliters of 0.1 M NaCl methanol/water (55:45) and 2.5 ml of hexane were added to each tube, and the mixture vortexed vigorously at high speed for 1 min. Samples were centrifuged at 2,000 rpm for 5 min. The hexane layer was collected, the remaining aqueous phase was washed with 2.5 ml of hexane, and then the collection process repeated as described above. The hexane extracts were combined, allowed to dry, and then resuspended in 500 μl of chloroform, and 10 μl of each extract was separated on a silica gel TLC plate using the chloroform/acetone (95:5 vol/vol) solvent system. Each treatment was repeated three times.

Statistical Analysis.

Statistical differences were analyzed using the JMP software package, version 3.2.6 (SAS Institute, Inc., Cary, N.C.). Multiple comparisons of results for all strains were calculated for growth diameter, lipase activity, and sporulation on seed. To assess the density-dependent development of each strain, sclerotial and conidial numbers were compared at three population levels. Statistically significant mean values, indicated with different letters in the figures, are significant at $P<0.05$.

Results.

Creation of veA and laeA mutant strains in *A. flavus*. This study required creating near-isogenic strains varying in the number of laeA and veA alleles in the same *A. flavus* isolate. As ΔlaeA and MC strains of the genome-sequenced strain *A.*

flavus 3357 already existed, the first goal was to obtain near-isogenic strains of *A. flavus* 3357 with loss of or overexpression of veA.

The sequence of the *A. flavus* 3357 veA ortholog was obtained by designing primers from the *A. flavus* ATCC MYA384 veA gene (GenBank DQ296645, SEQ ID NO: 140). The sequences of the two genes were found to be 99% identical. All primers and probes in this study were designed from this sequence (Table 6). FIG. **13**A shows the strategy of replacement of veA with *A. fumigatus* pyrG. Transformants were first screened for loss of production of sclerotia on GMM plus 2% sorbitol medium, a phenotype associated with the *A. flavus* ATCC MYA384 ΔveA mutant. Several asclerotial *A. flavus* 3357 transformants were identified and their DNA extracted and analyzed by PCR and Southern analysis. Seventeen out of 100 transformants were found to contain the 4.6-kb and 4.3-kb fragments expected of KpnI (FIG. **13**B) and SapI (data not shown) digests, respectively, as expected for a veA replacement with *A. fumigatus* pyrG. One of these strains, TSA 1.54, was chosen for further studies (FIG. **13**B). A strain with at least two copies of veA was obtained by transforming NRRL 3357.5 with plasmid pSA3.13. Several strains were obtained, as determined by Southern analysis, and one, the MCveA strain TSA 2.46, was chosen for further studies (FIG. **13**B). Next, a strain with at least two copies of both veA and laeA was obtained by transforming NRRL 3357.5 with plasmids pSA3.13 and pLRM11.1. One of these transformants, the MCveA-laeA strain TSA2.8, was chosen for further studies (FIG. **13**B).

The strains with the six genotypes (the wild type and five mutants) exhibited clear differences in development and morphology, as described below, and additionally, the ΔlaeA strain showed a statistically significant inhibition in growth diameter compared to the growth of most other strains under both light and dark conditions. Conversely, the MClaeA strain's growth diameter was greater than the growth diameters of most other strains in both light and dark regimes (FIG. **14**).

veA and laeA Affect Each Other's Transcription.

Kale et al. recently found that laeA expression negatively affects transcription of veA in *A. flavus*; this result was replicated in our work (FIG. **15**). We also found evidence for veA regulation of laeA expression. Although Northern analysis revealed that the ΔveA strain did not show an increase of laeA expression, the MCveA strain had decreased laeA expression compared to that of the wild type. The MCveA-laeA strain showed relatively high levels of expression of both veA and laeA but not as high as the individual MC strains. We also examined the expression of the aflatoxin-specific transcription factor aflR in all strains. As expected and as previously described, there was no aflR expression in ΔveA and ΔlaeA strains. Similarly to the MClaeA strain, both the MCveA and MCveA-laeA strain showed higher levels of aflR expression than the wild type with this treatment.

Conidial and Sclerotial Density-Dependent Production is Affected by VeA and LaeA.

A recent study has shown that conidial and sclerotial production is density dependent in *A. flavus*, for which low cell densities resulted in high sclerotial formation and high cell densities in low sclerotial formation, with an inverse effect on conidial production. This quorum-like signaling system regulating the sclerotial-to-conidial shift was impaired in oxylipin-generating oxygenase mutants. Because VeA has been shown to be important in oxylipin signaling responses and forms a complex with LaeA in the nucleus, we now show that changes in veA and laeA expression could affect the density-dependent sclerotial-to-conidial shift.

The relative abilities of the wild type and the veA and laeA mutants to form sclerotia and conidia were determined by inoculating 10^2, 10^4, and 10^6 conidia onto GMM plus 2% sorbitol plates which were placed in constant dark at 29° C. for 3 (conidia) and 7 (sclerotia) days. Similar to prior results, sclerotial production diminished and conidial production increased in the wild type with increasing cell population levels (FIGS. **16**A and B). The veA and laeA null mutants were incapable of producing sclerotia at any population level and yielded relatively constant levels of conidial production regardless of population levels (FIGS. **16**A and B).

However, clear differences between effects of loss of or overexpression (MC) of veA compared to the results for cognate laeA mutants emerged in both conidial and sclerotial development. Previous studies have suggested a "balance" in sclerotial and conidial production, i.e., when sclerotial production is low, conidial is high and vice versa. This appeared to hold true for the ΔlaeA strain (no sclerotial production at any cell density and high conidial counts at all densities) but not the ΔveA strain, for which conidial counts were very low at all population levels (FIG. **16**A) despite the lack of sclerotial production (FIG. **16**B). The MC mutants also showed clear differences in their density-dependent responses. The MCveA strain still exhibited a density-dependent response in sclerotial production with declining numbers in both light and dark regimes at high population levels (FIG. **16**B). This was in contrast to the MClaeA strain, which maintained constant sclerotial numbers at all population levels (FIG. **16**B). The MCveA-laeA double mutant exhibited an intermediate response. The trend to increased conidial numbers at high population levels was maintained in the MCveA and MCveA-laeA strains but not in the MClaeA strain (FIG. **16**A). These results are summarized in Table 7.

TABLE 7

Summary of density-dependnent phenomena in *A. flavus* mutants, morphological differentiations under indicated conditions.

Mutation	Light-Conidia	Light - Sclerotia	Dark-Conidia	Dark-Sclerotia
None (WT)	+	+	+	+
ΔveA	±	−	±	−
ΔlaeA	−	−	−	−
MCveA	±	+	±	+
MClaeA	−	−	−	−
MCveA-laeA	+	±	+	±

+ indicates the presence of density-dependent development.
± indicates an intermediate response.
− indicates the absence of density-dependent development

Density-Dependent Production of Aflatoxin is Controlled by LaeA.

We also examined the strains for possible effects of laeA and veA expression on aflatoxin production at all cell densities, as aflatoxin production in the wild type is highest at low population levels. Regardless of cell densities, the ΔveA and ΔlaeA strains never produced observable aflatoxin under the growth conditions used here, whereas all the MC strains produced aflatoxin in all treatments (FIG. **17**). The MCveA strain also showed a density-dependent decrease of aflatoxin with increasing cell population, similar to the wild type, whereas the MClaeA strain did not, and the double

mutant showed an intermediate result. Aflatoxin production correlated with sclerotial production.

VeA and LaeA are Important Factors for Seed Colonization.

Recently, Kale et al. reported that laeA mutants were aberrant in host colonization and aflatoxin production on both peanut and maize seed, but there are no reports for the role of VeA in *A. flavus* pathogenicity. Here, we examined and contrasted colonization attributes of the different veA and laeA mutants on two peanut cultivars and one maize hybrid.

Each fungal strain maintained similar growth patterns regardless of the host seed. FIG. **18**A shows that both null mutants produced fewer conidia than the wild type during growth on seeds, with the ΔveA strain developing significantly fewer conidia than the ΔlaeA strain. Visually, the ΔveA strain was most crippled in its ability to grow on any seed (data not shown). The MCveA and MCveA-laeA strains also produced fewer conidia than the wild type; however, the MClaeA strain was similar to the wild type in conidial production, depending on the host seed, as reported earlier. The MC strains also formed sclerotia on the seeds (data not shown).

The colonized seeds were next examined for aflatoxin contamination. All MC strains and the wild type produced aflatoxin in all hosts, in contrast to the lack of aflatoxin production by both the ΔveA and ΔlaeA strain (FIG. **18**B). The considerably higher aflatoxin production by some MC mutants in vitro (FIG. **17**), however, was not replicated in growth on seed under the conditions in this study.

To further investigate the ability of the strains to colonize seed, histological studies were performed. We were specifically interested in assaying for maceration effects and reasoned that this could be partially measured by host cell lipid utilization. The staining techniques did not show any obvious difference in host penetration by MC strains compared to that of the wild type (data not shown). However, the two null mutants exhibited different host invasion patterns. The results in FIGS. **19**A and B show that wild-type hyphae penetrated several layers of host epidermal and mesophyll cells, with accompanying dissolution of host lipid reserves. Although the ΔlaeA strain also penetrated the host cells intracellularly, host lipid reserves were largely intact and the cell integrity appeared less damaged (FIGS. **19**A and B). In contrast, hyphae of the ΔveA strain grew intercellularly in epidermal cells and did not appear to penetrate peanut cells as well as hyphae of other strains (FIG. **19**A). This mutant, like the ΔlaeA mutant, was also less able to degrade host cell lipid reserves than the wild type (FIG. **19**B). However, an in vitro assay for general lipase activity revealed no significant difference between these strains (data not shown).

The wild type and the ΔlaeA and ΔveA strains were then grown on media amended with different fatty acids either as sole carbon source or supplemented with glucose to determine if there might be any gross difference in the ability to utilize or be inhibited by short-, medium-, or long-chain fatty acids. The results did not support any critical difference between the wild type and the two mutants when grown on a fatty acid as the sole carbon source, but the two mutants showed significant inhibition of growth compared to that of the wild type when cultured on GMM amended with oleic acid (FIG. **20**). This experiment was repeated twice with similar results (data not shown).

Discussion.

In this study, we characterized the function and cross-regulation of VeA and LaeA in *A. flavus* development and pathogenesis. The results, while confirming that VeA and LaeA share functions in regulating aflatoxin and sclerotial production, also demonstrate distinct roles of VeA and LaeA in terms of vegetative growth, conidiation, density-dependent responses, and pattern of colonization of host tissues.

A Requirement for LaeA in Density-Dependent Sensing.

Quorum-sensing systems in bacteria contribute to the production of virulence factors and biofilm formation in interactions between bacteria and host. In fungi, a quorum-sensing system governing morphological shifts and virulence has been uncovered in the human pathogen *Candida albicans*. Recently, oxylipin-deficient lipoxygenase and dioxygenase mutants have been found to affect a newly discovered quorum-sensing-like, density-dependent sclerotial-to-conidial morphology shift in *A. flavus*. Because oxylipin signaling is dependent on VeA function and VeA is part of a nuclear complex with LaeA, we asked if VeA or LaeA mutants could be affected in this quorum-like morphology shift in *A. flavus*. Both null mutants were blocked in sclerotial formation regardless of cell population, and perhaps due to an inability to produce sclerotia, conidial production was relatively stable for each mutant at all three population levels, although it was much higher in the ΔlaeA strain.

The MC strains showed clear differences in density-dependent development in that an extra copy of LaeA but not VeA abolished this quorum-like phenomenon (FIGS. **16**A and B). To date, there are no chemical data identifying molecules regulating the sclerotial-to-conidial switch in *A. flavus*, although oxylipins are hypothesized to fulfill this function at least in part. Quorum-sensing molecules for *Candida albicans* (farnesol and tyrosol) and *Saccharomyces cerevisiae* (phenylethanol and tryptophol) are aromatic alcohols and control the morphological switch from the yeast to filamentous growth in these fungi.

Interestingly, the yeast-to-filamentous growth switch in the fungus *Ceratocystis ulmi* is attenuated by lipoxygenase inhibitors and may implicate oxylipins in quorum sensing in this tree pathogen. We speculate that *A. flavus* MClaeA mutants are aberrant in oxylipin production and/or sensing but that this can be remediated to some degree when VeA levels also increase, as demonstrated by the intermediate density-dependent phenotype of the MCveA-laeA strain. The effects of gene loss and gain on density-dependent development are summarized in Table 7.

VeA and LaeA Feedback Regulation.

Both veA and laeA have been reported to be global regulators of secondary metabolites in *A. flavus*, as well as in other aspergilli. Here, the results indicate that the MCveA and MClaeA strains—particularly the MClaeA strain—produce more aflatoxin and sclerotia than the wild type. The MCveA-laeA double mutant did not show increased toxin production compared to that of the single mutants or an additive effect on sclerotial production. Prior work indicated that LaeA negatively regulated veA expression, and here, we show evidence for VeA regulation of LaeA (FIG. **15**), as was described for *A. nidulans*. These results support a mechanism of mutual repression of veA and laeA expression and may explain, in part, a dampening of the expression of both genes in the MCveA-laeA strain compared to the expression of the single genes in the MCveA and MClaeA strains which, in turn, may affect aflatoxin and sclerotial output in the double mutant.

Requirement for VeA and LaeA in Host Cell Penetration and Degradation.

Host lipid reserves are depleted during seed colonization by *Aspergillus*, with lipase and esterase activities implicated in seed pathogenesis. Both null mutants were impaired in seed colonization, where neither strain could degrade lipid

reserves despite hyphal penetration of at least some layers of the host seeds (FIGS. **19**A and B). The crippled ability of both null mutants to utilize lipid reserves brings to mind several lipid biosynthesis mutants also impaired in *Aspergillus* colonization of seed, including β-oxidation mutants, odeA mutants [(delta)12-desaturase], and the oxylipin oxygenase mutants in *A. nidulans* and *A. flavus*. The inhibition of both null mutants by oleic acid (not seen in the wild type) (FIG. **20**) suggests a possible toxic effect of this fatty acid on these strains which may relate to their impairment in growth on seed. It is less likely that the inhibition is associated with defects in β-oxidation, since the mutants grew equally as well as the wild type on oleic acid as a sole carbon source (data not shown), although we cannot rule out this possibility. Regardless of mechanism, the results of all of these studies together may support lipid utilization and/or signaling as an important factor in *Aspergillus* seed pathogenesis.

Interestingly, the hyphal penetration patterns of the two null mutants as revealed by Gomori staining were quite diverse, whereas hyphae of the ΔveA strain remained largely intercellular (FIG. **19**A). This inability to penetrate intracellularly may indicate loss of degradative enzymes in this strain and may explain its poor production of conidia on host seed. However, we note that the strain is crippled in conidial production on medium also. The relative decrease of conidial production by the ΔlaeA strain on seed (compared to its vigorous conidial production in medium) might be attributable to a loss in lipid assimilation or the possible toxicity effects mentioned above.

Histology of the MC strains presented an invasion and lipid degradation pattern similar to that of the wild type. The relatively decreased conidial production on seed from these strains is possibly a function of their skewed sclerotial development rather than an inability to obtain nutrients from the seed.

In conclusion, this example provides additional evidence for distinct roles of LaeA and VeA in the development and pathogenesis of *A. flavus* despite the considerable overlapping of functions previously reported. The loss of both genes blocks the production of sclerotia and aflatoxin, but under our conditions, only laeA overexpression abolishes density-dependent phenomena, including a sclerotial-to-conidial shift and decreased aflatoxin production with cell population increase. The null mutants, while both were reduced in host lipid utilization, displayed distinct cell ingress abilities as reflected in patterns of hyphal penetration of host cells.

Other embodiments and uses of the invention will be apparent to those skilled in the art from consideration from the specification and practice of the invention disclosed herein. All references cited herein for any reason, including all journal citations and U.S./foreign patents and patent applications, are specifically and entirely incorporated herein by reference. It is understood that the invention is not confined to the specific reagents, formulations, reaction conditions, etc., herein illustrated and described, but embraces such modified forms thereof as come within the scope of the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 146

<210> SEQ ID NO 1
<211> LENGTH: 49
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 1

tttggccatg ggtggtagcg gtggtatggt gagcaagggc gaggagctg 49

<210> SEQ ID NO 2
<211> LENGTH: 40
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 2

aaaatttaag cttctacttg tacagttcgt ccatgccgtg 40

<210> SEQ ID NO 3
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 3

actcacgaat ccacgggata cat 23

<210> SEQ ID NO 4
<211> LENGTH: 36
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 4

ggcctgagtg gccgggtggg atacggtcca tcgaaa 36

<210> SEQ ID NO 5
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 5

ggccatctag gccgaccgta tattgtttca taaatcctt 39

<210> SEQ ID NO 6
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 6

tatgaccgcg tgagcaaata ggac 24

<210> SEQ ID NO 7
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 7

atgtttgaga tgggcccggt ggg 23

<210> SEQ ID NO 8
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 8

ttatcttaat ggtttcctag cctggt 26

<210> SEQ ID NO 9
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 9

atgtacgctg ttgaggatag ggc 23

<210> SEQ ID NO 10
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 10

ttagtattcg ttatccagac catcg 25

<210> SEQ ID NO 11
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 11

ctcgagttag tattcgttat ccagaccatc g 31

<210> SEQ ID NO 12
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 12

ccatggatgg ctacacttgc agcaccacca 30

<210> SEQ ID NO 13
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 13

ctcgagttaa cgcatggtgg caggctttga ga 32

<210> SEQ ID NO 14
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 14

atggtgagca agggcgagga g 21

<210> SEQ ID NO 15
<211> LENGTH: 51
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 15

ggtggtggtg ctgcaagtgt agccatcgtg gcgatggagc gcatgatata g 51

<210> SEQ ID NO 16
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 16

atggccgaca agcagaagaa c 21

<210> SEQ ID NO 17
<211> LENGTH: 54
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 17

acgagttccc accgggccca tctcaaacat gtggttcatg accttctgtt tcag 54

<210> SEQ ID NO 18
<211> LENGTH: 54
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 18

ggaatgcgcc ctatcctcaa cagcgtacat gtggttcatg accttctgtt tcag 54

<210> SEQ ID NO 19
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 19

gaattcatgc agcagcccaa gcgcgcgaga g 31

<210> SEQ ID NO 20
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 20

aaagggcccc gagaatgtcc gcctgacccg tgc 33

<210> SEQ ID NO 21
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 21

ccaagtctgc ccgacaagct cactg 25

<210> SEQ ID NO 22
<211> LENGTH: 66
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 22

cgccacagcg acgaggacga tggtctggat aacgaatacg gtggtagcgg tggtatggtg 60

agcaag 66

<210> SEQ ID NO 23
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 23

gtattcgtta tccagaccat cgtc 24

-continued

<210> SEQ ID NO 24
<211> LENGTH: 57
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 24

ctgcacatat accaggctag gaaaccatta agaggtggta gcggtggtat ggtgagc 57

<210> SEQ ID NO 25
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 25

tcttaatggt ttcctagcct ggta 24

<210> SEQ ID NO 26
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 26

cctcgccctc ctgcatcaat attcgg 26

<210> SEQ ID NO 27
<211> LENGTH: 78
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 27

gagacggcta tgaaattctt tttccatctt ctcttaccac cgctaccacc tcttaatggt 60

ttcctagcct ggtatatg 78

<210> SEQ ID NO 28
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 28

gagcaggcgc tctacatgag catgccctgc ccctgagagc aaaaggcgac cacatccagg 60

<210> SEQ ID NO 29
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 29

tcgtcaaccg cctcagctgg aacc 24

<210> SEQ ID NO 30
<211> LENGTH: 25
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 30

cctcctcgcc gcctctagta ccgtc 25

<210> SEQ ID NO 31
<211> LENGTH: 64
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 31

gaaattcttt ttccatcttc tcttaccacc gctaccaccg tattcgttat ccagaccatc 60

gtcc 64

<210> SEQ ID NO 32
<211> LENGTH: 62
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 32

cgagcaggcg ctctacatga gcatgccctg cccctgaaga ccgtatattg tttcataaat 60

cc 62

<210> SEQ ID NO 33
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 33

cggctgttta cattgtgttt tctgg 25

<210> SEQ ID NO 34
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 34

ccgtgaagaa cttggcgttg tag 23

<210> SEQ ID NO 35
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 35

ggaccgtcta attcaactca cag 23

<210> SEQ ID NO 36
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

-continued

<400> SEQUENCE: 36

cttccagcgg ttatcctccg ttg 23

<210> SEQ ID NO 37
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 37

atctgacaga gcggccgcaa ttgattacg 29

<210> SEQ ID NO 38
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 38

atatatgcgg ccgctcttgc atctttgttt 30

<210> SEQ ID NO 39
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 39

gataccaaac ggaactggct gttatgg 27

<210> SEQ ID NO 40
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 40

atcgacgcaa ccatcgaagc agc 23

<210> SEQ ID NO 41
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 41

gatctttgcc cggtgtatga aacc 24

<210> SEQ ID NO 42
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 42

tcggaggagg ccatggtgat gtctgctcaa gc 32

<210> SEQ ID NO 43

-continued

<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 43

gacatcacca tggcctcctc cgaggacgtc atc 33

<210> SEQ ID NO 44
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 44

ggctccagcg cctgcaccag ctccggcgcc ggtggagtgg cggc 44

<210> SEQ ID NO 45
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 45

ggagctggtg caggcgctgg agccactggc ggcaaatctg gtgg 44

<210> SEQ ID NO 46
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 46

atctggaggg gacaggcagt ttat 24

<210> SEQ ID NO 47
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 47

gggtttcgaa ctacatcaag ggtccaagac cgacatcgag gctctgtaca gtgaccggtg 60

<210> SEQ ID NO 48
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 48

agggaattct caggggcagg gcatgc 26

<210> SEQ ID NO 49
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 49

-continued

gaaggtcgat gatggtgtga tg 22

<210> SEQ ID NO 50
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 50

ctagaggtaa agatcaaggt ag 22

<210> SEQ ID NO 51
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 51

ctgatggctg aatgaagcac ag 22

<210> SEQ ID NO 52
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 52

tgctttacga cgatagccat gc 22

<210> SEQ ID NO 53
<211> LENGTH: 45
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 53

ggtgaagagc attgtttgag gcagcggcca gtctttagac aaatg 45

<210> SEQ ID NO 54
<211> LENGTH: 45
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 54

agtgcctcct ctcagacaga ataggataac gaatactaaa gaccg 45

<210> SEQ ID NO 55
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 55

tatgcactgg cactcaagca accg 24

<210> SEQ ID NO 56
<211> LENGTH: 24
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 56

gtgcatgacg gtcgtatctg gtcc 24

<210> SEQ ID NO 57
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 57

ggctgtagtc gctttgtt 18

<210> SEQ ID NO 58
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 58

gcccagtgta agaaagga 18

<210> SEQ ID NO 59
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 59

gctgtcgatc tttgtaccct g 21

<210> SEQ ID NO 60
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 60

cgttcctgga tgtggtcgcc t 21

<210> SEQ ID NO 61
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 61

atataagctt aatggctaca cttgcagcac cac 33

<210> SEQ ID NO 62
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 62

atatgtcgac ttaacgcatg gtggcaggct ttg 33

-continued

<210> SEQ ID NO 63
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 63

atataagctt aatgcagcag cccaagcgcg cgag 34

<210> SEQ ID NO 64
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 64

atatgaattc atgagtgcgg cgaactatcc ag 32

<210> SEQ ID NO 65
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 65

atatgtcgac tcaccgagga gttccgttcg ctg 33

<210> SEQ ID NO 66
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 66

atatgaattc atgtttgaga tgggcccggt gggaac 36

<210> SEQ ID NO 67
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 67

atatgtcgac ttatcttaat ggtttcctag cctg 34

<210> SEQ ID NO 68
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 68

atataagctt atcaacgagc atcagcacaa ac 32

<210> SEQ ID NO 69
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 69

atatgtcgac tccatattcc actgccgacg gac 33

<210> SEQ ID NO 70
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 70

atatgaattc tctgatagga cagccatgca aatc 34

<210> SEQ ID NO 71
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 71

atatgaattc atgtacgctg ttgaggatag 30

<210> SEQ ID NO 72
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 72

atatgtcgac ttagtattcg ttatccagac ca 32

<210> SEQ ID NO 73
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 73

atatgaattc acggtagcgc gggtatcgga g 31

<210> SEQ ID NO 74
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 74

atatgaattc atgtcttcat cgtatccacc ac 32

<210> SEQ ID NO 75
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 75

atatctcgag accaggcacc gggacggaga tg 32

-continued

<210> SEQ ID NO 76
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 76

atatctcgag agtaggaata gtccctactc gtg 33

<210> SEQ ID NO 77
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 77

atatctcgag tccaggccct ggagtaactg gctg 34

<210> SEQ ID NO 78
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 78

ttcgctagac agctcattct acg 23

<210> SEQ ID NO 79
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 79

tagtattcgt tatccagacc atcg 24

<210> SEQ ID NO 80
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 80

atacctggat aaaccaaatc gagc 24

<210> SEQ ID NO 81
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 81

aggttcattc gcagggctag ac 22

<210> SEQ ID NO 82
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

-continued

<400> SEQUENCE: 82

accactacag ctaccactct cc 22

<210> SEQ ID NO 83
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 83

tttcgatgct ctctgagacg gc 22

<210> SEQ ID NO 84
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 84

Arg Leu Glu Val Ile Ser Asn Pro Phe Ile Val Tyr Ser Ala Lys Lys
1 5 10 15

<210> SEQ ID NO 85
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 85

Arg Leu Glu Val Ile Ser Asn Pro Phe Ile Val Tyr Ser Ala Lys Lys
1 5 10 15

<210> SEQ ID NO 86
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 86

Arg Leu Glu Val Ile Ser Asn Pro Phe Ile Val Tyr Ser Ala Lys Lys
1 5 10 15

<210> SEQ ID NO 87
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 87

Lys Ile Gly Val Trp Phe Val Leu Gln Asp Leu Ser Val Arg Thr
1 5 10 15

<210> SEQ ID NO 88
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 88

Lys Ser Val Ser Asp Leu Pro Gln Ser Asp Ile Ala Glu Val Ile Asn
1 5 10 15

Lys Gly

<210> SEQ ID NO 89
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

-continued

<400> SEQUENCE: 89

Arg Ile Trp Ser Leu Gln Val Val Gln Gln Pro Ile Arg Ala
1 5 10

<210> SEQ ID NO 90
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 90

Lys Glu Ile His Ala Tyr Asn Ile Leu His Ile Tyr Gln Ala Arg Lys
1 5 10 15

<210> SEQ ID NO 91
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 91

Arg Tyr Ala Val Ala Gly Gly Pro Ala Pro Trp Asn Arg Asn
1 5 10

<210> SEQ ID NO 92
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 92

Arg Val Ser Glu Ser Leu Ile Tyr Ala Pro His Pro Thr Asn Gly Arg
1 5 10 15

Phe

<210> SEQ ID NO 93
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 93

Lys Ile Ile Gln Val Ala Leu Asp Gly Leu Glu Asn Ile Leu Lys Val
1 5 10 15

<210> SEQ ID NO 94
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 94

Lys Ile Gln Ala Val Ile Glu Ala Gly Ile Pro Arg Arg
1 5 10

<210> SEQ ID NO 95
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 95

Lys Thr Pro Gln Pro Asp Trp Asn Thr Ile Ala Pro Ala Leu Pro Val
1 5 10 15

Leu Ala Lys Leu
20

<210> SEQ ID NO 96
<211> LENGTH: 22

-continued

<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 96

Lys Gly Thr Ala Pro Ile Leu Ala Ser Thr Phe Ser Glu Pro Phe Gln
1 5 10 15

Val Phe Ser Ala Lys Lys
20

<210> SEQ ID NO 97
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 97

Lys Ile Gly Val Trp Phe Val Leu Gln Asp Leu Ser Val Arg Thr
1 5 10 15

<210> SEQ ID NO 98
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 98

Lys Ser Val Ser Asp Leu Pro Gln Ser Asp Ile Ala Glu Val Ile Asn
1 5 10 15

Lys Gly

<210> SEQ ID NO 99
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 99

Lys Asp Ala Thr Glu Gly Thr Gln Pro Met Pro Ser Pro Val Pro Gly
1 5 10 15

Lys Leu

<210> SEQ ID NO 100
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 100

Lys Lys Phe Pro Gly Leu Thr Thr Ser Thr Pro Ile Ser Arg Met
1 5 10 15

<210> SEQ ID NO 101
<211> LENGTH: 28
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 101

Lys Leu Met Thr Asn Gln Gly Ser Pro Val Leu Thr Gly Val Pro Val
1 5 10 15

Ala Gly Val Ala Tyr Leu Asp Lys Pro Asn Arg Ala
20 25

<210> SEQ ID NO 102
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

-continued

<400> SEQUENCE: 102

Lys Glu Ile His Ala Tyr Asn Ile Leu His Ile Tyr Gln Ala Arg Lys
1 5 10 15

<210> SEQ ID NO 103
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 103

Arg Ile Gln Gln Leu Ala Ala Asp Val Lys Ser
1 5 10

<210> SEQ ID NO 104
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 104

Arg Tyr Ala Val Ala Gly Gly Pro Ala Pro Trp Asn Arg Asn
1 5 10

<210> SEQ ID NO 105
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 105

Lys Asp Val Asp Asn Thr Asp Gly Gly Phe Phe Val Trp Gly Asp Leu
1 5 10 15

Ser Ile Lys Val
20

<210> SEQ ID NO 106
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 106

Arg Leu Lys Asp Val Asp Asn Thr Asp Gly Gly Phe Phe Val Trp Gly
1 5 10 15

Asp Leu Ser Ile Lys Val
20

<210> SEQ ID NO 107
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 107

Lys Glu Ile His Ala Tyr Asn Ile Leu His Ile Tyr Gln Ala Arg Lys
1 5 10 15

<210> SEQ ID NO 108
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 108

Arg Trp Tyr Asn Leu Ala Val Ser Glu Ser Ile Glu Asn Leu Ser Leu
1 5 10 15

Ala Pro Phe Ser Arg Val
20

<210> SEQ ID NO 109
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 109

Arg Tyr Ala Val Ala Gly Gly Pro Ala Pro Trp Asn Arg Asn
1 5 10

<210> SEQ ID NO 110
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 110

Lys Gly Thr Ala Pro Ile Leu Ala Ser Thr Phe Ser Glu Pro Phe Gln
1 5 10 15

Val Phe Ser Ala Lys Lys
20

<210> SEQ ID NO 111
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 111

Lys Ser Val Ser Asp Leu Pro Gln Ser Asp Ile Ala Glu Val Ile Asn
1 5 10 15

Lys Gly

<210> SEQ ID NO 112
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 112

Arg Ile Trp Ser Leu Gln Val Val Gln Gln Pro Ile Arg Ala
1 5 10

<210> SEQ ID NO 113
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 113

Arg Leu Glu Val Ile Ser Asn Pro Phe Ile Val Tyr Ser Ala Lys Lys
1 5 10 15

<210> SEQ ID NO 114
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 114

Arg Arg Pro Asp Gln Tyr Ala Gly Ser Asp Ala Tyr Ala Asn Ala Pro
1 5 10 15

Glu Arg Pro Arg Ser
20

<210> SEQ ID NO 115
<211> LENGTH: 19
<212> TYPE: PRT

-continued

<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 115

Arg Arg Pro Ser Ala Val Glu Tyr Gly Gln Pro Ile Ala Gln Pro Tyr
1 5 10 15

Gln Arg Pro

<210> SEQ ID NO 116
<211> LENGTH: 573
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 116

Met Ala Thr Leu Ala Ala Pro Pro Pro Pro Leu Gly Glu Ser Gly Asn
1 5 10 15

Ser Asn Ser Val Ser Arg Ile Thr Arg Glu Gly Lys Lys Ile Thr Tyr
20 25 30

Lys Leu Asn Ile Met Gln Gln Pro Lys Arg Ala Arg Ala Cys Gly Gln
35 40 45

Gly Ser Lys Ser His Thr Asp Arg Arg Pro Val Asp Pro Pro Pro Val
50 55 60

Ile Glu Leu Asn Ile Phe Glu Ser Asp Pro His Asp Asp Ser Asn Lys
65 70 75 80

Thr Asp Ile Thr Phe Val Tyr Asn Ala Asn Phe Phe Leu Phe Ala Thr
85 90 95

Leu Glu Pro Glu Arg Pro Ile Ala Thr Gly Lys Leu Met Thr Asn Gln
100 105 110

Gly Ser Pro Val Leu Thr Gly Val Pro Val Ala Gly Val Ala Tyr Leu
115 120 125

Asp Lys Pro Asn Arg Ala Gly Tyr Phe Ile Phe Pro Asp Leu Ser Val
130 135 140

Arg Asn Glu Gly Ser Tyr Arg Phe Ser Phe His Leu Phe Glu Gln Ile
145 150 155 160

Lys Asp Pro Lys Asp Ala Thr Glu Gly Thr Gln Pro Met Pro Ser Pro
165 170 175

Val Pro Gly Lys Leu Ser Ser Pro Gln Glu Phe Leu Glu Phe Arg Leu
180 185 190

Glu Val Ile Ser Asn Pro Phe Ile Val Tyr Ser Ala Lys Lys Phe Pro
195 200 205

Gly Leu Thr Thr Ser Thr Pro Ile Ser Arg Met Ile Ala Glu Gln Gly
210 215 220

Cys Arg Val Arg Ile Arg Arg Asp Val Arg Met Arg Arg Arg Gly Asp
225 230 235 240

Lys Arg Thr Glu Asp Tyr Asp Tyr Asp Asn Glu Arg Gly Tyr Asn Asn
245 250 255

Arg Arg Pro Asp Gln Tyr Ala Gly Ser Asp Ala Tyr Ala Asn Ala Pro
260 265 270

Glu Arg Pro Arg Ser Thr Ser Ile Ser Thr Asn Met Asp Pro Tyr Ser
275 280 285

Tyr Pro Ser Arg Arg Pro Ser Ala Val Glu Tyr Gly Gln Pro Ile Ala
290 295 300

Gln Pro Tyr Gln Arg Pro Met Ala Ser Thr Pro Ala Pro Ser Ser Thr
305 310 315 320

Pro Ile Pro Ala Pro Ile Pro Met Pro Gly Pro Val Ala Leu Pro Pro
325 330 335

-continued

```
Ser Thr Pro Ser Pro Ala Ser Ala His Ala Pro Ala Pro Pro Ser Val
            340                 345                 350

Pro Leu Ala Ala Pro Pro Pro Leu His Thr Pro Ser Tyr Gln Ser His
        355                 360                 365

Leu Ser Phe Gly Ala Thr Gln Thr Gln Tyr Pro Ala Pro Gln Leu Ser
    370                 375                 380

His Ile Pro Gln Gln Thr Thr Thr Pro Thr His Pro Tyr Ser Pro Arg
385                 390                 395                 400

Ser Ser Ile Ser His Ser Arg Asn Gln Ser Ile Ser Glu Tyr Glu Pro
                405                 410                 415

Ser Met Gly Tyr Pro Gly Ser Gln Thr Arg Leu Ser Ala Glu Arg Pro
            420                 425                 430

Ser Tyr Gly Gln Pro Ser Gln Thr Thr Ser Leu Pro Pro Leu Arg His
        435                 440                 445

Ser Leu Glu Pro Ser Val Asn Ser Arg Ser Lys Thr Pro Ser Asn Met
    450                 455                 460

Ile Thr Ser Leu Pro Pro Ile Gln Ser Leu Ser Glu Leu Pro Ser Thr
465                 470                 475                 480

Thr Ser Gln Pro Ser Ser Ala Ile Gly Ser Ser Pro Ala Asn Glu Pro
                485                 490                 495

Gly Pro Arg Leu Trp Glu Thr Asn Ser Met Leu Ser Lys Arg Thr Tyr
            500                 505                 510

Glu Glu Ser Phe Gly His Asp Asp Arg Pro Leu Tyr Asn Gly Met Arg
        515                 520                 525

Pro Asp Ser Glu Ser Tyr Pro Gly Gly Met Gln Arg Arg Pro Ser Tyr
    530                 535                 540

Glu Arg Ser Ser Leu Leu Asp Gly Pro Asp Gln Met Ala Tyr Lys Arg
545                 550                 555                 560

Ala Asn Gly Arg Met Val Ser Lys Pro Ala Thr Met Arg
                565                 570


<210> SEQ ID NO 117
<211> LENGTH: 369
<212> TYPE: PRT
<213> ORGANISM: Aspergillus nidulans

<400> SEQUENCE: 117

Met Tyr Ala Val Glu Asp Arg Ala His Ser Gly His His Pro Pro Pro
1               5                   10                  15

Leu Ser Met Asp Arg Ile Pro Pro Pro Ser Thr Met Tyr Pro Ser Ser
            20                  25                  30

Ala Gly Pro Ser Ala Met Val Ser Pro Ala Gly Gln Pro Glu Pro Glu
        35                  40                  45

Ser Leu Ser Thr Val His Asp Gly Arg Ile Trp Ser Leu Gln Val Val
    50                  55                  60

Gln Gln Pro Ile Arg Ala Arg Met Cys Gly Phe Gly Asp Lys Asp Arg
65                  70                  75                  80

Arg Pro Ile Thr Pro Pro Pro Cys Ile Arg Leu Ile Val Lys Asp Ala
                85                  90                  95

Gln Thr Gln Lys Glu Val Asp Ile Asn Ser Leu Asp Ser Ser Phe Tyr
            100                 105                 110

Val Val Met Ala Asp Leu Trp Asn Ala Asp Gly Thr His Glu Val Asn
        115                 120                 125

Leu Val Lys His Ser Ala Thr Ser Pro Ser Ile Ser Thr Ala Met Ser
```

-continued

```
    130                 135                 140

Ser Ser Tyr Pro Pro Pro Pro His Pro Thr Ser Ser Asp Tyr Pro Ala
145                 150                 155                 160

Ser Tyr Gln Thr Asn Pro Tyr Gly Gln Pro Val Gly Gln Pro Val Gly
                165                 170                 175

Gln Pro Val Gly Tyr Ala Gly Val Gly Asn Tyr Tyr Gly Gly Ser Thr
            180                 185                 190

Gln Leu Gln Tyr Gln Asn Ala Tyr Pro Asn Pro Gln Ala Gln Tyr Tyr
        195                 200                 205

Gln Pro Met Tyr Gly Gly Met Ala Gln Pro Gln Met Pro Ala Ala Gln
    210                 215                 220

Pro Val Thr Pro Gly Pro Gly Gly Met Phe Thr Arg Asn Leu Ile Gly
225                 230                 235                 240

Cys Leu Ser Ala Ser Ala Tyr Arg Leu Tyr Asp Thr Glu Asp Lys Ile
                245                 250                 255

Gly Val Trp Phe Val Leu Gln Asp Leu Ser Val Arg Thr Glu Gly Ile
            260                 265                 270

Phe Arg Leu Lys Phe Ser Phe Val Asn Val Gly Lys Ser Val Ser Asp
        275                 280                 285

Leu Pro Gln Ser Asp Ile Ala Glu Val Ile Asn Lys Gly Thr Ala Pro
    290                 295                 300

Ile Leu Ala Ser Thr Phe Ser Glu Pro Phe Gln Val Phe Ser Ala Lys
305                 310                 315                 320

Lys Phe Pro Gly Val Ile Glu Ser Thr Pro Leu Ser Lys Val Phe Ala
                325                 330                 335

Asn Gln Gly Ile Lys Ile Pro Ile Arg Lys Asp Gly Val Lys Gly Gln
            340                 345                 350

Gly Ser Arg Gly Arg His Ser Asp Glu Asp Asp Gly Leu Asp Asn Glu
        355                 360                 365

Tyr
```

<210> SEQ ID NO 118
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 118

acaaccctgg actctggaat 20

<210> SEQ ID NO 119
<211> LENGTH: 51
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 119

cgaagagggt gaagagcatt gtttgaggca gaggacgcgt tgactgtgat g 51

<210> SEQ ID NO 120
<211> LENGTH: 50
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 120

-continued

tgacgacaat acctcccgac gatacctggg ttgattcctg cttttcctcc 50

<210> SEQ ID NO 121
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 121

tctcgttctc ccatttacct 20

<210> SEQ ID NO 122
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 122

tgcctcaaac aatgctcttc 20

<210> SEQ ID NO 123
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 123

caaggtatcg tcgggaggt 19

<210> SEQ ID NO 124
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 124

aatcacggac ctcgaagcag 20

<210> SEQ ID NO 125
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 125

ggggtcttga tatggcgaat 20

<210> SEQ ID NO 126
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 126

caacaagacc gacatcacct tc 22

<210> SEQ ID NO 127
<211> LENGTH: 22
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 127

ccattcttgg gatagctgca ac 22

<210> SEQ ID NO 128
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 128

caacgaacta gtccgcctgc ccttaacctc ca 32

<210> SEQ ID NO 129
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 129

gcatacacta gtctcgcatg ccagtggatg gg 32

<210> SEQ ID NO 130
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 130

catcggttga ctacgctcgc a 21

<210> SEQ ID NO 131
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 131

gacctgtggt gaaacctgag g 21

<210> SEQ ID NO 132
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 132

ctagctggtc attatttgat ctcg 24

<210> SEQ ID NO 133
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 133

gttgtagagt ggacgatcat catg 24

<210> SEQ ID NO 134
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 134

ccttgtatga tgtatgtatg atgagc 26

<210> SEQ ID NO 135
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 135

gacagcgaaa gtgaagagga catc 24

<210> SEQ ID NO 136
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 136

gaagcggtct gaatctcctg 20

<210> SEQ ID NO 137
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 137

acagtccaag cgtggtatcc 20

<210> SEQ ID NO 138
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 138

agagtcttcc ttcagccagg tc 22

<210> SEQ ID NO 139
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 139

gtggggcttt tcttcattct cg 22

<210> SEQ ID NO 140
<211> LENGTH: 3662
<212> TYPE: DNA
<213> ORGANISM: Aspergillus flavus

-continued

<400> SEQUENCE: 140

acctcacagc tggctgagtt cccactggat cggccattct tctttttta ccccctcttc 60

tgtgacacca tccaccttcc cccattttag tgccatccgt gctgacccaa tacccaccat 120

atcggctcag tcgtgcagag ttagtgccgt cgtacatacc agctccatta gaaggtactg 180

tacatacgcc atgtatctac ggggtaattc cggttgccgt cgtcagaacg gataaacatc 240

tcctattgac cctctcgata agaaagagca agttcagagc gaataaaatg ctcgaagcgc 300

agaaatgcga ccgtagaccc atggtaccgg gatatttaag aacgcaagtt atgtatgggg 360

ccgtcagccc gatcaccatg ttgttggaac ttggaaccga tggaaaccgt caccgtcggt 420

aatcttacag taccacggct ccggagacga gacggttagg gtgttatagt tggttgcgat 480

agtgtgtgta cctgccgatt ctcaggctga ctcgtccttt gacttttccc gtcctcgctc 540

gctccacccc ctctcattca ttattcttcg tccccccgt atcaccaact tgacttttgt 600

tactcctctc ccataccttc tttcctcatc ctggacgggt caatcgctgg attgtctgtt 660

gtactgcctc ggcgcagcgg acccagttta aatttttttt ttttttaatt tcattatcct 720

tcttttcccc ttttggtcga cagttggaat ctctctcgtt ttccgtttcg cagacgactt 780

cgagaacatc cttgaccgac tggtcggttt cacggcttgc attcgtggga gtcacgcccg 840

acataaccag cacactagaa gaaaaccaga ttcacacggg aaacggggat agattacttg 900

cttgacgcaa gcactttccc atagcgttga ttttgtttgg ttggaccgag ggattgccaa 960

gtaagtccca agcttcattg ctagctggtc attatttgat ctcgaccatg aaattgtggt 1020

caattacgcc cgtcgaatct tgttgtgcta atcctggcag tttttcgcat cacagtcaag 1080

gcgtctccaa aatggcgaca cgagctcctt tggcgcctcc gccgaacgag acggaagcct 1140

ccgtcagccg gatcactcga gagggcaaga agctcaccta taaactcaat gtcatgcaac 1200

agcctgagcg tgcgcgagcc tgcggtgcag gtgcaaagtg tatgcgtcca accagcactc 1260

cataaccgga tagcatcaaa ctgatggttc tgactttata tagcctctgc ggaccgtcgt 1320

ccagtcgatc ctccaccggt cgtcgaactt cgagtgtacg agtccgatcc caacgacgac 1380

ctcaacaaga ccgacatcac cttcgcatac aacgccaatt tcttcctgta cgccactttg 1440

gaaaccgctc gtcccatggc ccaaggccgt tttgccccga atccgacttg tccagtattg 1500

accggtgtgc ccgtggctgg agtggcttac ttggaccgcc catctcaagc cggttacttc 1560

atcttccccg atctttccgt gcggcatgaa ggtgtatatc gattgaactt ccacctgtac 1620

gaggaaacca aggagagcaa ggatgcgaac gagaatgctc cgatccagtc catgtccaac 1680

ccaatgccat cgaagccgat ggcgccgaag tcattcctgg agtttcgtct cgaggtcgtt 1740

tccgttccgt tcaccgtatt taacgccaag aagttcccag gattggccac gagtacctcc 1800

ctgagtcggg tcattgcgga gcaaggttgt cgtgtgcgga ttcgacgtga tgtccgcatg 1860

agacgtcggg gagagaagcg caccgatgac tacgactacg atgaggagag agtctaccga 1920

tcttctgacc gaatctctac cccagatacc cacgggtacg ccggcactcc cgttgaacgt 1980

cctcgatcaa ccagtaccag cacggtggat ccctcattcc cctacggtgt cgatgctcag 2040

cgccggtcat ctggcgcgac cgagtatggt ttccagggtg cacagccgta ccaacgacca 2100

ttgccgcctg ctccgggtcc cgcaccagcc gctgtttcca cgcccgctcc tcccgctcct 2160

cccgcgccac catcccataa tcctggatat caatcgcatc tttcctttgg ctcgactcaa 2220

actcaatatc cagctcccca gctgcctcca actccacaga ccgcgtcgac attggcagct 2280

ccgtactcgc cccatccatc gtattctcat gctcggaatc catcgacgag ggccgagtat 2340

-continued

gaaacgcccg gttactccta tccgccatca cggatgtcaa cggaacgttc cagctatccc 2400

aagaatggct tgcctccgct ccgcttggaa ccgcctaagc cactaaatat gccatccggc 2460

gagccacgct cgtccgatct gaacgcatat cattccgtgg ctcaatcggc ggcaccccgg 2520

tctcagacac cgtcatccag tctggtgcct tcccttccgc ccctcaaggc tctatcgggg 2580

gattatccca acaacctctc tcaatcatcc agcagtacct ctcagagccc cagtcacgat 2640

ctcggcgctg gcaagaagtt cttctgggat acgggcgcca gcctgtccaa gcggtcgtac 2700

gaagattcgt ttggccatga tgatcgtcca ctctacaacg gcatgcgccc cgatacggaa 2760

agttatcctc ggaggctgtc agatgccagt cggaacttct acaacgaaac gcgcgatgaa 2820

atggcgtaca aacgagccaa cgggagaatg gccacgaaga tatcccctgc actccagtaa 2880

aacaagttga ttcctgcttt tcctcccgct catatagtga cggcgtcttg gcgtaacggt 2940

cgtcgattga tttctttccc gtaatctgtt ccttttccta atgtactctg gtgtgatggg 3000

cttcagggac tcttttaacg acccagactt ttgatgttta taccaccgtt ctttttcttc 3060

tttcctcgat ctttggcatt attgtacatg atgctctgca tgtggttttc aagatattcc 3120

ccggattgtt cttgtcttca gtttatatac ggccgctctc gtgtttatta tccgctgtgt 3180

ttccaggtcg gctggacctg gggcctctcc cttcccgcga atagaagtga gtgagcaata 3240

caaatgtgac attgtccaaa agtttggtga tctgaacgcg caacctggat gcattgatcc 3300

gagacaatca cggggtctta gacatgcgac atgtctgatt cactccttcg accatttcct 3360

tgtttatcca tgaccatgcc ccatccactg gcatgcgaga atgacgtatg cgacagataa 3420

gatcgacgat ctgccttata tatccgaatt gatccgattg tcaatactct ctcttagtgt 3480

tgtataagta tatatatgtg ctgtagagta tgtcctggct gtctcccata cagaagaagc 3540

catgtcgaga aagggtatgt ccaccagagt aagattgtac attccttgga catgtcattg 3600

tcatttcaca ggaaatatcg aagggtcatg gattcggagg aacattccag ggaagagaca 3660

cc 3662

<210> SEQ ID NO 141
<211> LENGTH: 4406
<212> TYPE: DNA
<213> ORGANISM: Aspergillus flavus

<400> SEQUENCE: 141

aatcacggac ctcgaagcag tgggccttct ccaccctcga actgcctgtt caagttgtta 60

ggtttttgta ttttaattat tattttcttt ttgtctgaat tttctcacaa cttatttgtt 120

atgcagccaa tgtctaaacc ccaccggacc caatgaccaa gccggccgca gtcgccatga 180

cccaacgacc gtaaccgcct gcccttaacc tccagctggc tgagttccca ctggatcggc 240

cattcttctt tttttacccc ctcttctgtg acaccatcca ccttcccccа ttttagtgcc 300

atccgtgctg acccaatacc caccatatcg gctcagtcgt gcagagttag tgccgtcgta 360

cataccagct ccattagaag gtactgtaca tacgccatgt atctacgggg taattccggt 420

tgccgtcgtc agaacggata aacatctcct attgaccctc tcgataagaa agagcaagtt 480

cagagcgaat aaaatgctcg aagcgcagaa atgcgaccgt agacccatgg taccgggata 540

tttaagaacg caagttatgt atggggccgt cagcccgatc accatgttgt tggaacttgg 600

aaccgatgga aaccgtcacc gtcggtaatc ttacagtacc acggctccgg agacgagacg 660

gttagggtgt tatagttggt tgcgatagtg tgtgtacctg ccgattctca ggctgactcg 720

-continued

tcctttgact tttcccgtcc tcgctcgctc caccccctct cattcattat tcttcgtccc 780

ccccgtatca ccaacttgac ttttgttact cctctcccat accttctttc ctcatcctgg 840

acgggtcaat cgctggattg tctgttgtac tgcctcggcg cagcggaccc agtttaaatt 900

ttttttttt tttaatttca ttatccttct tttccccttt tggtcgacag ttggaatctc 960

tctcgttttc cgtttcgcag acgacttcga gaacatcctt gaccgactgg tcggtttcac 1020

ggcttgcatt cgtgggagtc acgcccgaca taaccagcac actagaagaa aaccagattc 1080

acacgggaaa cggggataga ttacttgctt gacgcaagca ctttcccata gcgttgattt 1140

tgtttggttg gaccgaggga ttgccaagta agtcccaagc ttcattgcta gctggtcatt 1200

atttgatctc gaccatgaaa ttgtggtcaa ttacgcccgt cgaatcttgt tgtgctaatc 1260

ctggcagttt ttcgcatcac agtcaaggcg tctctgcctc aaacaatgct cttccaaaat 1320

ggcgacacga gctcctttgg cgcctccgcc gaacgagacg gaagcctccg tcagccggat 1380

cactcgagag ggcaagaagc tcacctataa actcaaatgt catgcaacag cctgagcgtg 1440

cgcgagcctg cggtgcaggt gcaaagtgta tgcgtccaac cagcactcca taaccggata 1500

gcatcaaact gatggttctg actttatata gcctctgcgg accgtcgtcc agtcgatcct 1560

ccaccggtcg tcgaacttcg agtgtacgag tccgatccca acgacgacct caacaagacc 1620

gacatcacct tcgcatacaa cgccaatttc ttcctgtacg ccactttgga accgctcgtc 1680

ccatggccca aggccgtttt gccccgaatc cgacttgtcc agtattgacc ggtgtgcccg 1740

tggctggagt ggcttacttg gaccgcccat ctcaagccgg ttacttcatc ttccccgatc 1800

tttccgtgcg gcatgaaggt gtatatcgat tgaacttcca cctgtacgag gaaaccaagg 1860

agagcaagga tgcgaacgag aatgctccga tccagtccca tgtccaaccc aatgccatcg 1920

aagcccgatg gcgccgaagt cattcctgga gtttcgtctc gaggtcgttt ccgttccgtt 1980

caccgtattt agcgccaaga agttcccagg attggccacg agtacctccc tgagtcgggt 2040

cattgcggag caaggttgtc gtgtgcggat tcgacgtgat gtccgcatga gacgtcgggg 2100

agagaagcgc accgatgact acgactacga tgaggagaga gtctaccgat cttctgaccg 2160

aatctctacc ccagataccc acgggtacgc cggcactccc gttgaacgtc ctcgatcaac 2220

cagtaccagc acggtggatc cctcattccc ctacggtgtc gatgctcagc gccggtcatc 2280

tggcgcgacc gagtatggtt tccagggtgc acagccgtac caacgaccat tgccgcctgc 2340

tccgggtccc gcaccagccg ctgtttccac gcccgctcct cccgctcctc ccgcgccacc 2400

atcccataat cctggatatc aatcgcatct ttcctttggc tcgactcaaa ctcaatatcc 2460

agctccccag ctgcctccaa ctccacagac cgcgtcgaca ttggcagctc cgtactcgcc 2520

ccatccatcg tattctcatg ctcggaatcc atcgacgagc gccgagtatg aaacgcccgg 2580

ttactcctat ccgccatcac ggatgtcaac ggaacgttcc agctatccca agaatggctt 2640

gcctccgctc cgcttggaac cgcctaagcc actaaatatg ccatccggcg agccacgctc 2700

gtccgatccg aacgcatatc attccgtggc tcaatcggcg gcaccccggt ctcagacacc 2760

gtcatccagt ctggtgcctt cccttccgcc cctcaaggct ctatcggggg attatcccaa 2820

caacctctct caatcatcca gcagtacctc tcagagcccc agtcacgatc tcggcgctgg 2880

caagaagttc ttctgggata cgggcgccag cctgtccaag cggtcgtacg aagattcgtt 2940

tggccatgat gatcgtccac tctacaacgg catgcgcccc gatacggaaa gttatcctcg 3000

gaggctgtca gatgccagtc ggaacttcta caacgaaacg cgcgatgaaa tggcgtacaa 3060

acgagccaac gggagaatgg ccacgaagat atcccctgca ctccagtaaa acaagttgat 3120

-continued

tcctgctttt cctcccgctc atataggacg gcgtcttggc gaacggtcgt cgattgattt 3180

ctttcccgta atctgttcct tttcctaatg tactctggtg tgatgggctt cagggactct 3240

tttaacgacc cagacttttg atgtttatac caccgttctt tttcttcttt cctcgatctt 3300

tggcattatt gtacatgatg ctctgcatgt ggttttcaag atattccccg gattgttctt 3360

gtcttcagtt tatatacggc cgctctcgtg tttattatcc gctgtgtttc caggtcggct 3420

ggacctgggg cctctccctt cccgcgaata gaagtgagtg agcaatacaa atgtgacatt 3480

gtccaaaagt ttggtgatct gaacgcgcaa cctggatgca ttgatccgag acaatcacgg 3540

ggtcttagac atgcgacatg tctgattcac tccttcgacc atttccttgt ttatccatga 3600

ccatgcccca tccactggca tgcgagaatg acgtatgcga cagataagat cgacgatctg 3660

ccttatatat ccgaattgat tcgattgtca atactctctc ttagtgttgt ataagtatat 3720

atatgtgctg tagagtatgt cctggctgtc tcccatacag aagaagccat gtcgagaaag 3780

ggtatgtcca ccagagtaag attgtacatt ccttggacat gtcattgtca tttcacagga 3840

aatatcgaag ggtcatggat tcggaggaac attccaggaa gagacaccag aaatgagttg 3900

gcacggatca gtaaacatgt agatctacat aaccttgttc attttcatga tgcactgaca 3960

ctagagcata gaggcgttta ctttacctct tatcaacgac taattgacat aaccaagcag 4020

tggaattttt atgattcaac gtcccagact atagtgccta ctgttatgat ctacctgcta 4080

ctttgatcgg tttcactttc tttgttggtt gatacttgtt gcgtatcttc tttgattact 4140

tatagtcaat agtccctgtt actatattag cgccgttcct agccattgta tatcctttga 4200

tccactactt gaaagaaaat tcgaacaagg gttttaatgg atgtatccat tctattttct 4260

cttttctttg gatgtaatga gatacaaagg tgttctaatc aaaaagtatg tattcaattc 4320

aaatacatct tcccagacaa tctgggaaga ggaataagca agagagataa ttctccgact 4380

cacactattc gccatatcaa gacccc 4406

<210> SEQ ID NO 142
<211> LENGTH: 4556
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Aspergillus flavus veA knockout with
Aspergillus fumigatus pyrG

<400> SEQUENCE: 142

aatcacggac ctcgaagcag tgggccttct ccaccctcga actgcctgtt caagttgtta 60

ggtttttgta ttttaattat tattttcttt ttgtctgaat tttctcacaa cttatttgtt 120

atgcagccaa tgtctaaacc ccaccggacc caatgaccaa gccggccgca gtcgccatga 180

cccaacgacc gtaaccgcct gcccttaacc tccagctggc tgagttccca ctggatcggc 240

cattcttctt tttttacccc ctcttctgtg acaccatcca ccttccccca ttttagtgcc 300

atccgtgctg acccaatacc caccatatcg gctcagtcgt gcagagttag tgccgtcgta 360

cataccagct ccattagaag gtactgtaca tacgccatgt atctacgggg taattccggt 420

tgccgtcgtc agaacggata aacatctcct attgaccctc tcgataagaa agagcaagtt 480

cagagcgaat aaaatgctcg aagcgcagaa atgcgaccgt agacccatgg taccgggata 540

tttaagaacg caagttatgt atggggccgt cagcccgatc accatgttgt tggaacttgg 600

aaccgatgga aaccgtcacc gtcggtaatc ttacagtacc acggctccgg agacgagacg 660

gttagggtgt tatagttggt tgcgatagtg tgtgtacctg ccgattctca ggctgactcg 720

-continued

tcctttgact tttcccgtcc tcgctcgctc caccccctct cattcattat tcttcgtccc 780

ccccgtatca ccaacttgac ttttgttact cctctcccat accttctttc ctcatcctgg 840

acgggtcaat cgctggattg tctgttgtac tgcctcggcg cagcggaccc agtttaaatt 900

ttttttttt tttaatttca ttatccttct tttccccttt tggtcgacag ttggaatctc 960

tctcgttttc cgtttcgcag acgacttcga gaacatcctt gaccgactgg tcggtttcac 1020

ggcttgcatt cgtgggagtc acgcccgaca taaccagcac actagaagaa aaccagattc 1080

acacgggaaa cggggataga ttacttgctt gacgcaagca ctttcccata gcgttgattt 1140

tgtttggttg gaccgaggga ttgccaagta agtcccaagc ttcattgcta gctggtcatt 1200

atttgatctc gaccatgaaa ttgtggtcaa ttacgcccgt cgaatcttgt tgtgctaatc 1260

ctggcagttt ttcgcatcac agtcaaggcg tctctgcctc aaacaatgct cttcaccctc 1320

ttcgcgggtc tgaaataccc tcacctggca acagcaattg gcgcttcatg gctgtttttc 1380

cgatctctct acttgtacgg ctatgtgtac tcgggtaagc cacaaggcaa gggcagattg 1440

ctgggaggtt tcttctggtt ttctcaaggc gctctgtggg ctctgagtgt gtttggtgtt 1500

gccaaagaca tgatctctta ctgagagtta ttctgtgtct gacgaaatat gttgtgtata 1560

tatatatatg tacgttaaaa gttccgtgga gttaccagtg attgaccaat gttttatctt 1620

ctacagttct gcctgtctac cccattctag ctgtacctga ctacagagta gtttaattgt 1680

ggttgacccc acagtcggag gcggaggaat acagcaccga tgtggcctgt ctccatccag 1740

attggcacgc aatttttaca cgcggaaaag atcgagatag agtacgactt taaatttagt 1800

ccccggcggc ttctatttta gaatatttga gatttgattc tcaagcaatt gatttggttg 1860

ggtcaccctc aattggataa tatacctcat tgctcggcta cttcaactca tcaatcaccg 1920

tcataccccg catataaccc tccattccca cgatgtcgtc caagtcgcaa ttgacttacg 1980

gtgctcgagc cagcaagcac cccaatcctc tggcaaagag acttttgag attgccgaag 2040

caaagaagac aaacgttacc gtctctgctg atgtgacgac aacccgagaa ctcctggacc 2100

tcgctgaccg tacggaagct gttggatcca atacatatgc cgtctagcaa tggactaatc 2160

aacttttgat gatacaggtc tcggtcccta catcgccgtc atcaagacac acatcgacat 2220

cctcaccgat ttcagcgtcg acactatcaa tggcctgaat gtgctggctc aaaagcacaa 2280

ctttttgatc ttcgaggacc gcaaattcat cgacatcggc aataccgtcc agaagcaata 2340

ccacggcggt gctctgagga tctccgaatg ggcccacatt atcaactgca gcgttctccc 2400

tggcgagggc atcgtcgagg ctctggccca gaccgcatct gcgcaagact tcccctatgg 2460

tcctgagaga ggactgttgg tcctggcaga gatgacctcc aaaggatcgc tggctacggg 2520

cgagtatacc aaggcatcgg ttgactacgc tcgcaaatac aagaacttcg ttatgggttt 2580

cgtgtcgacg cgggccctga cggaagtgca gtcggatgtg tcttcagcct cggaggatga 2640

agatttcgtg gtcttcacga cgggtgtgaa cctctcttcc aaaggagata agcttggaca 2700

gcaataccag actcctgcat cggctattgg acgcggtgcc gactttatca tcgccggtcg 2760

aggcatctac gctgctcccg acccggttga agctgcacag cggtaccaga aagaaggctg 2820

ggaagcttat atggccagag tatgcggcaa gtcatgattt cctcttggag caaaagtgta 2880

gtgccagtac gagtgttgtg gaggaaggct gcatacattg tgcctgtcat taaacgatga 2940

gctcgtccgt attggcccct gtaatgccat gttttccgcc cccaatcgtc aaggttttcc 3000

ctttgttaga ttcctaccag tcatctagca agtgaggtaa gctttgccag aaacgccaag 3060

-continued

gctttatcta tgtagtcgat aagcaaagtg gactgatagc ttaatatgga aggtccctca 3120

ggacaagtcg acctgtgcag aagagataac agcttggcat cacgcatcag tgcctcctct 3180

cagacagaat aagtcgccat aagttatcga ccgaacctag gtagggtata tttggtgacg 3240

acaatacctc ccgacgatac ctgggttgat tcctgctttt cctcccgctc atataggacg 3300

gcgtcttggc gaacggtcgt cgattgattt ctttcccgta atctgttcct tttcctaatg 3360

tactctggtg tgatgggctt cagggactct tttaacgacc cagacttttg atgtttatac 3420

caccgttctt tttcttcttt cctcgatctt tggcattatt gtacatgatg ctctgcatgt 3480

ggttttcaag atattccccg gattgttctt gtcttcagtt tatatacggc cgctctcgtg 3540

tttattatcc gctgtgtttc caggtcggct ggacctgggg cctctccctt cccgcgaata 3600

gaagtgagtg agcaatacaa atgtgacatt gtccaaaagt ttggtgatct gaacgcgcaa 3660

cctggatgca ttgatccgag acaatcacgg ggtcttagac atgcgacatg tctgattcac 3720

tccttcgacc atttccttgt ttatccatga ccatgcccca tccactggca tgcgagaatg 3780

acgtatgcga cagataagat cgacgatctg ccttatatat ccgaattgat tcgattgtca 3840

atactctctc ttagtgttgt ataagtatat atatgtgctg tagagtatgt cctggctgtc 3900

tcccatacag aagaagccat gtcgagaaag ggtatgtcca ccagagtaag attgtacatt 3960

ccttggacat gtcattgtca tttcacagga aatatcgaag ggtcatggat tcggaggaac 4020

attccaggaa gagacaccag aaatgagttg gcacggatca gtaaacatgt agatctacat 4080

aaccttgttc attttcatga tgcactgaca ctagagcata gaggcgttta ctttacctct 4140

tatcaacgac taattgacat aaccaagcag tggaattttt atgattcaac gtcccagact 4200

atagtgccta ctgttatgat ctacctgcta ctttgatcgg tttcactttc tttgttggtt 4260

gatacttgtt gcgtatcttc tttgattact tatagtcaat agtccctgtt actatattag 4320

cgccgttcct agccattgta tatcctttga tccactactt gaaagaaaat tcgaacaagg 4380

gttttaatgg atgtatccat tctattttct cttttctttg gatgtaatga gatacaaagg 4440

tgttctaatc aaaaagtatg tattcaattc aaatacatct tcccagacaa tctgggaaga 4500

ggaataagca agagagataa ttctccgact cacactattc gccatatcaa gacccc 4556

<210> SEQ ID NO 143
<211> LENGTH: 9329
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Aspergillus flavus multicopy veA strain with Aspergillus fumigatus pyrG in TOPO-TA cloning plasmid

<400> SEQUENCE: 143

agcgcccaat acgcaaaccg cctctccccg cgcgttggcc gattcattaa tgcagctggc 60

acgacaggtt tcccgactgg aaagcgggca gtgagcgcaa cgcaattaat gtgagttagc 120

tcactcatta ggcaccccag gctttacact ttatgcttcc ggctcgtatg ttgtgtggaa 180

ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac gccaagcttg 240

gtaccgagct cggatccact agtccgcctg cccttaacct ccagctggct gagttcccac 300

tggatcggcc attcttcttt ttttaccccc tcttctgtga caccatccac cttcccccat 360

tttagtgcca tccgtgctga cccaataccc accatatcgg ctcagtcgtg cagagttagt 420

gccgtcgtac ataccagctc cattagaagg tactgtacat acgccatgta tctacggggt 480

aattccggtt gccgtcgtca gaacggataa acatctccta ttgaccctct cgataagaaa 540

-continued

gagcaagttc agagcgaata aaatgctcga agcgcagaaa tgcgaccgta gacccatggt 600

accgggatat ttaagaacgc aagttatgta tggggccgtc agcccgatca ccatgttgtt 660

ggaacttgga accgatggaa accgtcaccg tcggtaatct tacagtacca cggctccgga 720

gacgagacgg ttagggtgtt atagttggtt gcgatagtgt gtgtacctgc cgattctcag 780

gctgactcgt cctttgactt ttcccgtcct cgctcgctcc acccctctc attcattatt 840

cttcgtcccc cccgtatcac caacttgact tttgttactc ctctcccata ccttctttcc 900

tcatcctgga cgggtcaatc gctggattgt ctgttgtact gcctcggcgc agcggaccca 960

gtttaaattt ttttttttt ttaatttcat tatccttctt ttccccttt ggtcgacagt 1020

tggaatctct ctcgttttcc gtttcgcaga cgacttcgag aacatccttg accgactggt 1080

cggtttcacg gcttgcattc gtgggagtca cgcccgacat aaccagcaca ctagaagaaa 1140

accagattca cacgggaaac ggggatagat tacttgcttg acgcaagcac tttcccatag 1200

cgttgatttt gtttggttgg accgagggat tgccaagtaa gtcccaagct tcattgctag 1260

ctggtcatta tttgatctcg accatgaaat tgtggtcaat tacgcccgtc gaatcttgtt 1320

gtgctaatcc tggcagtttt tcgcatcaca gtcaaggcgt ctccaaaatg gcgacacgag 1380

ctcctttggc gcctccgccg aacgagacgg aagcctccgt cagccggatc actcgagagg 1440

gcaagaagct cacctataaa ctcaatgtca tgcaacagcc tgagcgtgcg cgagcctgcg 1500

gtgcaggtgc aaagtgtatg cgtccaacca gcactccata accggatagc atcaaactga 1560

tggttctgac tttatatagc ctctgcggac cgtcgtccag tcgatcctcc accggtcgtc 1620

gaacttcgag tgtacgagtc cgatcccaac gacgacctca acaagaccga catcaccttc 1680

gcatacaacg ccaatttctt cctgtacgcc actttggaaa ccgctcgtcc catggcccaa 1740

ggccgttttg ccccgaatcc gacttgccca gtattgaccg gtgtgcccgt ggctggagtg 1800

gcttacttgg accgcccttc tcaagccggt tacttcatct tccccgatct ttccgtgcgg 1860

catgaaggtg tatatcgatt gaacttccac ctgtacgagg aaaccaagga gagcaaggat 1920

gcgaacgaga atgctccgat ccagtccctg tccaacccaa tgccatcgaa gccgatggcg 1980

ccgaagtcat tcctggagtt tcgtctcgag gtcgtttccg ttccgttcac cgtatttagc 2040

gccaagaagt tcccaggatt ggccacgagt acctccctga gtcgggtcat tgcggagcaa 2100

ggttgtcgtg tgcggattcg acgtgatgtc cgcatgagac gtcggggaga gaagcgcacc 2160

gatgactacg actacgatga ggagagagtc taccgatctt ctgaccgaat ctctacccca 2220

gatacccacg ggtacgccgg cactcccgtt gaacgtcctc gatcaaccag taccagcacg 2280

gtggatccct cattccccta cggtgtcgat gctcagcgcc ggtcatctgg cgcgaccgag 2340

tatggtttcc agggtgcaca gccgtaccaa cgaccattgc cgcctgctcc cggtcccgca 2400

ccagccgctg tttccacgcc cgctcctccc gctcctcccg cgccaccatc ccataatcct 2460

ggatatcaat cgcatctttc ctttggctcg actcaaactc aatatccagc tccccaactg 2520

cctccaactc cacagaccgc gtcgacattg gcagctccgt actcgcccca tccatcgtat 2580

tctcatgctc ggaatccatc gacgagcgcc gagtatgaaa cgcccggtta ctcctatccg 2640

ccatcacgga tgtcaacgga acgttccagc tatcccaaga atggcttgcc tccgctccgc 2700

ttggaaccgc ctaagccact aaatatgcca tccggcgagc cacgctcgtc cgatccgaac 2760

gcatatcatt ccgtggctca atcggcggca ccccggtctc agacaccgtc atccagtctg 2820

gtgccttccc ttccgcccct caaggctcta tcgggggatt atcccaacaa cctctctcaa 2880

tcatccagca gtacctctca gagccccagt cacgatctcg gcgctggcaa gaagttcttc 2940

-continued

tgggatacgg gcgccagcct gtccaagcgg tcgtacgaag attcgtttgg ccatgatgat 3000

cgtccactct acaacggcat gcgccccgat acggaaagtt atcctcggag gctgtcagat 3060

gccagtcgga acttctacaa cgaaacgcgc gatgaaatgg cgtacaaacg agccaacggg 3120

agaatggcca cgaagatatc ccctgcactc cagtaaaaca agttgattcc tgcttttcct 3180

cccgctcata taggacggcg tcttggcgaa cggtcgtcga ttgatttctt tcccgtaatc 3240

tgttcctttt cctaatgtac tctggtgtga tgggcttcag ggactctttt aacgacccag 3300

acttttgatg tttataccac cgttcttttt cttctttcct cgatctttgg cattattgta 3360

catgatgctc tgcatgtggt tttcaagata ttccccggat tgttcttgtc ttcagtttat 3420

atacggccgc tctcgtgttt attatccgct gtgtttccag gtcggctgga cctggggcct 3480

ctcccttccc gcgaatagaa gtgagtgagc aatacaaatg tgacattgtc caaaagtttg 3540

gtgatctgaa cgcgcaacct ggatgcattg atccgagaca atcacggggt cttagacatg 3600

cgacatgtct gattcactcc ttcgaccatt tccttgttta tccatgacca tgccccatcc 3660

actggcatgc gagactagta acggccgcca gtgtgctggg cccttccagg tatcgtcggg 3720

aggtattgtc gtcaccaaat ataccctacc taggttcggt cgataactta tggcgactta 3780

ttctgtctga gaggaggcac tgatgcgtga tgccaagctg ttatctcttc tgcacaggtc 3840

gacttgtcct gagggacctt ccatattaag ctatcagtcc actttgctta tcgactacat 3900

agataaagcc ttggcgtttc tggcaaagct tacctcactt gctagatgac tggtaggaat 3960

ctaacaaagg gaaaaccttg acgattgggg gcggaaaaca tggcattaca ggggccaata 4020

cggacgagct catcgtttaa tgacaggcac aatgtatgca gccttcctcc acaacactcg 4080

tactggcact acacttttgc tccaagagga aatcatgact tgccgcatac tctggccata 4140

taagcttccc agccttcttt ctggtaccgc tgtgcagctt caaccgggtc gggagcagcg 4200

tagatgcctc gaccggcgat gataaagtcg gcaccgcgtc caatagccga tgcaggagtc 4260

tggtattgct gtccaagctt atctcctttg gaagagaggt tcacacccgt cgtgaagacc 4320

acgaaatctt catcctccga ggctgaagac acatccgact gcacttccgt cagggcccgc 4380

gtcgacacga aacccataac gaagttcttg tatttgcgag cgtagtcaac cgatgccttg 4440

gtatactcgc ccgtagccag cgatcctttg gaggtcatct ctgccaggac caacagtcct 4500

ctctcaggac cataggggaa gtcttgcgca gatgcggtct gggccagagc ctcgacgatg 4560

ccctcgccag ggagaacgct gcagttgata atgtgggccc attcggagat cctcagagca 4620

ccgccgtggt attgcttctg gacggtattg ccgatgtcga tgaatttgcg gtcctcgaag 4680

atcaaaaagt tgtgcttttg agccagcaca ttcaggccat tgatagtgtc gacgctgaaa 4740

tcggtgagga tgtcgatgtg tgtcttgatg acggcgatgt agggaccgag acctgtatca 4800

tcaaaagttg attagtccat tgctagacgg catatgtatt ggatccaaca gcttccgtac 4860

ggtcagcgag gtccaggagt tctcgggttg tcgtcacatc agcagagacg gtaacgtttg 4920

tcttctttgc ttcggcaatc tcaaaaagtc tctttgccag aggattgggg tgcttgctgg 4980

ctcgagcacc gtaagtcaat tgcgacttgg acgacatcgt gggaatggag ggttatatgc 5040

ggggtatgac ggtgattgat gagttgaagt agccgagcaa tgaggtatat tatccaattg 5100

agggtgaccc aaccaaatca attgcttgag aatcaaatct caaatattct aaaatagaag 5160

ccgccgggga ctaaatttaa agtcgtactc tatctcgatc ttttccgcgt gtaaaaattg 5220

cgtgccaatc tggatggaga caggccacat cggtgctgta ttcctccgcc tccgactgtg 5280

-continued

gggtcaacca caattaaact actctgtagt caggtacagc tagaatgggg tagacaggca 5340

gaactgtaga agataaaaca ttggtcaatc actggtaact ccacggaact tttaacgtac 5400

atatatatat atacacaaca tatttcgtca gacacagaat aactctcagt aagagatcat 5460

gtctttggca acaccaaaca cactcagagc ccacagagcg ccttgagaaa accagaagaa 5520

acctcccagc aatctgccct tgccttgtgg cttacccgag tacacatagc cgtacaagta 5580

gagagatcgg aaaaacagcc atgaagcgcc aattgctgtt gccaggtgag ggtatttcag 5640

acccgcgaag agggtgaaga gcattgtttg aggcaaaggg caattcgccc ttaagggcga 5700

attctgcaga tatccatcac actggcggcc gctcgagcat gcatctagag ggcccaattc 5760

gccctatagt gagtcgtatt acaattcact ggccgtcgtt ttacaacgtc gtgactggga 5820

aaaccctggc gttacccaac ttaatcgcct tgcagcacat ccccctttcg ccagctggcg 5880

taatagcgaa gaggcccgca ccgatcgccc ttcccaacag ttgcgcagcc tgaatggcga 5940

atggacgcgc cctgtagcgg cgcattaagc gcggcgggtg tggtggttac gcgcagcgtg 6000

accgctacac ttgccagcgc cctagcgccc gctccttttcg ctttcttccc ttcctttctc 6060

gccacgttcg ccggctttcc ccgtcaagct ctaaatcggg ggctcccttt agggttccga 6120

tttagtgctt tacggcacct cgaccccaaa aaacttgatt agggtgatgg ttcacgtagt 6180

gggccatcgc cctgatagac ggtttttcgc cctttgacgt tggagtccac gttctttaat 6240

agtggactct tgttccaaac tggaacaaca ctcaacccta tctcggtcta ttcttttgat 6300

ttataaggga ttttgccgat ttcggcctat tggttaaaaa atgagctgat ttaacaaaaa 6360

tttaacgcga attttaacaa aattcagggc gcaagggctg ctaaaggaag cggaacacgt 6420

agaaagccag tccgcagaaa cggtgctgac cccggatgaa tgtcagctac tgggctatct 6480

ggacaaggga aaacgcaagc gcaaagagaa agcaggtagc ttgcagtggg cttacatggc 6540

gatagctaga ctgggcggtt ttatggacag caagcgaacc ggaattgcca gctggggcgc 6600

cctctggtaa ggttgggaag ccctgcaaag taaactggat ggctttcttg ccgccaagga 6660

tctgatggcg caggggatca agatctgatc aagagacagg atgaggatcg tttcgcatga 6720

ttgaacaaga tggattgcac gcaggttctc cggccgcttg ggtggagagg ctattcggct 6780

atgactgggc acaacagaca atcggctgct ctgatgccgc cgtgttccgg ctgtcagcgc 6840

aggggcgccc ggttcttttt gtcaagaccg acctgtccgg tgccctgaat gaactgcagg 6900

acgaggcagc gcggctatcg tggctggcca cgacgggcgt tccttgcgca gctgtgctcg 6960

acgttgtcac tgaagcggga agggactggc tgctattggg cgaagtgccg gggcaggatc 7020

tcctgtcatc ccaccttgct cctgccgaga aagtatccat catggctgat gcaatgcggc 7080

ggctgcatac gcttgatccg gctacctgcc cattcgacca ccaagcgaaa catcgcatcg 7140

agcgagcacg tactcggatg gaagccggtc ttgtcgatca ggatgatctg gacgaagagc 7200

atcaggggct cgcgccagcc gaactgttcg ccaggctcaa ggcgcgcatg cccgacggcg 7260

aggatctcgt cgtgacccat ggcgatgcct gcttgccgaa tatcatggtg gaaaatggcc 7320

gcttttctgg attcatcgac tgtggccggc tgggtgtggc ggaccgctat caggacatag 7380

cgttggctac ccgtgatatt gctgaagagc ttggcggcga atgggctgac cgcttcctcg 7440

tgctttacgg tatcgccgct cccgattcgc agcgcatcgc cttctatcgc cttcttgacg 7500

agttcttctg aattgaaaaa ggaagagtat gagtattcaa catttccgtg tcgcccttat 7560

tccctttttt gcggcatttt gccttcctgt ttttgctcac ccagaaacgc tggtgaaagt 7620

aaaagatgct gaagatcagt tgggtgcacg agtgggttac atcgaactgg atctcaacag 7680

-continued

cggtaagatc cttgagagtt ttcgccccga agaacgtttt ccaatgatga gcacttttaa 7740

agttctgcta tgtggcgcgg tattatcccg tattgacgcc gggcaagagc aactcggtcg 7800

ccgcatacac tattctcaga atgacttggt tgagtactca ccagtcacag aaaagcatct 7860

tacggatggc atgacagtaa gagaattatg cagtgctgcc ataaccatga gtgataacac 7920

tgcggccaac ttacttctga caacgatcgg aggaccgaag gagctaaccg ctttttgca 7980

caacatgggg gatcatgtaa ctcgccttga tcgttgggaa ccggagctga atgaagccat 8040

accaaacgac gagcgtgaca ccacgatgcc tgtagcaatg gcaacaacgt tgcgcaaact 8100

attaactggc gaactactta ctctagcttc ccggcaacaa ttaatagact ggatggaggc 8160

ggataaagtt gcaggaccac ttctgcgctc ggcccttccg gctggctggt ttattgctga 8220

taaatctgga gccggtgagc gtgggtctcg cggtatcatt gcagcactgg ggccagatgg 8280

taagccctcc cgtatcgtag ttatctacac gacggggagt caggcaacta tggatgaacg 8340

aaatagacag atcgctgaga taggtgcctc actgattaag cattggtaac tgtcagacca 8400

agtttactca tatatacttt agattgattt aaaacttcat ttttaattta aaaggatcta 8460

ggtgaagatc ctttttgata atctcatgac caaaatccct taacgtgagt tttcgttcca 8520

ctgagcgtca gaccccgtag aaaagatcaa aggatcttct tgagatcctt ttttttctgcg 8580

cgtaatctgc tgcttgcaaa caaaaaaacc accgctacca gcggtggttt gtttgccgga 8640

tcaagagcta ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa 8700

tactgttctt ctagtgtagc cgtagttagg ccaccacttc aagaactctg tagcaccgcc 8760

tacatacctc gctctgctaa tcctgttacc agtggctgct gccagtggcg ataagtcgtg 8820

tcttaccggg ttggactcaa gacgatagtt accggataag gcgcagcggt cgggctgaac 8880

gggggttcg tgcacacagc ccagcttgga gcgaacgacc tacaccgaac tgagatacct 8940

acagcgtgag ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg acaggtatcc 9000

ggtaagcggc agggtcggaa caggagagcg cacgagggag cttccagggg gaaacgcctg 9060

gtatctttat agtcctgtcg ggtttcgcca cctctgactt gagcgtcgat ttttgtgatg 9120

ctcgtcaggg gggcggagcc tatggaaaaa cgccagcaac gcggcctttt tacggttcct 9180

ggccttttgc tggccttttg ctcacatgtt ctttcctgcg ttatcccctg attctgtgga 9240

taaccgtatt accgccttttg agtgagctga taccgctcgc cgcagccgaa cgaccgagcg 9300

cagcgagtca gtgagcgagg aagcggaag 9329

<210> SEQ ID NO 144
<211> LENGTH: 7814
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Aspergillus flavus laeA knockout with
Aspergillus fumigatus pyrG

<400> SEQUENCE: 144

gggcgaattg ggcccgacgt cgcatgctcc cggccgccat ggccgagacc tactagttaa 60

tagctccgat cgagtgatac gtaccatcct catgccagac ctctcccagc taggtatcga 120

cttagaaccc gccaacatca agcttcaggt cgaacataag ttccaggacg tagtcaacag 180

actaagttgg aaccatgtca cattttcttc aacgagtgaa ttcgtcaccg catccacctt 240

catgaaccct gacatttacg tttgggaacg gagtcacggt tccctggtga agatcctcga 300

gggtcctaga gaagaactgg gcgtcgtgga atggcaccct tctcgcccta tggttgtcgc 360

-continued

ttgcggttta gaatctggat gcatctacac atggtcgatt gtgacgcctc aaaaatggtc 420

cgcgctggca cctgattttg gtgaagtcga ggaaaacgtc gagtatgttg agcgcgaaga 480

cgaatttgac gttcaccctg ccgaagaaat tcaccaacgc cggcttgacc aggaagacga 540

agttcctgac gtattaacga tcgagcccca caaaagcggt acggatgagg agatggaatc 600

cttccgcatg cctgtgcttc tagatatttc tgacagcgaa agtgaagagg acatcattgc 660

cgtcggtccc ggaacaatgc ggaggcgtag ccccggcgct ggccgtgact gggccagcgg 720

agatggtgag aaagaaagta ctggaggtag aaacggtacc tcccggggac aaaagggccg 780

ccggcgttaa agtgatatca ttgtatgagt tcacattata gtattagata atttacagga 840

gcatctgtct tgggtcattg ggtgggcggg tgtcttgaag gctatcgagg cgttttggcg 900

aaatacccaa agactggtat ctcacacact tgcatttccg gttcatgtta gctggtagtg 960

agaccttaca aacgatcaca tggataaaat tctttgcatt gtattatata aatttttata 1020

ttctttttaa gtgatatcat gttatgaatc tcgaatatag caataaccat gattggatga 1080

tgtcgtcaca gatagaatga actaaaccgg gtatacagtt atcaacatta cactcaccca 1140

aaacgccata aatatgctgt ctttggcaag cgggaaagca tgcaatgcca gggaatgatg 1200

tggtcctgaa gtgtgatgaa ggagccacag ccaggttaag agcaggcaga gggcagaggg 1260

cagagggcat gccatgccgt gtcctattaa tgacctgcca gtattctgca gccccattgg 1320

ttcgtccata ggggcaagag ctgcatcgcg atgtattttt tggacgaaat gatctttgac 1380

ttgcctgttt ggcctgggta atttgtataa ccccccttcgc aagacgtacg cccgcctcat 1440

gctcggacct atgataatca aagcaaactc tgtatatttc catcaacctt ctaagtgcta 1500

ctggagtgat acaggcagct cagtgcatcg tcgggatagg cgttaattcg cggcatacgg 1560

tgtctaatcc aggtatcgtc gggaggtatt gtcgtcacca aatataccct acctaggttc 1620

ggtcgataac ttatggcgac ttattctgtc tgagaggagg cactgatgcg tgatgccaag 1680

ctgttatctc ttctgcacag gtcgacttgt cctgagggac cttccatatt aagctatcag 1740

tccactttgc ttatcgacta catagataaa gccttggcgt ttctggcaaa gcttacctca 1800

cttgctagat gactggtagg aatctaacaa agggaaaacc ttgacgattg ggggcggaaa 1860

acatggcatt acaggggcca atacggacga gctcatcgtt taatgacagg cacaatgtat 1920

gcagccttcc tccacaacac tcgtactggc actacacttt tgctccaaga ggaaatcatg 1980

acttgccgca tactctggcc atataagctt cccagccttc tttctggtac cgctgtgcag 2040

cttcaaccgg gtcgggagca gcgtagatgc ctcgaccggc gatgataaag tcggcaccgc 2100

gtccaatagc cgatgcagga gtctggtatt gctgtccaag cttatctcct ttggaagaga 2160

ggttcacacc cgtcgtgaag accacgaaat cttcatcctc cgaggctgaa gacacatccg 2220

actgcacttc cgtcagggcc cgcgtcgaca cgaaacccat aacgaagttc ttgtatttgc 2280

gagcgtagtc aaccgatgcc ttggtatact cgcccgtagc cagcgatcct ttggaggtca 2340

tctctgccag gaccaacagt cctctctcag gaccataggg gaagtcttgc gcagatgcgg 2400

tctgggccag agcctcgacg atgccctcgc cagggagaac gctgcagttg ataatgtggg 2460

cccattcgga gatcctcaga gcaccgccgt ggtattgctt ctggacggta ttgccgatgt 2520

cgatgaattt gcggtcctcg aagatcaaaa agttgtgctt ttgagccagc acattcaggc 2580

cattgatagt gtcgacgctg aaatcggtga ggatgtcgat gtgtgtcttg atgacggcga 2640

tgtagggacc gagacctgta tcatcaaaag ttgattagtc cattgctaga cggcatatgt 2700

-continued

attggatcca acagcttccg tacggtcagc gaggtccagg agttctcggg ttgtcgtcac 2760

atcagcagag acggtaacgt ttgtcttctt tgcttcggca atctcaaaaa gtctctttgc 2820

cagaggattg gggtgcttgc tggctcgagc accgtaagtc aattgcgact tggacgacat 2880

cgtgggaatg gagggttata tgcggggtat gacggtgatt gatgagttga agtagccgag 2940

caatgaggta tattatccaa ttgagggtga cccaaccaaa tcaattgctt gagaatcaaa 3000

tctcaaatat tctaaaatag aagccgccgg ggactaaatt taaagtcgta ctctatctcg 3060

atcttttccg cgtgtaaaaa ttgcgtgcca atctggatgg agacaggcca catcggtgct 3120

gtattcctcc gcctccgact gtggggtcaa ccacaattaa actactctgt agtcaggtac 3180

agctagaatg gggtagacag gcagaactgt agaagataaa acattggtca atcactggta 3240

actccacgga acttttaacg tacatatata tatatacaca acatatttcg tcagacacag 3300

aataactctc agtaagagat catgtctttg gcaacaccaa acacactcag agcccacaga 3360

gcgccttgag aaaaccagaa gaaacctccc agcaatctgc ccttgccttg tggcttaccc 3420

gagtacacat agccgtacaa gtagagagat cggaaaaaca gccatgaagc gccaattgct 3480

gttgccaggt gagggtattt cagacccgcg aagagggtga agagcattgt ttgaggcaat 3540

cactagtggc cgcgtagtac gagtcgtgtg gtggtgaggc catcgccgga agacgctgtc 3600

cagtctggcc gtttccaaac attccgtgtg gtgaagaagg gtcggtaaga agtttggtac 3660

tttaagatgg tgacgagggg aagaatgccg acgtcgatgg cgacaagctg atgtcagtag 3720

cgtggacgct tgtaggttgt gtatatggta tatatattga gtgacgaata aaacatagag 3780

tagaatgggg ctgagcctag tgaatggacg gcaagttcat tcataaattt aagggagtga 3840

aaagcgaaac acaagatatc attcgcagta ttagaaagag agacgaggat tcaggggggag 3900

aatcagaaaa gtaaacagag aaaaataaga aaagaaaaga aaaaaaaatt aaaatcaaaa 3960

atcaaaaatc aaaaatcaga atctaaaaaa ataagaaaag ttggagatag gaccaggcag 4020

agaatcaaag gtcacgtcca cttaaacaca gaagggcaga aacggaaaaa ccaagacggt 4080

gaccagccaa aagtaccgac aggcaaagag ataataatag agaacgccgt gctgtctccc 4140

cgcgatgaag cgatgccagt cgggaaatcc acagaagaag tagcggtcac ggcgcaagca 4200

atcactgggc gcaaatcgtc aacaacggac aggagttgtc acggctaacc atggatgggt 4260

ggtcgatcca aggtcatcaa ttgggacgaa ttcacccagc accataccat ggaaaagaag 4320

attaatgagc ggagccctga gggggcgaga attggtagtg gtggacgagg gggaagcgag 4380

aagaagccct gtaatggaaa gcctgccttt aaggttgttg cagccgctgt cttgtccccg 4440

ttgggcccac ggctgcgagg gcggggcggt taaggaagaa gcctgaggct gtccttgcac 4500

tgtccggtaa gtatcctttc gtaatactct ttttctttcc ctctttcctc tctcctttcc 4560

agcagaagat gggcgtaagc aacgctggga tgtatgagca tgccctctat ttgtgtgtta 4620

tttgacagtt caacgaacta atcgccttaa ataaatgtat ccgacaacag agtgtcgatt 4680

tagagaaggt gttgtggttg gtatcccatc ggatttattg gctggagagg ttaaaactgc 4740

ccctccataa accatggtat atcccctaat tagtacctgt ccgtcatcaa caaccctaca 4800

tggattatct tttagtggtt actagtctta aaaagactct ggtagcgccc attcaaccta 4860

tccatggatc ttgaacagcc ggttgcacaa cttggatata atctaggtat gttgtattca 4920

tgtacatata tactgtattc tatagtgtca cctaaatagc ttggcgtaat catggtcata 4980

gctgtttcct gtgtgaaatt gttatccgct cacaattcca cacaacatac gagccggaag 5040

cataaagtgt aaagcctggg gtgcctaatg agtgagctaa ctcacattaa ttgcgttgcg 5100

-continued

ctcactgccc gctttccagt cgggaaacct gtcgtgccag ctgcattaat gaatcggcca 5160

acgcgcgggg agaggcggtt tgcgtattgg gcgctcttcc gcttcctcgc tcactgactc 5220

gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct cactcaaagg cggtaatacg 5280

gttatccaca gaatcagggg ataacgcagg aaagaacatg tgagcaaaag gccagcaaaa 5340

ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc cataggctcc gccccctga 5400

cgagcatcac aaaaatcgac gctcaagtca gaggtggcga aacccgacag gactataaag 5460

ataccaggcg tttcccccctg gaagctccct cgtgcgctct cctgttccga ccctgccgct 5520

taccggatac ctgtccgcct ttctcccttc gggaagcgtg gcgctttctc atagctcacg 5580

ctgtaggtat ctcagttcgg tgtaggtcgt tcgctccaag ctgggctgtg tgcacgaacc 5640

ccccgttcag cccgaccgct gcgccttatc cggtaactat cgtcttgagt ccaacccggt 5700

aagacacgac ttatcgccac tggcagcagc cactggtaac aggattagca gagcgaggta 5760

tgtaggcggt gctacagagt tcttgaagtg gtggcctaac tacggctaca ctagaagaac 5820

agtatttggt atctgcgctc tgctgaagcc agttaccttc ggaaaaagag ttggtagctc 5880

ttgatccggc aaacaaacca ccgctggtag cggtggtttt tttgtttgca agcagcagat 5940

tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc ttttctacgg ggtctgacgc 6000

tcagtggaac gaaaactcac gttaagggat tttggtcatg agattatcaa aaaggatctt 6060

cacctagatc cttttaaatt aaaaatgaag ttttaaatca atctaaagta tatatgagta 6120

aacttggtct gacagttacc aatgcttaat cagtgaggca cctatctcag cgatctgtct 6180

atttcgttca tccatagttg cctgactccc cgtcgtgtag ataactacga tacgggaggg 6240

cttaccatct ggccccagtg ctgcaatgat accgcgagac ccacgctcac cggctccaga 6300

tttatcagca ataaaccagc cagccggaag ggccgagcgc agaagtggtc ctgcaacttt 6360

atccgcctcc atccagtcta ttaattgttg ccgggaagct agagtaagta gttcgccagt 6420

taatagtttg cgcaacgttg ttgccattgc tacaggcatc gtggtgtcac gctcgtcgtt 6480

tggtatggct tcattcagct ccggttccca acgatcaagg cgagttacat gatcccccat 6540

gttgtgcaaa aaagcggtta gctccttcgg tcctccgatc gttgtcagaa gtaagttggc 6600

cgcagtgtta tcactcatgg ttatggcagc actgcataat tctcttactg tcatgccatc 6660

cgtaagatgc ttttctgtga ctggtgagta ctcaaccaag tcattctgag aatagtgtat 6720

gcggcgaccg agttgctctt gcccggcgtc aatacgggat aataccgcgc cacatagcag 6780

aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg cgaaaactct caaggatctt 6840

accgctgttg agatccagtt cgatgtaacc cactcgtgca cccaactgat cttcagcatc 6900

ttttactttc accagcgttt ctgggtgagc aaaaacagga aggcaaaatg ccgcaaaaaa 6960

gggaataagg gcgacacgga aatgttgaat actcatactc ttccttttc aatattattg 7020

aagcatttat cagggttatt gtctcatgag cggatacata tttgaatgta tttagaaaaa 7080

taaacaaata ggggttccgc gcacatttcc ccgaaaagtg ccacctgatg cggtgtgaaa 7140

taccgcacag atgcgtaagg agaaaataccc gcatcaggaa attgtaagcg ttaatatttt 7200

gttaaaattc gcgttaaatt tttgttaaat cagctcattt tttaaccaat aggccgaaat 7260

cggcaaaatc ccttataaat caaaagaata gaccgagata gggttgagtg ttgttccagt 7320

ttggaacaag agtccactat taaagaacgt ggactccaac gtcaaagggc gaaaaaccgt 7380

ctatcagggc gatggcccac tacgtgaacc atcaccctaa tcaagttttt tggggtcgag 7440

-continued

gtgccgtaaa gcactaaatc ggaaccctaa agggagcccc cgatttagag cttgacgggg 7500

aaagccggcg aacgtggcga gaaaggaagg gaagaaagcg aaaggagcgg gcgctagggc 7560

gctggcaagt gtagcggtca cgctgcgcgt aaccaccaca cccgccgcgc ttaatgcgcc 7620

gctacagggc gcgtccattc gccattcagg ctgcgcaact gttgggaagg gcgatcggtg 7680

cgggcctctt cgctattacg ccagctggcg aaaggggat gtgctgcaag gcgattaagt 7740

tgggtaacgc cagggttttc ccagtcacga cgttgtaaaa cgacggccag tgaattgtaa 7800

tacgactcac tata 7814

<210> SEQ ID NO 145
<211> LENGTH: 9453
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Partial sequence of plasmid containing
Aspergillus parasiticus niaD and Aspergillus flavus laeA

<400> SEQUENCE: 145

atggatttcc tacgtcttca atacaaacca tcagacgtcc tggaagctat cattacgtcg 60

cgatcgctta acaagtatga tcgtcttttc aagcatctgc ttcgactcct tcgaatggtt 120

tcggtcgtca aaggtctcat tcgtgattct acggggagag actccctatc tgggcaccct 180

cgaaacgtgt accagaaatt tcgcattgac tgccagcatt tcgtgctctc attgagtgat 240

tattgctttc atgtcggcat tggctcgact tggcagcggt tccaagatag cctggctaag 300

attgaacgct gcctcgaccg cggtgatatt gatggcacga tagaagcagc acattctgtc 360

cctagactta gagattatca tgaagatatt ctcgatcaaa tgctttttgc gctctttctc 420

agcaaaagac atgctgatgc agcgaagctg ctggaaagta ttttcggtac gattttgaca 480

tttgctccat tgtcgaggat ggatggaacg agcggcgtgc gccacgaaac tgaggctatt 540

gcctatcagc tctttgctac attccggaaa caaacatccc tttttgtgaa ttatctacgc 600

aacttagatg gcgtgaacgc atcttcaaag tctttcggca ggtccggcac gacttttgca 660

tccagagaag cgcctacatg tgtattcgac cacctcctag cgcgcttgga tatgaggaaa 720

tattactgag agtcgaaaac aagctccacc gcaccagctc ttcttggagt tttatattaa 780

agaatattcc cagctcgttg tattattctt tttctaccgt gctaatgtat caaggacttt 840

ggtacctatt aacgttatta ttcgtgtgct attcccaaac ataaccctgt atatgtttcg 900

aacgccgtta tgacccatgt cttacatact cattaagtca ttcccttgga taatcccaat 960

ttagaagaag tgaaggtctg attctttcca tccttccgcc aacagtatcc tccgagccga 1020

ttcttccatg gctggcggac cacaaatcag gaccatactc tcatcttctg gagccgcgta 1080

ctcctttagg agctcttcgg atatgcgtcc tcggcggcca gtccatgagt ccggcgcttt 1140

ggatagggtg tgtattatat tacaccttct gctgtcggtt gccatgaagc cgtcgagctc 1200

agcccggcaa aggatatctt cctcctgtct gtttccattg aggactgtac aagaggtggg 1260

atcttgccgg tcctgaacca cggcgcgcaa gacctggaag atcggtgtga taccggttcc 1320

tccacaaatc atcttaaacg accgaacatg gcgttccttc ccacttatga caactcgtcc 1380

atttccaagg tattcgaatc tgcctgtcgg acccttgcat tccaccacgg agcccaatgg 1440

cagcctatcc agggccatcg tcatcttgcc gcctgccgag gtggctgttg caaagtatac 1500

tttaaccagc aagtccacgg tccctttctg gctggtttca gaaattgggg tgtatgagcg 1560

gatgatggct tcgttgttgg atgatgtgtc gaggactttg atcataagat gctggccgac 1620

-continued

tggtaaaccc aatgtttgat cttcgtgttc caatttgaaa ctaaatattc gtgtatccca 1680

ggatatgtct ttcctttctt tcaatgttgc ctttgtccaa gaccgtgatt ggaggaacac 1740

tgggcgaatt tcatcggtgg aggatgatgc atcatccttg agtgctttta aaccttccgg 1800

atccatcgtt ccaatatggt actcaggcat catcgccttt gccgtctcgc tatctatgga 1860

taggtgtcaa tagatggtac aattgcagtg tgatattttt gggactcacg aatagcaagg 1920

aattcctcag agacatccag accagcagag gagataatac tctgcgctcc gccagggtgg 1980

ccttcaagaa atgcttgacc atcatacact tctccattca cgatgaacca tggcttctca 2040

tcgcaggaat tctccttgaa ttcttcaaaa ccaatcactc ggcttagccc gtctttcttc 2100

atattaatgt cttgcacggg ctccggctcc gtcggctcct ctccttcgtg tctttctccc 2160

cagttaccat tcgtcaggtc acccccagcc tttttgacgc gttccatcca tcctgtaggc 2220

atactagggt gggtagggtg ctcgaatctc aagttcccgt tttccttcgt aattgtaacc 2280

cggaaccacg ggttgttcat cattccgaga acggaccagt acatatcgcg aggctgcacg 2340

cccaatgctt cgtccatggc tcttacaagg atggcatcac tgttctcaag ctctgggatg 2400

gtgatgctta gagaccaaaa acaccagcag aagcaagttt cgcgccagta catatctact 2460

ttgcctccaa aaagctcgcc ttcaaaatca cgatacttgt cttcggcata ttcgatttcc 2520

gccaatctcc aagctataag tccgttagct ttgataagca ttctcacaca tcgagcgagc 2580

gagggtgcgt acatttgcct ttgtctaggg atatttctac cctggtaacc ctgcggcccc 2640

caccggcgta tgcatatcct ctgacagtat atgacggccc tgcgaccagg agatttaaga 2700

cctcattgtt ttggggatat gcaacggcgg agttggtgtt taggtcataa atcgcatacc 2760

gctcatcgtg ccaccaattt cggttatttg atgccatctc aggcgagacc attgttctgg 2820

gttagggagt tagacaaatg atggaaatat aaaataagtg ccctttagac atacggtaag 2880

acgcggttgt cattgatatg gtaccagttg tcgcttggtg catcggtcaa gatcagcctc 2940

ttcagccact taacacttcg tcctcctatt tgaccgggca cgacggccct cagcggacga 3000

ccatgatctg ggcgaagaga ctccccgttc attttatgtg caagcatgat ccccctgttg 3060

gggtccaggg cccagttcaa tttaatagat gtgccgtagt gaccattggg ctgcggcgaa 3120

cttagcaatt atcatcataa gatagaggta cagcatacca gcttatccgc tccttccata 3180

cagacgtatt tcgctttacg caggggtttc gcactgcgga gaatatccgc cagcaatggg 3240

ccagtgaaga gggcagtcga tagtcccgcc gatccccagg aaaaaccttt cgttttacgt 3300

acattgtttt gctctttgcg tcgattgcca gcacatacga gggtgatagg cgctgttatt 3360

tggtcgtact gctgcaacac ttgtcggaag tttagtacca aaggcttctc taccagtcta 3420

tactttggtt aacggatgtt tggcagagaa cctagcacta tactaaccct tcgatgctaa 3480

tttcccagtg agggatatct tcatccttga tatgagggac tgggccatga tttcgaacat 3540

agaagagctc cggcgatgtt aaaaaccctt tcagagtgtg agaatgtaac ggctcaaggg 3600

gacaagcatg acagccggtg caagcaacct gataaggata ggagtggagc agttataact 3660

cataccttct ttatacagat ctgtgagagg tggctcaaca ttaaacggat gaacacccgt 3720

taatctgata agccgagggt cacgaggaac atggctatct ggagttcctt tatctacgct 3780

cagcacttct gtcggccgtt ttgatggcgg tggcagaggg atatcagaca ggtctctcgt 3840

cgagatctct tcgctttcga ttttgatctg acctgtctta agaacgaggt cagttgggac 3900

gagcgcatcc gtccgcacct cggtgatggt tgccatgtta ccggcaggga aggccaatga 3960

aagtaaaatt acgagggagg gagcatgaac aaggatgctg agtatgaata agtcgaatgg 4020

-continued

tcagccagtg cattaactcc aaataaggag gcaatccacc acactaaaat actcttgcct 4080

atcgtatgat ggcacgcagt acgtgttacc catgcgcggg cagtggacat tctattaggt 4140

cacggcagta actccttgtt accatataac gcctcggaga aaggtcacaa taagcaatgc 4200

tcctaggaac ccaccagcga tttccgcgga gtcccaaaat cagctcattc tgggaggtgg 4260

gacgctcgaa attagggcaa gccttcaggc tggacggcgt cccaccgctt aaccaagcgt 4320

tgaggcaaat aaatcgcgtt gacccacaca acactctcga ggctccagcc atttgtccgc 4380

tcaaccttgc aggatttctt tttcgtcata ttaattggtt ctttgaagaa tgatggagac 4440

aatgccgtga agccatgtgc aacttccaat tagaagtgtt gttgcttatc gtccgaatga 4500

gcctggttcg cgtggagaat gggccagatg ggagctcacg gctgttagag cggagctact 4560

actctgtacg taccccttcaa aggaattctc ggtaagtttg ttagagggat attgctcacg 4620

tttaattggc actccaggat cctttaaatc caggcaaaaa tcgctcgatc tggctttttt 4680

tgccaatctt ggaagtctac cgtatacttg tagttacacc cttgaggatt taccacatga 4740

gaagaacacc aacctaactg cgtgatttaa aacgccattg ctatgatgct tgaagagtgc 4800

cggatatatc ggcatctaac ttaggatttg tcttacgtac aatatttatg acctgtggtg 4860

aaacctgagg caacaagggg gcgcgattta ccagactggc gttcacatac caatacagtg 4920

cttaattgta ggtctcatgg gtggaatgag atgaccttcc ctttcatcta ttcttaagag 4980

gaacagggat ggtacccaca ccataccccg aagagctcgt gatgtaatag acccctttcgt 5040

agtatgcggg tttttattga gatgccgata tgcaaacttg tagtaagact aataataaca 5100

ggtgcaatta attgaatttg gggcctgtta gcttatcctc cacaaagcct ttcgtaaaat 5160

aactaaccaa ctcaccacta tcagcctaaa tgagtcgatc gaacctccta ccagtaccaa 5220

tctgcttcgt atataataga aggttgtcgg ctccttctga caagacataa tctaatctaa 5280

gatttaactg tggcttttgt gcttaatcga tttatctttt ttatctatct acggagtagt 5340

tattcacgga tttttagctg ataatctagg ctacattttc agactgaatt acgcacaatt 5400

ttggggaagt gagaaaacag acagaaagag gagaaaaaaa agaaaaagaa aaaagcatgg 5460

gctaatgtgt gcccactgcc cagacatcta taccttgtat gatgtatgta tgatgagcaa 5520

acataactgt acatacatat accatacata ccctataata cacccatacg gggtatattt 5580

acgtaccttt taggtgtacc cgtatgtata ttgtatgcat gcatgtatat atgtacatga 5640

atacaacata cctagattat atccaagttg tgcaaccggc tgttcaagat ccatggatag 5700

gttgaatggg cgctaccaga gtctttttaa gactagtaac cactaaaaga taatccatgt 5760

agggttgttg atgacggaca ggtactaatt aggggatata ccatggttta tggaggggca 5820

gttttaacct ctccagccaa taaatccgat gggataccaa ccacaacacc ttctctaaat 5880

cgacactctg ttgtcggata catttattta aggcgattag ttcgttgaac tgtcaaataa 5940

cacacaaata gagggcatgc tcatacatcc cagcgttgct tacgcccatc ttctgctgga 6000

aaggagagag gaaagaggga aagaaaaaga gtattacgaa aggatactta ccggacagtg 6060

caaggacagc ctcaggcttc ttccttaacc gccccgccct cgcagccgtg ggcccaacgg 6120

ggacaagaca gcggctgcaa caaccttaaa ggcaggcttt ccattacagg gcttcttctc 6180

gcttcccccct cgtccaccac taccaatttct cgccccctca gggctccgct cattaatctt 6240

cttttccatg gtatggtgct gggtgaattc gtcccaattg atgaccttgg atcgaccacc 6300

catccatggt tagccgtgac aactcctgtc cgttgttgac gatttgcgcc cagtgattgc 6360

-continued

ttgcgccgtg accgctactt cttctgtgga tttcccgact ggcatcgctt catcgcgggg 6420

agacagcacg gcgttctcta ttattatctc tttgcctgtc ggtacttttg gctggtcacc 6480

gtcttggttt ttccgtttct gcccttctgt gtttaagtgg acgtgacctt tgattctctg 6540

cctggtccta tctccaactt ttcttatttt tttagattct gatttttgat ttttgatttt 6600

tgattttaat tttttttttct tttcttttct tatttttctc tgtttacttt tctgattctc 6660

cccctgaatc ctcgtctctc tttctaatac tgcgaatgat atcttgtgtt tcgcttttca 6720

ctcccttaaa tttatgaatg aacttgccgt ccattcacta ggctcagccc cattctactc 6780

tatgttttat tcgtcactca atatatatac catatacaca acctacaagc gtccacgcta 6840

ctgacatcag cttgtcgcca tcgacgtcgg cattcttccc ctcgtcacca tcttaaagta 6900

ccaaacttct taccgaccct tcttcaccac acggaatgtt tggaaacggc cagactggac 6960

agcgtcttcc ggcgatggcc tcaccaccac acgactcgta ctactcacag tcattggcat 7020

ctagtcgatc aaggaataac tcggatgcta tggatatcta cgccatcaca gacagagatc 7080

ctccggcacg agaaccctct ggttatagcc agtggtaccg taatggttct ccaagtgtga 7140

attccattca tagcaagtaa ttcttccctg tttccttaaa tctgccgttg aatttctctc 7200

tgggctgcgt cagttgttca ctctgccgaa gctgttattg ttggacgact aatgttcttc 7260

tctgttgtta ctgtctctct ctaggagttc tgaaaaacag cctttctatg aagaaaacgg 7320

acgaatgtat catgcgtacc gcaaaggggt atatatgcta ccatgcgatg agcaggagca 7380

agatcgcctt gatatcttcc acaaattatt cacggtggca agggtgtcgg atggcctaat 7440

gtacgccccg catcccagga acggccgatt tctagacttg ggctgcggga ccgggatatg 7500

ggcaattgat gttgccaaca aatacccaga cgctttcgtt gttggggttg accttgctcc 7560

catacagccc tcaaaccacc caaagaattg cgaattttac gccccattcg acttcgagag 7620

tccttgggcc atgggcgagg attcttggga cctgattcac ctgcaaatgg ggtgtggaag 7680

tgtgatggga tggccgaacc tgtaccggag aatattcgct caccttcgac ccggggcttg 7740

gtttgaacag gtggagatcg actttgaacc gcggtgcgat gaccgtcctc tcgagggact 7800

agctattcga cagtggtatc agtatctaaa gcaagctaca caagatgcca tgcgacctat 7860

aaaccacaac tctcgtgata caatccgaga tctgcaggag gctggtttta ccgatattga 7920

tcatcaaatg gtggggttgc cccttaaccc atggcatcaa gacgagcacg aaagaaaggt 7980

tgctcgctgg tacaatttgg ctgtctcgga gagtattgag tcgctcagta tggcgccttt 8040

cagtcgtatt tttaattggg acttggacag aatcaggcgc atttcgtcag aagtcaagtc 8100

ggaggcgttc aacaaagaaa tacacgccta caatatcctt catatatacc aagcacggaa 8160

acctgcgaac tgattcttct accaacatgc gcacgacgga catccaaaca tgcgccagca 8220

gcgtcactag tgcccaagct ccgagttatg gggtgggcga attaccatcc aggcagtcac 8280

ctttatctgc tcttttatga gctctccaaa gatgcagcga gttgatatga gcttgtgtgg 8340

tgccacttgt tagcttgcac acaacggtcc cgagcagtca ttgcttgcgt actgcaaagc 8400

aaaatcgaac tcatacgggt ctgtgatctc tatctatctg gaaaatccag tgtgtcggga 8460

gagctccatt actgggtatt cggtccgaga cgtcctgttt aggctgttgg ttatggcagc 8520

-continued

cacgaacgat gcactgagct gcctgtatca ctccagtagc acttagaagg ttgatggaaa 8580

tatacagagt ttgctttgat tatcataggt ccgagcatga ggcgggcgta cgtcttgcga 8640

aggggttat acaaattacc caggccaaac aggcaagtca aagatcattt cgtccaaaaa 8700

atacatcgcg atgcagctct tgcccctatg gacgaaccaa tggggctgca gaatactggc 8760

aggtcattaa taggacacgg catggcatgc cctctgccct ctgccctctg cctgctctta 8820

acctggctgt ggctccttca tcacacttca ggaccacatc attccctggc attgcatgct 8880

ttcccgcttg ccaaagacag catatttatg gcgttttggg tgagtgtaat gttgataact 8940

gtatacccgg tttagttcat tctatctgtg acgacatcat ccaatcatgg ttattgctat 9000

attcgagatt cataacatga tatcacttaa aaagaatata aaaatttata taatacaatg 9060

caaagaattt tatccatgtg atcgtttgta aggtctcact accagctaac atgaaccgga 9120

aatgcaagtg tgtgagatac cagtctttgg gtatttcgcc aaaacgcctc gatagccttc 9180

aagacacccg cccacccaat gacccaagac agatgctcct gtaaattatc taatactata 9240

atgtgaactc atacaatgat atcactttaa cgccggcggc ccttttgtcc ccgggaggta 9300

ccgtttctac ctccagtact ttctttctca ccatctccgc tggcccagtc acggccagcg 9360

ccggggctac gcctccgcat tgttccggga ccgacggcaa tgatgtcctc ttcactttcg 9420

ctgtcagaaa tatctagaag cacaggcatg cgg 9453

<210> SEQ ID NO 146
<211> LENGTH: 1455
<212> TYPE: DNA
<213> ORGANISM: Aspergillus flavus

<400> SEQUENCE: 146

atgtttggaa acggccagac tggacagcgt cttccggcga tggcctcacc accacacgac 60

tcgtactact cacagtcatt ggcatctagt cgatcaagga ataactcgga tgctatggat 120

atctacgcca tcacagacag agatcctccg gcacgagaac cctctggtta tagccagtgg 180

taccgtaatg gttctccaag tgtgaattcc attcatagca agaacggccg atttctagac 240

ttgggctgcg ggaccgggat atgggcaatt gatgttgcca acaaataccc agacgctttc 300

gttgttgggg ttgaccttgc tcccatacag ccctcaaacc acccaaagaa ttgcgaattt 360

tacgccccat tcgacttcga gagtccttgg gccatgggcg aggattcttg ggacctgatt 420

cacctgcaaa tggggtgtgg aagtgtgatg ggatggccga acctgtaccg gagaatattc 480

gctcaccttc gacccggggc ttggtttgaa caggtggaga tcgactttga accgcggtgc 540

gatgaccgtc ctctcgaggg actagctatt cgacagtggt atcagtatct aaagcaagct 600

acacaagatg ccatgcgacc tataaaccac aactctcgtg atacaatccg agatctgcag 660

gaggctggtt ttaccgatat tgatcatcaa atggtggggt tgccccttaa cccatggcat 720

caagacgagc acgaaagaaa ggttgctcgc tggtacaatt tggctgtctc ggagagtatt 780

gagtcgctca gtatggcgcc tttcagtcgt atttttaatt gggacttgga cagaatcagg 840

cgcatttcgt cagaagtcaa gtcggaggcg ttcaacaaag aaatacacgc ctacaatatc 900

cttcatatat accaagcacg gaaacctgcg aactgattct tctaccaaca tgcgcacgac 960

ggacatccaa acatgcgcca gcagcgtcac tagtgcccaa gctccgagtt atggggtggg 1020

cgaattacca tccaggcagt caccttttatc tgctctttta tgagctctcc aaagatgcag 1080

cgagttgata tgagcttgtg tggtgccact tgttagcttg cacacaacgg tcccgagcag 1140

tcatttgcgt actgcaaaag caaaatcgaa ctcatacggg tctgtgatct ctatctatct 1200

-continued

```
ggaaaatcca gtgtgtcggg agagctccat tactgggtat tcggtccgag acgtcctgtt   1260

taggctgttg gttatggcag ccacgaacga tgcactgagc tgcctgtatc actccagtag   1320

cacttagaag gttgatggaa atatacagag tttgctttga ttatcatagg tccgagcatg   1380

aggcgggcgt acgtcttgcg aaggggggtta tacaaattac ccaggccaaa caggcaagtc   1440

aaagatcatt tcgtc                                                    1455
```

What is claimed is:

1. A method of increasing the production of a secondary metabolite in a fungus cell or organism comprising the steps of:

(a) transforming a fungus cell or an organism capable of biosynthesizing a secondary metabolite with a nucleic acid encoding a veA polypeptide comprising the amino acid sequence of SEQ ID NO:116; and

(b) culturing the transformed cell or organism under conditions conducive to production of secondary metabolites, whereby the transformed cell or organism produces more of a secondary metabolite directly or indirectly regulated by VeA as compared to a non-transformed cell or organism.

2. The method of claim **1** wherein the fungus cell or an organism is a *Acremonium, Fusarium*, or *Penicillium* species.

3. The method of claim **2** wherein the *Fusarium* species is *F. graminearum.*

4. A method of producing an isolated secondary metabolite comprising the steps of:

(a) transforming a fungus cell or organism with a nucleic acid encoding a veA polypeptide comprising the amino acid sequence of SEQ ID NO:116, wherein the fungus cell or organism is an *Acremonium, Fusarium*, or *Penicillium* species;

(b) culturing the transformed cell or organism under conditions conducive to production of a secondary metabolite that the fungus cell or organism is capable of biosynthesizing; and

(c) recovering the secondary metabolite from the cultured, transformed cell or organism in an isolated form.

5. The method of claim **4** wherein the *Fusarium* species is *F. graminearum.*

* * * * *